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Background: Fissure sealant (FS) and fluoride varnish (FV) have been shown to be effective in preventing
dental caries when tested against a no-treatment control. However, the relative clinical effectiveness and
cost-effectiveness of these interventions is unknown.
Objective: To compare the clinical effectiveness and cost-effectiveness of FS and FV in preventing dental
caries in first permanent molars (FPMs) in 6- and 7-year-olds and to determine their acceptability.
Design: A randomised controlled allocation-blinded clinical trial with two parallel arms.
Setting: A targeted population programme using mobile dental clinics (MDCs) in schools located in areas
of high social and economic deprivation in South Wales.
Participants: In total, 1016 children were randomised, but one parent subsequently withdrew permission
and so the analysis was based on 1015 children. The randomisation of participants was stratified by school
and balanced for sex and primary dentition baseline caries levels using minimisation in a 1 : 1 ratio for
treatments. A random component was added to the minimisation algorithm, such that it was not completely
deterministic. Of the participants, 514 were randomised to receive FS and 502 were randomised to receive FV.
Interventions: Resin-based FS was applied to caries-free FPMs and maintained at 6-monthly intervals.
FV was applied at baseline and at 6-month intervals over the course of 3 years.
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Main outcome measures: The proportion of children developing caries into dentine (decayed, missing,
filled teeth in permanent dentition, i.e. D4–6MFT) on any one of up to four treated FPMs after 36 months.
The assessors were blinded to treatment allocation; however, the presence or absence of FS at assessment
would obviously indicate the probable treatment received. Economic measures established the costs and
budget impact of FS and FV and the relative cost-effectiveness of these technologies. Qualitative interviews
determined the acceptability of the interventions.
Results: At 36 months, 835 (82%) children remained in the trial: 417 in the FS arm and 418 in the FV
arm. The proportion of children who developed caries into dentine on a least one FPM was lower in the FV
arm (73; 17.5%) than in the FS arm (82, 19.6%) [odds ratio (OR) 0.84, 95% confidence interval (CI) 0.59
to 1.21; p = 0.35] but the difference was not statistically significant. The results were similar when the
numbers of newly decayed teeth (OR 0.86, 95% CI 0.60 to 1.22) and tooth surfaces (OR 0.85, 95% CI
0.59 to 1.21) were examined. Trial fidelity was high: 95% of participants received five or six of the six
scheduled treatments. Between 74% and 93% of sealants (upper and lower teeth) were intact at
36 months. The costs of the two technologies showed a small but statistically significant difference; the
mean cost to the NHS (including intervention costs) per child was £500 for FS, compared with £432 for FV,
a difference of £68.13 (95% CI £5.63 to £130.63; p = 0.033) in favour of FV. The budget impact analysis
suggests that there is a cost saving of £68.13 (95% CI £5.63 to £130.63; p = 0.033) per child treated if
using FV compared with the application of FS over this time period. An acceptability score completed by
the children immediately after treatment and subsequent interviews demonstrated that both interventions
were acceptable to the children. No adverse effects were reported.
Limitations: There are no important limitations to this study.
Conclusions: In a community oral health programme utilising MDCs and targeted at children with high
caries risk, the twice-yearly application of FV resulted in caries prevention that is not significantly different
from that obtained by applying and maintaining FSs after 36 months. FV proved less expensive.
Future work: The clinical effectiveness and cost-effectiveness of FS and FV following the cessation of
active intervention merits investigation.
Trial registration: EudraCT number 2010-023476-23, Current Controlled Trials ISRCTN17029222 and
UKCRN reference 9273.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 21.
See the NIHR Journals Library website for further project information.
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Plain English summary
Tooth decay is a very common problem. The biting surfaces of the first adult molar teeth, which eruptat the age of 6 years, are very vulnerable to decay. Rates of decay are especially high in children who
live in disadvantaged communities. Two widely used treatments, fissure sealant (FS) (plastic coatings) and
fluoride varnish (FV), can prevent decay. We do not know which works better or which is better value for
money. This study aimed to answer this. Just over 1000 children were treated with either FS or FV over
3 years. After 3 years, 835 children were still taking part in the study, which was a sufficient number for
the research teams to be able to see if one of the treatments was better than the other. Of the children
who had the FV treatment, 17.5% had decay in their molars that was bad enough to need a filling or for
the tooth to be taken out. In the sealant-treated group, 19.6% of children had decay in their first molars.
Although fewer children treated with FV had tooth decay, this was not significantly different from the
sealant-treated children. Over the 3 years, there was a cost saving of £68.13 per child in the FV group
compared with those receiving sealants. Both treatments were acceptable to the children. The main
conclusions from the study are that in a community programme such as this, there is no difference in the
benefits gained from the treatments, although FV is slightly cheaper.
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Scientific summary
Background
Dental caries (tooth decay) is among the most common diseases to affect humankind and correlates
closely with social and economic deprivation. Within the mouth, teeth differ in their susceptibility to dental
decay. This largely reflects the fact that dental plaque (oral biofilm) is more likely to form in specific areas.
One such area is the occlusal (or biting) surface of first permanent molar (FPM) teeth. These teeth erupt
at the age of 6 or 7 years and are particularly prone to decay shortly after they erupt. There are two
preventative dental technologies that have the potential to be targeted specifically at the occlusal surfaces
of FPMs: pit and fissure sealant (FS) and fluoride varnish (FV). These treatments have been used for
several decades and have been shown to be effective in preventing dental caries when tested against
no-treatment controls. However, it is not clear which treatment is the more clinically effective and
cost-effective. An answer to this question would help NHS dental services to plan for more effective and
efficient planning of preventative dental care.
Objectives
Primary objective
The primary objective of this study was to compare the clinical effectiveness of FS and FV in preventing
dental caries in FPMs in children aged 6 and 7 years, as determined by the:
l proportion of children developing new caries on any one of up to four treated FPMs
l number of treated FPM teeth caries free at 36 months.
Secondary objectives
The secondary objectives of this study were to:
l establish the costs and budget impact of FS and FV delivered in a community/school setting and the
relative cost-effectiveness of these technologies
l examine the impact of FS and FV on children and their parents/carers in terms of quality of life and
treatment acceptability
l examine the implementation of treatment in a community setting with respect to the experience of
children, parents, schools and clinicians.
Study design
A randomised controlled, assessor-blinded clinical trial with two parallel arms.
Setting
A Community Dental Service-targeted population programme delivered in mobile dental clinics (MDCs) in
primary schools located in areas of high social and economic deprivation in South Wales.
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Participants
Inclusion criteria
Children were eligible for inclusion if:
l they were aged 6 or 7 years and attended the schools participating in the current Cardiff and Vale
University Health Board Designed to Smile programme
l the person with parental responsibility had provided written informed consent
l they had at least one fully erupted FPM free of caries into dentine.
Exclusion criteria
Children were ineligible for inclusion if:
l their medical history precluded inclusion [i.e. they had a history of hospitalisation for asthma, severe
allergies or allergy to Elastoplast (Beiersdorf AG, Hamburg, Germany), which was determined from a
medical history form (MHF) that was completed by parents]
l they had a known sensitivity to colophony, or any of the product ingredients (e.g. methylacrylate in FS,
determined from a MHF that was completed by parents)
l they had any abnormality of the lips, face or soft tissues of the mouth that would cause discomfort in
the provision of FS/FV
l they were currently participating in another clinical trial involving an investigational medicinal product
(determined from a MHF that was completed by parents)
l they showed obvious signs of systemic illness (e.g. colds, influenza, chickenpox) (determined at
baseline examination).
Methods
Treatments
Eligible participants was randomised to receive either FS or FV and remained on the intervention to which
they were randomised for the duration of the study.
Resin-based FS was applied at baseline to included FPMs, including part-erupted upper teeth. Sealants
were checked at 6-month intervals and deficiencies were repaired. FV was applied, using a standard
clinical protocol, to all eligible FPMs at baseline and at 6, 12, 18, 24 and 30 months.
Clinical dental examination
Study participants were examined supine in the MDC, under a standard overhead dental clinical light,
using a plane dental mirror and ball-ended probe at baseline and at 12, 24 and 36 months. Dental caries
was recorded by trained and calibrated examiners, who were blinded to treatment allocation. Teeth were
not dried prior to clinical dental examination. Gross debris was removed using a toothbrush.
Health economics
The costs associated with the interventions for each trial participant were collected and summarised into
the following categories.
l Implementation costs of the interventions.
l Health-care utilisation costs associated with travel or caregiving/time off work for families.
l Costs associated with the schools (e.g. as a result of child absence). Published unit costs were used or,
when these were unavailable, local financial records were used to value resources in monetary terms
using 2015 as the price year.
l Utility data were captured using the Child Health Utility Index 9D, and quality-adjusted life-years
(QALYs) and quality-adjusted tooth-years were calculated. A budget impact analysis was undertaken.
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Treatment acceptability assessment and process evaluation
Treatment acceptability was assessed in three ways: (1) acceptability scales were completed by clinical staff,
(2) acceptability scales were completed by children participating in the trial and (3) qualitative interviews
were conducted with a subsample of children, their parents, school staff and clinical staff.
The acceptability of delivering this type of preventative intervention via a mobile dental unit in a school setting
was also investigated through questionnaires and interviews with children, parents, school staff and clinical staff.
Statistical issues
All comparative analyses were carried out on an intention-to-treat basis (without imputation). The primary
outcome (decayed, missing, filled teeth in permanent dentition, i.e. D4–6MFT) was analysed using a logistic
regression model to compare arms. The results for binary outcomes are presented as unadjusted and
adjusted odds ratios (ORs) for the FV arm compared with the FS arm (the reference arm). All models were
adjusted for the randomisation balancing variables, sex and baseline caries in the primary dentition.
Sample size
Based on existing local epidemiological data, for an individually randomised trial at a power of 80% with a
significance level of 5%, at least 313 children per group were required for a comparison of caries incidence
of 20% versus 30% at the 36-month follow-up.
Results
A total of 1016 children were randomised 1 : 1 to participate in the trial. Arms were well balanced for all key
characteristics at baseline. At 36 months, 835 (82%) children underwent a final clinical examination, on which
the following results are based. The number completing the FS arm was 418 and the number completing the
FV arm was 417. The most common reason for not completing the trial was moving away from the area or
moving to a school that was not participating in the trial, which was reported as lost to follow-up. The
number of children who withdrew from the trial was five in the FS arm and seven in the FV arm.
Clinical outcome
Proportion of children developing caries into dentine
The proportion of children who developed dentine caries (D4–6MFT) on at least one FPM at 36 months was
broadly similar in both the FS (19.6%) and FV (17.5%) arms.
The OR of developing caries in the FV arm (compared within the FS arm) was 0.87 [95% confidence
interval (CI) 0.61 to 1.23] in the unadjusted model, that is, children who received FV were slightly less likely
to develop caries than those who received FS, but this difference was not statistically significant.
As sex and baseline caries prevalence were used to balance the randomisation, an adjusted model was
also performed and was taken as the primary analysis. The OR for developing caries in the FV arm was
0.84 (95% CI 0.59 to 1.21) in the adjusted model.
To determine the impact of potential confounding factors, a covariate analysis of the primary outcome was
undertaken from two perspectives: one at child level and one at school level.
Numbers for the child-level covariate analyses were substantially lower than for the primary outcome
because of questionnaire non-response. The only covariates that were significantly associated with outcome
were frequency of tooth brushing (OR 0.36, 95% CI 021 to 0.60) and toothpaste type (OR 0.45, 95% CI
0.27 to 0.75). Those brushing twice a day or more often were less likely to develop caries on their FPMs
than those brushing once a day or less often. Those using children’s or other toothpaste were less likely to
develop caries on their FPMs at 36 months. None of the covariates altered the main effect for arm.
DOI: 10.3310/hta21210 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 21
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chestnutt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxxi
Proportion of first permanent molar teeth developing caries into
dentine (D4–6MFT)
In both the FS and FV arms of the trial, 7.5% of all teeth developed caries into dentine, required a
restoration or were extracted. A multilevel model adjusted for the number of decayed primary teeth at
baseline and sex confirmed that the difference between children receiving FS and those receiving FV was
not statistically significant (OR 0.97, 95% CI 0.73 to 1.28; p = 0.83).
Number of first permanent molar tooth surfaces developing caries into
dentine (D4–6MFT)
Ordinal regression modelling was undertaken on the number of FPM surfaces developing caries in each
child. Those children in whom between 5 and 20 surfaces were affected were combined into one group
because of the small number of children in these categories. There was no statistically significant difference
between those receiving FS and those receiving FV, the model having been adjusted to account for the
number of surfaces with caries per child, the number of decayed primary teeth at baseline and sex
(OR 0.85, 95% CI 0.59 to 1.21; p = 0.363).
Occlusal versus non-occlusal surfaces
Overall, the proportion of occlusal surfaces that had developed caries into dentine at 36 months was
significantly greater than the proportion of smooth surfaces developing caries (6.4% vs. 1.1%). It is clear
that the proportion of occlusal surfaces affected by dentine caries was remarkably similar in the FS and FV
arms of the trial, at 6.5% and 6.3%, respectively. The difference between intervention arms in the
proportion of smooth surfaces of FPMs developing caries observed at 36 months was also minimal
(1.0% vs. 1.3%). No significant difference was observed between trial arms for the main effect or for the
interaction of arm with surface type, indicating no differential effect of treatment on occlusal and
non-occlusal surfaces (OR 1.25, 95% CI 0.89 to 1.77).
Fidelity
Trial fidelity was high: 95% of participants were treated at five or six of the six treatment visits. Overall,
71.6% of treatments were within the treatment window throughout the trial, and a further 26.1% were
outside the schedule on only one occasion.
Health economics
The main findings of the health economic analysis were as follows.
l It is feasible to undertake a comprehensive health economic evaluation alongside a randomised
controlled trial of preventative health technologies within the context of a MDC setting.
l The intervention costs of the two technologies were £74.12 for FS and £64.16 for FV per child over the
course of the trial.
l The costs of the two technologies showed a small but statistically significant difference; the mean cost
to the NHS (including intervention costs) per child was £500 for FS, compared with £432 for FV, a
difference of £68.13 (95% CI £5.63 to £130.63; p = 0.033) in favour of FV.
l When a partial societal perspective was included (with intervention costs), the costs were £529 for FS
and £457 for FV, with a mean difference of £71.96 (95% CI £7.21 to £136.71; p = 0.029) in favour
of FV.
l The budget impact analysis at 3 years showed that FV resulted in a cost saving of £68.13 (95% CI
£5.63 to £130.63; p = 0.033) compared with FS. In addition, when three different scenarios were
examined, the results did not change and FV remained dominant.
l Owing to the non-significant numerical differences in outcomes, the incremental cost-effectiveness
ratio (ICER) was very sensitive to very small numerical differences in outcomes. All outcomes showed a
non-statistically significant difference or no clinically important differences between FS and FV and,
thus, the ICER calculation should be treated with appropriate caution. However, results remained
consistent across all three outcomes used in the health economic analysis, that is, FV was less costly
than FS, with similar outcomes achieved.
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l The cost-effectiveness acceptability curves (CEACs) showed that there was a 70% probability of FV
cost-effectiveness at a societal willingness-to-pay (WTP) threshold of £20,000 per QALY.
l The model-based analysis to estimate the incremental cost per QALY over longer-term horizons showed
consistent results with the results of the within-trial analysis, with fewer costs and small QALY gains
achieved, which made FV dominant in the ICER calculation. The CEACs showed that there was a 99%
and 96% probability of FV being cost-effective within a societal WTP threshold of £20,000 per QALY.
However, there are a number of uncertainties in the model, particularly the dearth of evidence on
longer-term costs and outcomes associated with FV and FS in a preventative dental health context.
Acceptability of fissure sealant and fluoride varnish treatments
An important element of the clinical trial was the determination of the acceptability of FS and FV treatments.
An acceptability score (called the Delighted–Terrible Faces scale), which was completed by the children
immediately post treatment and in subsequent interviews with children and parents, demonstrated that both
interventions are acceptable to children.
At baseline, the children in the FV arm were significantly more likely than those in the FS arm to report
being happy (OR 0.38, CI 0.29 to 0.50; p < 0.001), with this situation being reversed at the final treatment
at 30 months (OR 3.63, 95% CI 2.60 to 5.05; p < 0.001). In the course of the trial, those receiving FS
became happier as the trial progressed; in contrast, in the FV arm there was a modest decrease in the
number of children who chose a happy face.
Perceptions of undergoing treatment were influenced by aspects of treatment (especially taste) but also
wider factors associated with a child-friendly MDC. Ultimately, the high number of children completing
the trial can be taken as evidence of the acceptability of these interventions delivered in this setting.
Acceptability to parents and school staff was also high.
Adverse effects
No adverse effects were reported as a result of the treatments provided.
Conclusions
The findings of this trial demonstrate that, in community oral health programmes targeted at children who
are at high risk of caries, the application of FV as a caries-preventative measure will result in caries prevention
that is not significantly different from that achieved by applying and maintaining FS for 36 months. There is a
cost saving of £68.13 per child treated, using FV compared with the application of FS over this time period.
Both treatments are acceptable to children aged 6–10 years, and acceptability to parents and to schools was
also high.
Trial registration
This trial is registered as EudraCT number 2010-023476-23, ISRCTN17029222 and UKCRN reference 9273.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction, background and
objectives
Introduction
Dental caries (tooth decay) is among the most common diseases to affect humankind. In 2010, it was
estimated that 35% of the global population, that is, 2.4 billion people, had untreated caries in their
permanent dentition.1 The NHS in England spends around £3.4B per year on dental services, and it is
estimated that the private market accounts for a further £2.3B annually.2
Dental caries results from the metabolism of sugars by bacteria that are normally resident in the oral cavity.
The acids produced cause the demineralisation (breakdown) of the tooth surface. Initially, the caries lesion
is confined to the dental enamel. In its early stages, the disease process can be halted or even reversed by
a process known as remineralisation. This is facilitated by the presence of fluoride at the interface between
the tooth surface and the overlying biofilm of the dental plaque.
Untreated, the disease process continues to involve the underlying dentine and eventually the dental pulp
becomes inflamed, resulting in pain: toothache. Once the dentine is involved, the tooth requires a
restoration to halt caries progression. Ultimately, an inflamed pulp will die and a dental abscess may result.
Resolution will require either root-filling or the extraction of the tooth.
The past four decades have seen great improvement in oral health in England and Wales. In 1973, the
mean number of decayed, missing, filled teeth in permanent dentition (DMFT) in 15-year-olds was 8.4.3 By
2013 this had fallen to 1.4.4 This improvement is widely attributed to the introduction and the widespread
use of fluoride-containing toothpaste in the 1970s. However, improvements in oral health have not been
uniformly distributed across the population.
Children at risk of dental caries
Mean population values of dental caries prevalence mask an important fact. Similar to many chronic,
lifestyle-associated diseases, caries prevalence is markedly linked to social and economic deprivation,5,6 and
the prevalence is markedly skewed. At the age of 5 years, the prevalence of dental decay in children resident
in the most deprived localities is more than twice that of children living in the least deprived communities.
As oral health has improved, dental caries has become concentrated in children from poorer backgrounds.
Teeth at risk of dental caries
Individual teeth differ in their susceptibility to dental decay. This largely reflects the fact that dental plaque
(oral biofilm) is more likely to form in specific areas. One such area is the occlusal (or biting) surface of
molar teeth. This fissured surface predisposes teeth to oral bacteria multiplying in the depths of the fissures
and forming an environment favourable to the fermentation of sugars into acid.
The first permanent molars (FPMs) erupt at the back of the mouth around 6 years of age. The occlusal surface
of these teeth is particularly prone to dental caries, often within a short period of eruption into the mouth.
Management of occlusal caries on permanent molars has proven to be a great challenge to the dental
profession.7 Occlusal caries accounts for the majority of affected tooth surfaces in adolescents and adults.8–11
It is, therefore, apparent that preventing dental caries on the occlusal surfaces of FPMs is a key objective in
preventative dental care. These surfaces represent the surfaces most susceptible to decay and are present
in susceptible children. Actions to prevent and arrest dental caries, targeted at these surfaces, have the
potential to significantly improve oral health and to address inequalities.
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Preventative dental technologies
There are two preventative dental technologies that have the potential to be targeted specifically at
occlusal surfaces of FPMs: pit and fissure sealant and fluoride varnish (FV). The terms ‘pit and fissure
sealant’ and ‘fissure sealant’ (FS) refer to the same material. Unless referring to the term used specifically
by a referenced source, the term FS is used throughout this report.
Pit and fissure sealant
Pit and fissure sealant contains a bisphenol A and glycidyl methacrylate (bis-GMA) resin, which hardens on
exposure to light. It is applied to the tooth surface using acid-etch technology. FS prevents dental caries by
physically obliterating the pit and fissure system that has great potential to harbour cariogenic organisms.
Eliminating the pit and fissure system removes this ecological niche and reduces the initiation of caries in
this highly susceptible site. First developed in the 1960s, FS is an established technology and is widely used
in clinical practice.
Numerous studies have investigated the clinical effectiveness of FS. A 2013 Cochrane systematic review12
of sealants for preventing dental decay in the permanent teeth concluded that, in 12 trials in which
resin-based sealants were compared with no sealant controls, the sealed teeth were significantly less likely
to be carious at 2 years’ follow-up [odds ratio (OR) 0.12, 95% confidence interval (CI) 0.07 to 0.19],
although five of these trials were conducted in the 1970s, when caries prevalence was higher than it is
now. The authors of the review concluded that the application of sealants was recommended to prevent
and control dental caries. They found that the application of FS to occlusal surfaces of permanent molars
was clinically effective when compared with unsealed control teeth up to 48 months but, beyond that
time, effectiveness was uncertain. They further concluded that, although sealing was effective in high-risk
children, evidence in other circumstances is scarce, and they were unable to achieve a primary objective
of determining the effectiveness of sealants in relation to the baseline prevalence of dental caries in
the population.12
Fluoride varnish
The caries-preventative effect of fluoride has been recognised for > 100 years. Evidence arising from
ecological studies in the early twentieth century linked the presence of fluoride in the public water supply
to reduced caries prevalence in the population.13 Subsequently, fluoride has been incorporated into a
range of caries-preventative products for both professional use and self-use.
Fluoride primarily exerts cariostatic properties by a topical effect.14 The presence of fluoride at the tooth
surface prevents demineralisation of the dental enamel and encourages remineralisation.
Fluoride-containing varnishes were developed in the 1960s. They contained fluoride at a much higher
concentration [22,600 parts per million (p.p.m.)] than that present in water fluoridation programmes
(0.5–1 p.p.m. fluoride) or toothpaste (1000–1500 p.p.m fluoride). FVs were developed to prolong the
contact of fluoride ions with the tooth surface, thereby enhancing their cariostatic effect.
The most widely used FV preparation in the UK is Duraphat® varnish [Colgate-Palmolive (UK) Ltd, Manchester,
UK], marketed by Colgate®. This product contains 5% of sodium fluoride (22,600 p.p.m. of fluoride). Owing
to the high fluoride content, the product is licensed as a prescription-only medicine and can be prescribed
only by a medical or dental professional. FV is designed for application by a dental professional to specific
at-risk tooth surfaces or early caries lesions. The recommended frequency of application is 2–4 times per year.
The clinical effectiveness of FV has been the subject of a recent Cochrane systematic review.15 The authors
identified 13 studies that compared FV with a placebo or no treatment, and concluded that the pooled
decayed, missing, filled tooth surfaces in permanent dentition (DMFS)-prevented fraction was 43%
(95% CI 30% to 57%; p > 0.0001). However, the reviewers reported that the quality of the evidence was
moderate, as it mainly included studies that were at a high risk of bias with considerable heterogeneity.15
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Fissure sealant versus fluoride varnish
From the above reviews it is evident that both FS and FV are effective caries preventative agents. The
question arises, therefore, as to which is the more effective, particularly in relation to the prevention of
dental caries in FPMs.
Ahovuo-Saloranta et al.16 have recently published a Cochrane systematic review on the relative effectiveness
of FS versus FV. This updates a previous version of the review published in 2010.17 The review identified
four trials that had compared resin-based FS with FV. Two of these four studies, involving 358 children,
suggested that, compared with FV, FS prevented more caries in FPMs at 2-year follow-up. The pooled OR
was 0.65 (95% CI 0.50 to 0.94; p = 0.02). The authors stated that the body of evidence was assessed as
low. Ahovuo-Saloranta et al.16 concluded that the conclusion of the updated review remained the same as
the last update in 2010, that is, as a result of the limited number of data available it is was not possible to
draw clear conclusions about possible differences in effectiveness for preventing or controlling dental caries
on occlusal surfaces of permanent molars.
The importance of establishing the relative clinical effectiveness, cost-effectiveness
and patient preferences in relation to fissure sealant or fluoride varnish
Although the relative clinical effectiveness of FS and FV is important, a number of other factors should also
be considered when choosing between these technologies.
Application and equipment
The application of FS requires the use of the acid-etch technique to achieve adhesion of the sealant to the
tooth surface. Adequate moisture control is known to be a critical component of achieving a satisfactory
bond.18 This means that sealants can reasonably be applied only in the confines of a ‘dental surgery’, be that
fixed or mobile. The use of a ‘3-in-1’ water/air spray is required, along with adequate aspirating facilities.
In contrast, the application of FV is much less technique sensitive and does not require the degree of
specialist equipment needed for sealant placement. FV can simply be painted onto teeth using a small
brush. Moisture control using cotton wool rolls or pads is sufficient. As a result, FV can be applied in a
school medical room or other private location and does not necessarily need to be done within a clinic or
traditional health-care setting.
Personnel required for placement
Whereas FS can be applied only by a dentist, dental therapist or dental hygienist in the UK, FV can be
applied by an appropriately trained dental nurse. These factors raise the question of the relative costs
associated with providing either FS or FV. Although the equipment and personnel costs required to provide
FS are potentially higher, these need to be offset against the requirement for FV to be applied every
6 months and the single application and subsequent periodic check-up/top-up required for FS.
Patient acceptability
A further consideration is the relative acceptability of FS and FV to patients. At the age of 6 years, children
may have limited experience of dental care. The more technically involved procedure of FS application
may pose a greater challenge to an anxious or nervous child than the apparently more straightforward
application of FV.
Approaches to improve oral health
There are three main approaches to improving oral health: a whole-population approach, a targeted-population
approach and a high-risk individual approach.19
The Designed to Smile programme in Wales, part of the Welsh Government’s National Oral Health
Improvement Programme, takes a targeted population approach. There are several elements to the Designed
to Smile programme, one of which is a FS scheme. This work is delivered in schools via the Community Dental
Service (CDS) using mobile dental clinics (MDCs). This setting provided the backdrop to the current study.
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To ascertain whether FS or FV is the more effective technology in preventing occlusal caries in FPMs is of
importance to the NHS. This was recognised in the call by the National Institute for Health Research Health
Technology Assessment Board, which commissioned the research reported here. In addition to clinical
effectiveness, cost-effectiveness is of interest. As discussed above, FV requires less time than FS and can be
applied by staff with less training. However, although FV requires twice-yearly application, FS require only
periodic checking and maintenance. It is therefore possible that the technologies will differ in their costs and,
thus, in their cost-effectiveness.
Finally, the preference of children and their parents for FS or FV merits investigation. The less invasive
nature of FV placement compared with FS placement means that examination of the relative acceptability
of these treatments is required.
The aims and objectives of the trial were, therefore, as follows.20
Trial aims and objectives
Trial aim
The overall aim of the study was to identify and compare the relative clinical effectiveness and cost-
effectiveness of two established technologies, FS and FV, for the prevention of dental caries in FPM teeth
in children aged 6 or 7 years.
Trial objectives
Primary objective
The primary objective of this trial was to compare the clinical effectiveness of FS and FV in preventing
dental caries in FPMs in 6- and 7-year-olds, as determined by the:
l proportion of children developing new caries on any one of up to four treated FPMs
l number of treated FPM teeth that are caries free at 36 months.
Secondary objectives
The secondary objectives of this trial were to:
l establish the costs and budget impact of FS and FV delivered in a community/school setting and the
relative cost-effectiveness of these technologies
l examine the impact of FS and FV on children and their parents/carers in terms of quality of life (QoL)
and treatment acceptability measures
l examine the implementation of treatment in a community setting with respect to the experience of
children, parents, schools and clinicians.
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Chapter 2 Methods
Trial design
The study was a Phase IV randomised, allocation-blinded, two-arm, parallel-group trial. The participants
were randomised on a 1 : 1 allocation ratio to receive one of:
l resin-based FS
l FV.
There were no significant changes to the trial methodology after trial commencement. With the exception
of some minor changes to improve the return rate of follow-up questionnaires, the trial was conducted as
per the original protocol.20
Approvals obtained
The Research Ethics Committee (REC) for Wales 3 (formerly known as the REC for Wales) approved the
study on 15 February 2011 (reference 11/MRE09/6). The details of the REC and the NHS Research and
Development department approvals and clinical trials authorisation from the Medicines and Healthcare
products Regulatory Agency (MHRA) are provided in Appendices 1–3.
Participants
The target population were children aged 6 or 7 years attending primary schools in designated Communities
First areas; the Welsh Government has identified these localities as areas of social and economic deprivation.
All children in such schools are deemed to be at high risk of caries, according to Public Health England and
the Scottish Intercollegiate Guidelines Network, and qualify for FS/FV application.21,22
Participant selection and eligibility criteria
Children were considered eligible to join the trial if they met all of the inclusion criteria and none of the
exclusion criteria.20 It was possible to assess whether or not children met some of these criteria prior to a
clinical dental examination; however, for other eligibility criteria, examination by a dentist was required.
Inclusion criteria
Children were eligible for inclusion if:
l they were aged 6 or 7 years and attended the schools participating in the current Cardiff and Vale
University Health Board Designed to Smile programme
l the person with parental responsibility has provided written informed consent
l they had at least one fully erupted FPM free of caries into dentine.
Exclusion criteria
Children were ineligible for inclusion if:
l their medical history precluded inclusion [i.e. those with a history of hospitalisation for asthma, severe
allergies or allergy to Elastoplast (Beiersdorf AG, Hamburg, Germany), which was determined from a
medical history form (MHF) that was completed by parents]
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l they had a known sensitivity to colophony, or any of the product ingredients (e.g. methylacrylate in FS,
determined from a MHF that was completed by parents)
l they had any abnormality of the lips, face or soft tissues of the mouth that would cause discomfort in
the provision of FS/FV
l they were currently participating in another clinical trial involving an investigational medicinal product
(determined from a MHF that was completed by parents)
l they showed obvious signs of systemic illness (e.g. colds, influenza, chickenpox; determined at
baseline examination).
Recruitment into the trial
Number of participants
It was planned to recruit 920 participants, who would be randomised equally (n = 460 per arm) to the two
technologies (FS and FV) investigated in this trial. The statistical justification for this number is discussed below.
Recruitment of schools
Eligible schools involved in the Cardiff and Vale University Health Board (UHB) CDS Designed to Smile
programme were invited to participate in the trial. The trial management team visited those schools that
expressed an interest in participating to discuss the practical and logistical aspects of the trial. When
applicable, agreement to participate in the trial was documented.
Recruitment of participants
In line with the procedures for informing parents of children of the existing Designed to Smile programme,
teachers distributed invitation packs to children for them to take home to their parents.
The following documents were included in the invitation packs:
l participant information sheet (PIS) for parents (see Appendix 4)
l MHF (see Appendix 5)
l informed consent form (ICF) (see Appendix 6).
Participant information sheet for parents
The PIS was developed in conjunction with a parents’ group and approved by the REC (detailed in Design
of study materials and strategy for maximising questionnaire follow-up rates). The PIS contained all of the
necessary information for a parent or legal guardian to make an informed choice about their child’s
participation in the trial, as detailed in section 4.8 of the International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice.23
Medical history
The medical history of potential participating children was ascertained by asking their parents or legal
guardian to complete a MHF. Data were collected that specifically related to allergies, asthma (including
whether or not this had resulted in hospitalisation) and sensitivity to constituents of either FS or FV,
and if the child was currently participating in a clinical trial involving an investigational medicinal product.
Whether or not the child was registered with a general dental practitioner was also ascertained.
Following a child’s enrolment into the trial, any changes to their relevant medical history (as described
above) was established via a brief MHF (see Appendix 7), which was sent to parents in advance of the
annual clinical dental examination at 12 and 24 months. Parents were instructed to complete and return
the MHF to the dental team only if there had been a change in their child’s relevant medical history.
METHODS
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Informed consent
So that the trial could be conducted as pragmatically as possible, the consent process from the existing CDS
FS programme was utilised, in that consent was provided remotely by parents completing consent forms at
home and returning them to the school via their children. The consent rates for the existing FS programme
are usually > 70% (depending on the school); therefore, effectively communicating the concept of the trial
to parents without negatively affecting recruitment was key to the success of the trial. Given the setting and
the low-risk nature of the trial, obtaining consent remotely was successfully justified to the REC.
The PIS included in the Seal or Varnish? (SoV) invitation pack introduced the trial to the parents and asked
them to take the time to read the PIS before deciding whether or not they wanted their child to participate.
Parents were also informed of the option for their child to enter the existing Designed to Smile programme
instead of the trial. Explicit in the PIS was the opportunity to discuss any aspect of the trial with a member
of the trial team over the telephone. A dedicated telephone number was provided for this purpose, with the
provision for parents to leave a telephone number and e-mail address to be contacted by a member of the
trial team at the next available opportunity. Parents were also asked to discuss the trial with their child.
After considering the information provided in the SoV invitation pack, and discussing the trial with a
member of the trial team (if required), parents who wanted their child to participate were asked to sign
and date the ICF (see Appendix 6). They were also asked to confirm on the ICF that they had been given
the opportunity to discuss the trial with a member of the trial team or, alternatively, if they did not require
any further information, to make a decision regarding their child’s participation.
Children returned the completed ICF and MHF forms to their class teacher. On receipt of the ICF and MHF,
a designated member of the SoV MDC team liaised with an appropriate member of school staff to verify
that the name and signature on the ICF were in agreement with the school’s records for the person with
parental responsibility for that child.
Interventions
Study setting
The study interventions took place in the MDC, which visited schools in areas of high social and economic
deprivation in the Cardiff and Cwm Taf Health Board areas in South Wales, UK. The MDCs were operated
by the CDS, Cardiff and Vale UHB, under the Designed to Smile programme,24 which was a national oral
health improvement programme.
Technologies evaluated
The two technologies evaluated in this trial (FS and FV) are well established and have been used routinely
for several decades to prevent dental caries, as discussed in Chapter 1. Eligible participants were
randomised to receive either FS or FV and remained on the intervention to which they were randomised
for the duration of the study.
Pit and fissure sealant
The FS used was Delton® Light Curing Opaque Pit and Fissure Sealant (Dentsply Ltd, Stonehouse, UK;
CE0086). This is one of the most commonly used FS brands in the UK. FS was supplied as 2.7-ml bottles
for multiple applications and applied topically as a thin layer to the occlusal surface of eligible FPMs. The
standard clinical protocol, as described by the product manufacturers, was used to apply the FS (Box 1).
The full details of the clinical protocol for FS application are given in Appendix 8.
The initial application of FS took place within 2 weeks of the baseline dental examination and was performed
by a suitably qualified and trained dental hygienist. In the case of partially erupted molars, sealant was
applied if sufficient tooth surface was available. This situation was most common in the case of upper
molars. The same two dental hygienists provided treatments throughout the trial using two MDCs.
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The condition of the FS was re-examined at 6, 12, 18, 24 and 30 months. FS was reapplied if the existing
sealant had become detached or if occlusal coverage was considered insufficient as a result of either
further eruption of the tooth or part of the sealant becoming lost.
All applications of FS were documented on treatment record forms, which captured the date, batch number,
participant identification (ID) number and number of teeth (one to four) treated.
Fluoride varnish
The FV used for evaluation in the study was Duraphat 50 mg/ml dental suspension (PL 00049/0042),
equivalent to 22,600 p.p.m. fluoride. This is the most commonly used FV brand in the UK. FV was supplied
in 10-ml tubes for multiple applications and applied topically as a thin layer to the pits, fissures and smooth
surfaces of eligible FPMs. As per the Duraphat summary of product characteristics (see Appendix 9), the
dosage per single application did not exceed 0.4 ml. The standard clinical protocol was used to apply the
FV, as described in Box 2.
The initial application of FV occurred within 2 weeks of the baseline dental examination and was
performed by a qualified and trained dental hygienist in accordance with the conventional clinical protocol
established by the CDS (see Box 2). FV was reapplied at 6, 12, 18, 24 and 30 months, that is, on six
occasions at 6-monthly intervals in the course of the trial. The full details of the clinical protocol for FV
application are given in Appendix 10.
BOX 2 Procedure for application of FV
1. Prior to FV application, teeth are cleaned with a toothbrush if necessary.
2. The tooth is isolated using a cotton roll in the buccal sulcus.
3. The tooth is dried using a cotton roll.
4. A thin layer of FV is applied to the pits, fissures and smooth surfaces of FPMs using a disposable microbrush.
5. The cotton roll is removed from the buccal sulcus.
6. This procedure is repeated for all FPMs included in the trial.
7. The child is advised not to eat or drink for 30 minutes and not to brush their teeth for 4 hours after application.
BOX 1 Procedure for application of FS
1. Prior to sealing, if necessary, teeth are cleaned with a toothbrush.
2. The tooth is isolated using dry guards/cotton wool rolls and saliva ejectors to aid moisture control.
3. The tooth surface is dried.
4. The etchant is applied to all the pits and fissures and a few millimetres beyond the final margin of the
sealant for 30–60 seconds in accordance with the manufacturer’s instructions.
5. The etchant material is washed from the tooth for at least 30 seconds and the tooth dried until it has a
chalky, frosted appearance. Teeth that fail to etch properly are re-etched for a further 20 seconds.
Great care is taken to avoid salivary contamination, as there is agreement that moisture contamination
at this stage of the process is the most common cause of sealant failure.
6. The sealant material is applied to the occlusal surface and cured by shining a polymerisation light on the
tooth surface for at least 20 seconds.
7. The sealant is evaluated visually and tactically and an attempt is made to dislodge it with a probe.
Any deficiencies in the material are repaired to ensure an intact sealant surface.
METHODS
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All applications of FV were documented on treatment record forms, which captured the date, batch number,
participant ID number and number of teeth (one to four) treated.
Clinical assessments
Participant eligibility
The demographic and medical history information collected from the parents was reviewed to determine if
the child met the inclusion/exclusion criteria prior to a clinical examination. Children considered eligible
underwent a baseline clinical examination to determine their eligibility, based on the clinical inclusion/
exclusion criteria detailed in Inclusion criteria and Exclusion criteria.
Clinical dental examination
Study participants were examined in the MDC while supine under a standard overhead dental clinical light,
using a plane dental mirror and a ball-ended probe. The probe was used only to remove debris and to
determine surface texture. It was not used to probe for cavitation. Teeth were not dried prior to clinical
dental examination. Gross debris was removed using a toothbrush.
Caries assessment using International Caries Detection and Assessment System
Caries status was assessed and recorded at baseline, for all children considered eligible, by trained and
calibrated dentists using conventional diagnostic caries criteria at the d1/D1–d6/D6 level in accordance
with nationally recognised diagnostic criteria.25 Data were recorded using charts specifically designed for
the collection of International Caries Detection and Assessment System (ICDAS) dental codes26 (see
Appendix 11). An assessment of molar incisor hypomineralisation (MIH) was also carried out.
Further clinical examination, including ICDAS caries assessment, was performed at 12-month intervals for
36 months. Experienced community dental officers undertook the clinical dental examinations. A total of
six officers were used during the study, with one examiner involved in all years of the project.
Training and calibration
An intensive training and calibration exercise was undertaken in advance of each round of annual clinical
examinations. Prior to each calibration exercise, the examiners were asked to complete the online
e-learning package developed by the ICDAS team.26 At each calibration event, the examiner team received
an interactive lecture to review the ICDAS caries criteria. The calibration exercise was based on projected
images of 74 extracted primary teeth. The gold standard was determined by Professor Chris Deery (a
trained and calibrated ICDAS examiner), who provided the images. At each calibration exercise, the images
were projected under standardised conditions and compared with the gold standard examiner. The caries
code (the second digit of the ICDAS code) was recoded as 0, ‘free of caries into dentine’ (caries code 0–3),
and 4, ‘caries at ICDAS level 4 or higher‘, that is, ‘caries into dentine’ (caries code 4–6). Calibration was
based on these categorisations at the ‘caries into dentine’ level.
As part of the annual caries assessment, approximately 5% of study participants were re-examined to
determine intra-examiner reproducibility. The details of the analysis of ICDAS caries data are provided in
Statistical methods.
Nomenclature for recording dental caries in the Seal or Varnish? trial
In the SoV trial dental caries was recorded using ICDAS.26 As there is potential for confusion between the
different codes and thresholds used to describe dental caries when using ICDAS and previous caries indices/
scoring systems, Table 1 describes the terms used to define thresholds and levels of dental caries experience.
In this study, dental caries status is described using the following principal terms: caries free, free of caries
into dentine, enamel caries and dentine caries.
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Treatment acceptability assessment
Treatment acceptability was assessed in three ways. A modified version of the Delighted–Terrible Faces
(DTF) scale27,28 was used with children to determine participant acceptability (see Appendix 12). During the
clinical placement of the technologies under investigation, the treating dental hygienist and dental nurse
recorded the following indicators of participant acceptability and adverse outcomes: vomiting, crying,
gagging, excessive arm/leg movements and other signs of distress.29 As part of the process evaluation,
children and their parents from each trial arm were interviewed in order to compare their experiences of FS
and FV treatment (see Chapter 5).
Caries risk-related habits
For children deemed eligible to participate in the trial, information relating to the caries risk-related habits
was obtained via a dental health questionnaire (DHQ) (see Appendix 13) sent to parents at baseline and at
12, 24 and 36 months post treatment.
The questionnaire asked about tooth brushing frequency, if the child brushed on their own or with parental
assistance, the type of toothpaste used and the quantity of toothpaste dispensed to the toothbrush. An
enquiry was also made as to the age at which tooth brushing started. The use of mouthwash, fluoride
drops and fluoride tablets was determined, as was any previous application of FV by the child’s own dentist.
Attendance at a dentist outside the Designed to Smile programme was ascertained, as was the frequency of
dental attendance. Parents were asked about lifetime residency in South Wales. The annual questionnaire
also collected data on dietary habits, with an emphasis on the frequency of the consumption of sugar-rich
food and drinks. The remaining questions enquired about the use of dental services, which informed the
economic analysis of the trial.
Dental care during the trial
Parents were asked for details of their child’s dentist. The principal investigator wrote to the dentist and
informed them that the child was participating in the SoV trial. Dentists were asked to refrain from
providing FS or FV treatment for the duration of the study. For children who were patients of the CDS,
a flag was placed on their dental record to indicate that they were participants in the SoV study and
therefore should not receive FS or FV treatments.
TABLE 1 The terms used to describe dental caries status in the SoV clinical trial
Terms used in this
study (designation)
ICDAS caries
codes
Traditional caries scores,
(e.g. BASCD, WHO) Notes
Caries free 00 Sound Describes the condition as free of either
enamel or dentine caries
Free of caries into
dentine
00, 01, 02
and 03
Sound, D1 and D2 This is the status traditionally regarded as
‘caries-free’. This is the principal diagnostic
level used for both primary and secondary
outcomes in the study
Enamel caries (d1–3/D1–3) 01, 02 and 03 D1 and D2 Caries lesions limited to enamel
Dentine caries (d4–6/D4–6) 04, 05 and 06 D3, both cavitated and
non-cavitated
Caries lesions involving dentine, also
referred to as obvious dental decay
BASCD, British Association for the Study of Community Dentistry; WHO, World Health Organization.
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Children and their parents continued with their usual oral hygiene regime, details of which were gathered
via the annual questionnaire detailed in Caries risk-related habits.
Participant flow
Participant flow through the trial is illustrated in Figure 1.20
1–3 months
pre-enrolment
Baseline
Within
 2 weeks
of baseline
examination
Invitation to participate distributed to parents (via schools)
Informed consent obtained, screening and baseline 
dental examination performed, patient eligibility determined
6 months Follow-up visit 1: FS condition check/reapplication
(if required)/FV application
Randomisation
FV
initial application
Pit and FS
initial application
12 months Follow-up visit 2: dental examination/FS condition 
check/reapplication (if required)/FV application
36–42 months
18 months
Follow-up visit 3: FS condition check/reapplication
(if required)/FV application
24 months
Follow-up visit 4: dental examination/FS condition 
check/reapplication (if required)/FV application
30 months
Follow-up visit 5: FS condition check/reapplication
(if required)/FV application
36 months
Final analysis of outcome measures
Final follow-up visit: dental examination and assessment 
of clinical outcome measures
FIGURE 1 Participant flow diagram.20
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Data collection regime
The data collection regime is shown in Table 2.
TABLE 2 Data collection regime
Data type
Prior to
baseline
evaluation
Baseline
evaluation
Randomisation
and initial FS/FV
application
Follow-up period (months)
6 12 18 24 30 36
Clinical data
Medical/dental history/
demographics
✗ ✗ ✗
Eligibility (inclusion/exclusion
criteria)
✗ ✗
Caries risk-related habits ✗ ✗ ✗ ✗
ICDAS caries assessment ✗ ✗ ✗ ✗
Pre-treatment assessmenta ✗ ✗ ✗ ✗ ✗ ✗
Adverse event assessment ✗ ✗ ✗ ✗ ✗ ✗ ✗
Health economics data
NHS resource usage interviews ✗ ✗ ✗ ✗
Parental Resource Questionnaire ✗ ✗ ✗ ✗
School Resource Questionnaire ✗ ✗ ✗ ✗
Health-related quality of life
(CHU-9D)
✗ ✗ ✗
Treatment acceptability and process evaluation data
Observational scaleb ✗ ✗ ✗ ✗ ✗ ✗
DTF scale ✗ ✗ ✗ ✗ ✗ ✗
Interviews with children ✗ ✗
Interviews with parents ✗ ✗
Questionnaires/interviews with
schools
✗ ✗
Interviews with dental teamc ✗ ✗ ✗ ✗
Interviews with non-consenting
parents
✗ ✗ ✗
Interviews with non-responding
parent
✗ ✗ ✗
Interviews with withdrawing
parents
d d d d d d d
CHU-9D, Child Health Utility Index 9D.
a Assessment limited to condition of previously applied FS and/or pre-application risk assessment for FS/FV.
b Completed by both dental hygienist and dental nurse during/immediately after treatment.
c Dental team composed of dental officer, dental hygienist and dental nurse.
d As required.
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Trial outcomes
Outcome measures for dental caries
The primary outcome measure was the development of dental caries on FPMs at 36 months. This was
recorded as:
l the proportion of children developing new caries in dentine on any one of up to four treated FPMs at
36 months
l the number of treated FPM teeth that were free of caries into dentine at 36 months.
Outcome measures for health economic analysis
Indicators of clinical effectiveness were used alongside costs to estimate the relative cost-effectiveness of
FS and FV.
Two additional outcome measures were used for the cost-effectiveness analysis. These were used to
estimate incremental costs per quality-adjusted life-year (QALY) estimates.
Health-related quality of life: Child Health Utility Index 9D
A generic preference-based measure of health-related quality of life (HRQoL), the Child Health Utility Index
9D (CHU-9D),30 was used to determine HRQoL. Designed specifically for use with children, the CHU-9D
consists of a set of nine questions (dimensions), with five levels of responses available per question. It has a
recall period of today/last night and is intended to be self-completed by the child (see Appendix 14).
Quality-adjusted tooth-years
Utility values were measured as quality-adjusted tooth-years (QATYs),31,32 which is the production of
additional years of life (tooth-year) of each tooth adjusted for the quality of the tooth. An unrestored tooth
has a QATY equal to 1 in the year it was restoration free, and a restored, crowned or root canal-treated
tooth has a QATY of less than perfect (i.e. < 1) in the year that it was restored and in subsequent years.
The QATY for an extracted tooth is equal to 0 in that year and in subsequent years. Data to inform the
calculation of QATYs were derived from the clinical data collected.
Sample size
Data from a previous cohort study among primary school children under the care of the Cardiff and Vale
UHB CDS were used to derive the caries incidence in children (mean age 6.5 years) with at least one
erupted FPM.33 Overall, 40% of children had caries in one or more of their FPMs by the age of 10 years.
Based on recent Cochrane reviews, it is estimated that FV would reduce the 3-year incidence from 40% to
30% in this population,15 whereas FS would reduce it further to 20%.12 For an individually randomised trial
at a power of 80% with a significance level of 5%, at least 313 children per group were required for a
comparison of caries incidence of 20% versus 30% at 36-month follow-up.
Randomisation
The randomisation of participants was stratified by school and balanced for sex and primary dentition
baseline caries levels using minimisation in a 1 : 1 ratio for treatments. A random component was added to
the minimisation algorithm,34 such that it was not completely deterministic. The algorithm that allocated
children to the study arm minimised imbalance with respect to sex and baseline caries levels, with a
probability of 0.8 reducing the predictability of allocation.35
DOI: 10.3310/hta21210 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 21
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chestnutt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
Sequence generation
Randomisation was carried out in the South East Wales Trials Unit (SEWTU) using lists of pupil sex and
caries chart data collected by the CDS from each school they visited for the screening examination. Eligible
children were randomised using the minimisation algorithm. Allocation lists were produced and provided
to the CDS, with a 2-week window before the CDS returned to the school for the baseline treatments.
Allocation concealment mechanism
All randomisation and allocation lists were produced by SEWTU independently of the recruiting and
examining personnel in the CDS.
Implementation
The CDS carried out an initial screening examination at all schools. Data from these visits were provided to
SEWTU and used to produce the allocation lists for the CDS. Allocations were provided to the CDS prior to
each return school visit, ready for the children’s baseline treatment.
Blinding
The physical nature of the technologies under test limited the scope for blinding. Both the participant and
the dental hygienist were aware of the treatment provided. The dentist undertaking the clinical dental
examinations at baseline and at 12, 24 and 36 months was not informed of the arm to which the
participant had been randomised. However, the presence or absence of FS at assessment would obviously
indicate the likely treatment received.
Statistical methods
All comparative analyses were carried out on an intention-to-treat basis (without imputation). The primary
outcome (D4–6MFT) was analysed using a logistic regression model to compare arms. The results for binary
outcomes are presented as unadjusted and adjusted ORs for the FV arm compared with the FS arm (the
reference arm). All models were adjusted for the randomisation balancing variables, sex and baseline
caries, in the primary dentition. Baseline caries (decayed, missing, filled teeth in primary dentition, i.e.
D4–6MFT) was categorised as none, one or two, or three or more. The number of FPMs per child in the trial
was also added to the models as a covariate but removed if non-significant. As the intervention was
carried out within schools, a two-level logistic model was used to determine if there was any significant
clustering by school. If clustering was found to be negligible, the primary analysis outcome was taken to
be the single-level model. Intraclass correlation coefficients (ICCs) are given in tables or text for all
two- and three-level models. For subgroup analyses, the appropriate addition of main effects and
interaction terms was made to the primary model, as was the addition of any covariate effects.
For categorical outcomes with multiple categories, ordinal regression was fitted. The test of parallel lines
was conducted to check that the assumption of proportional odds was satisfied. Count data were analysed
using Poisson and negative binomial regression models. When the data were found to be overdispersed
(greater variance than might be expected in a Poisson distribution), the negative binomial regression model
was taken as the better-fitting model. When an inflation of zeros in the data was found, zero-inflated
Poisson regression and zero-inflated negative binomial regression models were employed. The Akaike
information criterion was used to determine the best-fitting model. The results were presented as adjusted
incidence rate ratios in the FV arm compared with the FS arm.
METHODS
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For continuous outcomes, a linear regression model was fitted after transformation to normality, if
required. When a natural log transformation was employed, the results were interpreted as percentage
difference between the arms. When baseline measurements were taken into consideration, an analysis of
covariance was used, with baseline measurement as a covariate. This model extends the usual logistic
regression model to include correlated interim outcome data. It allows the main treatment effects to be
adjusted for changes over time and for differences between time points to be examined. Differential
changes over time in caries outcome between trial arms can be examined through the inclusion of a
treatment × time interaction term.
When data were collected over several time points, a repeated measures model (using a generalised
logistic mixed model) was used with time points (12, 24 and 36 months). For tooth- and surface-level
binary outcomes, two- and three-level logistic models were used when appropriate. An interaction term
was used in the three-level models to investigate any differential effect of treatment on occlusal versus
non-occlusal surfaces. For all primary and secondary outcomes, 95% CIs and p-values are presented.
Primary outcome calculation
The primary outcome was the proportion of children experiencing caries into dentine at ICDAS level 4–6
on any one of up to four FPMs in the trial at 36 months. The D4–6MFT variable was calculated (and
converted to a binary outcome) from the full caries charts of those children attending the 36-month
examination and included only those FPMs in the trial. FPMs that were already sealed, carious into dentine,
filled or affected by post-eruptive breakdown (PEB) at baseline were excluded from the trial.
Secondary outcomes calculation
Secondary caries models at child, tooth and surface levels were as follows:
l the number of FPMs remaining free of caries into dentine per child for those FPMs included in the trial
(child-level ordinal analysis)
l the caries status of the FPMs (treated or untreated caries code 4, 5 or 6) included in the trial
(tooth-level binary analysis)
l the number of surfaces on each FPM remaining dentine caries free per tooth within child for those
FPMs included in the trial (tooth-level ordinal analysis)
l the caries status of treated or untreated caries on each surface of each FPM, caries code 4, 5 or 6
(surface-level binary analysis)
l the binary outcome of caries occurrence on occlusal versus non-occlusal surfaces of each FPM
(surface-level binary analysis with an interaction term for surface type × arm).
The primary analysis was undertaken using 12- and 24-month follow-up time points (child-level binary
analyses). In addition, an investigation of the treatment differences on the earlier stages of caries
development (enamel caries) was carried out using level 1, 2 and 3 of the ICDAS classification of caries at
36 months (child-level binary analysis). One additional post hoc analysis was carried out as a surface-level
analysis of the binary outcome of all caries (ICDAS 1–6) with an interaction term for surface type to
investigate occlusal versus non-occlusal surface interaction with treatment.
Treatment time
The treatment times at each time point were examined and found to be non-normally distributed. A natural
log-transformation of the treatment time data was performed and a linear regression analysis was used to
compare arms. Treatment effects are, therefore, interpreted as percentage difference between arms. The
regression model was adjusted for the randomisation balancing variables sex and baseline caries.
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Sealant retention
The sealant status at each treatment visit and the retention at each clinical examination were tabulated.
Molar incisor hypomineralisation
The presence and severity of MIH in the FPMs was tabulated at each dental examination, and the
prevalence was reported by treatment arm. Severe MIH presenting with PEB at baseline excluded a FPM
from the study.
Secondary analysis of primary outcomes
Additional important covariates were collected via the DHQ. The variables relating to tooth brushing
frequency, toothpaste, mouthwash, fluoride tablets and fluoride drops were utilised in the primary model if
there were ≥ 10 percentage points of difference between the binary categories. The variables relating to
tooth brushing, amount of toothpaste and FV/gel applied were utilised in the primary model if there were
≥ 20 percentage points of difference between the binary categories. The following categorisations were
used for covariates added to the primary analysis:
l frequency of tooth brushing – ‘twice or more a day’ versus ‘once or less a day’
l toothpaste type – ‘family toothpaste’ versus ‘children’s toothpaste or other’
l amount of toothpaste – ‘smear, pea or never’ versus ‘cover bristles’
l additional fluoride intake – ‘any mouthwash, drops or tablets or gel’ versus ‘none’.
Global oral hygiene regimen
A combined global rating scale of fluoride use and tooth brushing regimen was created as a summed
score of the binary categories for tooth brushing frequency (twice a day); who carries out tooth brushing
(adult or observed); toothpaste type (family toothpaste); amount of toothpaste (cover bristles); and
additional fluoride (any yes response). This resulted in a score of 0–6, which was collapsed into four
categories (0–1.49, 1.5–2.49, 2.5–3.49 and 3.5–6).
Length of time tooth brushing
The age of a child in months at baseline minus the age at which they started tooth brushing (in months)
was converted to years (divided by 12). The distribution for length of time spent tooth brushing had slight
negative skew but was entered into a linear regression untransformed.
Cariogenic score
The cariogenic score was calculated by summating the seven cariogenic items (scored 0–5) asked as part of
the diet question in the DHQ (these items were c, d, e, g, h, k and m). At least four of these items had to
be completed for a score to be calculated; if three or fewer of these items were ticked, the sugar intake
score was set to missing. Following summation, the score was divided by (five times the number of
completed items) and then multiplied by 100.
School and child deprivation
From the parental questionnaire, the child’s postcode was used to calculate the Welsh Index of Multiple
Deprivation (WIMD) 2011.36 The WIMD is categorised as quintiles and these were compared with the
population of Wales as a whole. For analyses, the WIMD was trichotomised into categories 1–3, 4 or 5.
The school postcode was coded in the same way and categorised as quintile for school-level analyses.
School size was also tested in these two-level regression models.
Socioeconomic group
Parental occupation had five categories: ‘higher managerial, administrative and professional occupations’,
‘intermediate occupations’, ‘routine and manual occupations’, ‘unemployed’ and ‘homemaker, carer, student
or grandparent’. These categories were based on those described by the Office for National Statistics.37
METHODS
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Sensitivity analyses specific to primary outcomes
l Adjustment of the primary analysis for all treatments within the specified time window, 4 weeks either
side of the scheduled treatment due date.
l The efficacy of the number of FV treatments on the primary outcome was estimated in a way that
preserves randomisation using complier average causal effect (CACE) modelling. As-treated or
per-protocol analyses have been widely used as secondary analyses if the effect of treatments when
actually received is of interest. However, these secondary analysis methods may yield seriously biased
estimates of treatment effects. Given the questionable validity of these analyses, statistical methods
such as CACE estimation have been developed to better estimate treatment efficacy, taking into
account non-compliance. The efficacy of the number of treatments on the primary outcome is
estimated in a way that preserves randomisation. The structural mean model (SMM) approach for
CACE was implemented here by fitting an instrumental variables regression. Applications of SMMs
were developed to adjust for adherence in trials with active treatments and an untreated control arm.
Although SoV has two active treatments, we have assumed, for the purposes of the CACE analysis,
that the sealant is a one-off standard treatment comparable with a control arm, and so treatment visits
were set to a constant zero. SoV also has a binary outcome, whereas CACE is more usually applied to
linear outcomes. Hence, the standard instrumental variables regression in Stata® (version 13, StataCorp
LP, College Station, TX, USA) was applied with the addition of robust standard errors. Adherence in the
FV arm was defined as the number of FV treatment visits that a child attended (the instrumental
variable) and the outputted estimate is interpreted as the efficacy per visit. A small, non-significant
efficacy estimate indicates little effect of additional treatment visits and negligible adherence effects in
the trial. Future work beyond the scope of this report will take these methods further and adjust for
compliance, as well as for predictors of compliance in both arms.
l The SMM approach was implemented by fitting an instrumental variables regression.38 Adherence was
defined as the number of FV treatment visits that a child attended.
Subgroup analyses specific to primary outcome
Appropriate interaction terms were entered into the primary regression analysis in order to conduct
prespecified subgroup analyses: cohort, baseline caries group. The trial was not powered to detect
significant interactions and, as such, these analyses are exploratory only. ORs and 95% CIs were reported.
Imputation
Imputation was to be considered after an examination of the number of missing primary outcome data
and the likely mechanism for missing data. If the primary outcome was deemed to be missing completely
at random and the proportion of data missing for reasons other than moving out of the SoV area was less
than 10%, then imputation would not be performed and a compete case analysis would be carried out to
estimate an unbiased treatment effect. If differential dropout was observed between arms, this would
indicate a missing at random or missing not at random mechanism. Mixed modelling is appropriate if the
data are missing at random, whereas multiple imputation and associated sensitivity analyses may be more
appropriate if the missing data were determined to be missing not at random.
Reliability
Calibration of the dental examiners was carried out each year of the study, and kappa scores were
calculated for reliability. At each clinical examination, a 5% sample was re-examined and caries charts
were completed a second time.
Statistical software employed
All analyses were carried out in IBM SPSS Statistics version 20 (IBM Corporation, Armonk, NY, USA), except
the zero-inflated Poisson regression, zero-inflated negative binomial regression and ivregress (CACE)
models, which were carried out in Stata.
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Assessment of adverse effects
During the course of the study, the occurrence of any serious adverse events or serious adverse reactions
was ascertained and recorded using the study serious adverse events form (see Appendix 15).
As per the Design to Smile programme, the clinical staff involved in the delivery of the intervention
monitored participants during and immediately following the administration of FS or FV, and were available
to manage any adverse events or serious adverse reactions in accordance with current clinical practice.
Parents were asked to tell the CDS team if their child experienced any dental or medical problems during
the 48 hours after each treatment.
Design of study materials and strategy for maximising questionnaire
follow-up rates
Participant information sheet
As described in section 4.8 of the ICH Guideline for Good Clinical Practice,23 in order that research
participants (or their legal guardians) are able to make an informed decision on whether or not to take part
in a clinical trial, all relevant information must be provided to the participants in such a way that it is as
non-technical and understandable as possible.
With this in mind, it was essential that all participant materials (including the PIS) were developed taking
into consideration the diverse literacy levels of the target population (i.e. parents of children in Communities
First areas).
To achieve this, the PIS was developed in consultation with a parents’ group in Newport. This group is in a
Communities First area of South Wales but one that is not served by the Cardiff and Vale CDS; therefore,
it was not within the catchment area of the trial.
After the initial draft by the SoV project team, the PIS and consent form were reviewed by the parents’
group, and the following points that they made were taken into account for subsequent revisions.
l All of the parents agreed that the overall amount of information/text presented was too extensive and
would be very likely to discourage them from thoroughly reading the information sheet (if they read it
at all). Furthermore, they felt that the tone of the wording needed to be made more ‘positive’. Once
the parents had had time to digest the information and understand the study, they agreed that it was
a ‘positive’ thing and would want their children to participant if a similar study was run in their area.
l Parents felt that having separate information sheets for parents and children was unnecessary, and that it
would be easier for parents to be given one simplified information sheet, which they could use to discuss
the study with their child. Parents felt that the wording used in the information sheet for children was much
more accessible and that the one simplified information sheet should contain wording more similar to this.
l Parents showed a strong aversion to the word ‘research’ being used (the image of children being used
as ‘guinea pigs’ was expressed by several parents). They felt that ‘evaluation’ or ‘assessment’ conveyed
the same concept in a more acceptable and understandable way.
l The use of cartoons/graphics/photographs was encouraged.
l Parents felt that the duplication of wording in the information sheet and the consent form was
unnecessary, and that cross-referencing should be used to help the parents understand better which
items on the consent form referred to which parts of the PIS.
Despite considering the recommendations of the parents’ group, we were mindful of the guidance
provided in section 4.8.10 of ICH topic E 6 (Guideline for Good Clinical Practice23), and tried to convey to
those in the group that a minimum level of information was required when developing an information
METHODS
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sheet for a clinical trial of an investigational medicinal product (CTIMP). The revised PIS was therefore
intended to represent a risk-based approach to the information provided to parents for a CTIMP.
In addition to ensuring that the content of the PIS was suitable, the visual appeal of the document was further
developed by a graphic designer, incorporating the child-friendly logos and colour schemes of the CDS.
Follow-up questionnaires: development and return rate
Information relating to caries risk-related habits and parental resource utilisation was obtained from parents via
a single combined DHQ (see Appendix 13) at baseline and at 12, 24 and 36 months. This was accompanied
(at the 12-, 24- and 36-month time points only) by the CHU-9D (see Appendix 14), both of which were
distributed to participants’ homes at the required time points.
The initial return rates of these questionnaires were lower than expected. The initial follow-up strategy
allowed for one follow-up telephone call 2 weeks after the questionnaires were handed out. However,
unanswered calls and inactive numbers made this strategy ineffective.
Initially, a £5 shopping voucher was included with the questionnaires in an effort to boost return rates,
but responses remained poor, with an overall return rate of 53%. A consultation exercise followed with
parents of children at a primary school in a Communities First area not involved in the trial. Between this
consultation and ideas developed by the trial management group, the following changes to the strategy
for follow-up of questionnaires were made.
l The questionnaire pack was to be given to the child at treatment/examination.
l A trial-branded giveaway (pen, eraser or fridge magnet) was included.
l A text message reminder was sent if the questionnaire was not returned 1 week after distribution.
l A second copy of the questionnaire was sent to participants’ homes if the original was not received
2 weeks after distribution.
l A telephone call was made directly to parents to remind them/aid with questionnaire completion
(DHQ only) and return.
l Participants were informed that all returned questionnaires gained entry to a prize draw for an iPad®
(Apple Inc., Cupertino, CA, USA) at each time point.
l The questionnaires were reformatted to increase their visual appeal, and were designed to be
consistent with the PIS and ICF, using the colours and graphics of the Designed to Smile programme.
Patient and public involvement
Patient and public involvement (PPI) in the SoV trial has been utilised in two main ways. The first has been
described in previous sections regarding the development of the study materials with the help of members
of a parents’ group in Newport. This PPI input was pivotal in producing user-friendly materials, contributing
to the successful recruitment to target. Without this detailed input, we would not have been able to justify
the carefully judged brevity and clarity of the PIS to the REC.
The second major use of PPI was in the redesign of participant-facing materials, as described in Design of
study materials and strategy for maximising questionnaire follow-up rates. This helped to boost the return
rate of follow-up questionnaires, thereby increasing our overall data collection.
Patient and public involvement was maintained throughout the trial via lay member representation
on the Trial Steering Committee (TSC). Our TSC lay member is a member of the Involving People network,
a Welsh Government-funded organisation that promotes PPI in research across Wales. The contribution
of this member to TSC meetings was invaluable, bringing a lay perspective to deliberations.
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Health economic assessment
A health economic evaluation was conducted alongside the trial. The evaluation set out to:
l estimate the costs of providing FS versus FV and the outcomes for the NHS, children and their families
and education in order to consider a partial societal perspective
l establish the relative cost-effectiveness of FS versus FV
l calculate the budget impact on the NHS of FS and FV delivered in a community/school setting.
The costs associated with the interventions for each trial participant were collected and summarised into
the following categories:
l Implementation costs of the interventions.
l Health-care utilisation costs associated with travel or caregiving/time of work for families.
l Costs associated with the schools, for example as a result of child absence. Published unit costs were
used or, when unavailable, local financial records were used to value resources in monetary terms using
2015 as the price year.
A series of within-trial incremental cost-effectiveness ratios (ICERs) were calculated (based on a NHS
perspective) to estimate the cost per:
l caries increment avoided
l QALY, using the CHU-9D to derive health utilities
l QATY as an exploratory analysis.
Post-trial modelling was conducted to estimate the longer-term cost-effectiveness of the interventions.
One-way sensitivity analysis was undertaken to assess the impact on changes to individual parameters on
the base-case results with probabilistic sensitivity analysis undertaken to estimate the joint uncertainty
around parameters. A budget impact analysis was undertaken to estimate the impact on NHS budgets in
delivering the interventions. A detailed report on the health economic methods is provided in Chapter 4.
Treatment acceptability assessment and process evaluation
Treatment acceptability was assessed in three ways:
1. acceptability scales were completed by clinical staff
2. acceptability scales were also completed by the children participating in the trial
3. qualitative interviews were conducted with a subsample of children.
The treatment acceptability scales and the qualitative interviews are described in Chapter 5.
METHODS
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Chapter 3 Clinical results
This chapter describes the clinical findings of the trial.
Introduction
The chapter begins with a description of the number of children randomised to the trial, and a
Consolidated Standards of Reporting Trials (CONSORT) diagram39 describes participant flow through the
trial. The baseline characteristics of the participants are described in relation to trial arm and to those
starting, completing and failing to complete the trial. Next, potential confounding factors such as fluoride
exposure, diet and dental attendance are reported. Participation and retention data are also described.
The main clinical results of the study in relation to the primary outcome measure, the proportion of
children developing caries into dentine on any treated FPM, are reported. The impact of baseline caries
experience, school attended, deprivation status and trial cohort is examined, before the impact of oral
hygiene habits, diet and dental attendance is analysed.
The second main trial outcome, the number of teeth developing dentine caries (D4–6MFT) at 36 months,
is reported next at both tooth and tooth-surface level. Fidelity is then described using CACE analysis.
Compliance with treatment windows is also reported.
The effect of including enamel caries (D1–6MFT) in the analysis is then described. This is followed by
examining the impact of the FS and FV treatments on all permanent teeth, not only FPMs. Trial outcomes at
12 and 24 months are reported to illustrate the shorter-term impact of the trial interventions. Finally, the
following data are presented: sealant retention, examiner reproducibility, adverse effects and treatment time.
Participant screening for participation in the trial
In total, 1303 children for whom parental consent had been obtained were screened for participation in
the trial (Figure 2). Of these, 1016 were deemed eligible for inclusion, but one participant subsequently
withdrew consent for participation and for the use of any of their data. At screening, 287 children were
excluded. The participants were recruited in two cohorts between October and January in the school years
2011/12 and 2012/13.
Participant randomisation
Participants were randomised to receive FS (514 children) or FV (501 children), as described in Chapter 2.
Characteristics of included participants at baseline
The characteristics of the study participants who were randomised at baseline are shown in Table 3.
There were no apparent differences between trial arms in sex or in the proportion of children with caries
experience in their primary dentition. The high prevalence of dental caries experienced in the primary
dentition at baseline (54.1%) reflects the fact that the programme was specifically targeted at schools in
areas of high social and economic deprivation. As shown in Figure 3, 78.6% of children randomised lived
in the bottom two quintiles of deprivation in Wales. Within quintiles of deprivation, the distribution of
children across trial arms was broadly similar.
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FIGURE 3 Social and economic profile of trial participants at baseline by trial arm and by quintile of WIMD (2011).
TABLE 3 Characteristics at baseline of the 1015 children randomised to participate in the trial
Characteristic
Intervention arm
Total, n (%)FS, n (%) FV, n (%)
Children randomised 514 (50.6) 501 (49.4) 1015 (100)
Sex
Male 237 (46.1) 235 (46.9) 472 (46.5)
Female 277 (53.9) 266 (53.1) 543 (53.5)
Children with dentine caries in the primary dentition (d4–6) 286 (55.6) 266 (53.1) 552 (54.1)
Children with dentine caries in the primary dentition (d4–6mft) 342 (66.5) 339 (67.7) 681 (67.1)
Children with untreated dentine caries in any FPM (D4–6) 22 (4.3) 23 (4.6) 45 (4.4)
Children with dentine caries in any FPM (D4–6MFT) 27 (5.3) 31 (6.2) 58 (5.7)
d4–6mft, mean (SD) 3.2 (3.4) 3.2 (3.3) 3.2 (3.3)
d1–6mft, mean (SD) 4.6 (3.8) 4.6 (3.7) 4.6 (3.7)
d4–6mfs, mean (SD) 8.9 (12.3) 9.6 (12.4) 9.3 (12.3)
d1–6mfs, mean (SD) 11.0 (12.9) 11.6 (12.9) 11.3 (12.9)
dmfs, decayed, missing, filled tooth surfaces in primary dentition; SD, standard deviation.
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The characteristics at baseline of the 835 children who completed the trial and of the 180 children who
either were lost to follow-up or withdrew are shown in Tables 4 and 5. There were no marked differences
in the baseline characteristics of either of these groups in relation to dental caries experience at baseline.
TABLE 4 Characteristics at baseline of the 835 children who were examined at 36 months
Characteristic
Intervention arm
Total, n (%)FS, n (%) FV, n (%)
Children completing the trial 418 (50.1) 417 (49.9) 835 (100)
Sex
Male 193 (46.2) 196 (47.0) 389 (46.6)
Female 225 (53.8) 221 (53.0) 446 (53.4)
Children with dentine caries in the primary dentition (d4–6) 228 (54.5) 219 (52.5) 447 (53.5)
Children with dentine caries in the primary dentition (d4–6mft) 271 (64.8) 280 (67.1) 551 (66.0)
Children with untreated dentine caries in any FPM (D4–6) 16 (3.8) 17 (4.1) 33 (4.0)
Children with dentine caries in any FPM (D4–6MFT) 18 (4.3) 24 (5.8) 42 (5.0)
d4–6mft, mean (SD) 3.1 (3.4) 3.2 (3.3) 3.2 (3.4)
d1–6mft, mean (SD) 4.5 (3.7) 4.6 (3.7) 4.5 (3.7)
d4–6mfs, mean (SD) 8.8 (12.4) 9.7 (12.7) 9.3 (12.5)
d1–6mfs, mean (SD) 10.9 (12.9) 11.7 (13.2) 11.3 (13.1)
dmfs, decayed, missing, filled tooth surfaces in primary dentition; SD, standard deviation.
TABLE 5 Characteristics at baseline of the 180 children who were lost to follow-up or withdrew from the trial
Characteristic
Intervention arm
Total, n (%)FS, n (%) FV, n (%)
Children randomised 96 (53.3) 84 (46.7) 180 (100)
Sex
Male 44 (45.8) 39 (46.4) 83 (46.1)
Female 52 (54.2) 45 (53.6) 97 (53.9)
Children with dentine caries in the primary dentition (d4–6) 58 (60.4) 47 (56.0) 105 (58.3)
Children with dentine caries in the primary dentition (d4–6mft) 71 (74.0) 59 (70.2) 130 (72.2)
Children with untreated dentine caries in any FPM (D4–6) 6 (6.2) 6 (7.1) 12 (6.7)
Children with dentine caries in any FPM (D4–6MFT) 9 (9.4) 7 (8.3) 16 (8.9)
d4–6mft, mean (SD) 3.4 (3.3) 3.3 (3.1) 3.4 (3.2)
d1–6mft, mean (SD) 4.8 (3.9) 4.7 (3.4) 4.8 (3.6)
d4–6mfs, mean (SD) 9.5 (11.8) 9.2 (11.2) 9.4 (11.5)
d1–6mfs, mean (SD) 11.7 (12.9) 11.3 (11.5) 11.5 (12.3)
dmfs, decayed, missing, filled tooth surfaces in primary dentition; SD, standard deviation.
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Characteristics of first permanent molars in children
randomised to the trial
The status of the FPMs by quadrant is shown in Table 6. From this, it is apparent that the prevalence of
decay into dentine was very low at baseline, the D4–6MFT ranging from 1.2% of upper-right permanent first
molars to 2.9% of lower-right FPMs. A greater proportion of upper FPMs (9.2–9.4%) were unerupted than
lower FPMs (4.7–5.9%). The percentage of erupted (or partially erupted) FPMs that were free of caries into
dentine was recorded as 89.7% in the upper-right quadrant and 93.5% in the lower-right quadrant.
With 1015 children randomised to participate in the trial and assessed at baseline, the overall number of
FPMs was 4060. In total, 161 (4%) of these were excluded at baseline because of the presence of FS
(71 teeth), caries into dentine (56 teeth), filled teeth (17 teeth) and teeth with PEB (17 teeth) (Table 7).
Baseline characteristics: fluoride exposure, diet and
dental attendance
A questionnaire distributed to the participants’ parents was used to collect information on exposure to
fluoride, dietary intake and dental attendance. At the baseline examination, 597 questionnaires were
returned, representing 58.8% of the study participants.
Fluoride exposure
From Table 8, it is apparent that the arms were reasonably well matched in terms of reported exposure
to fluoride outside the trial interventions. Reported tooth brushing frequency was higher in the FV group,
with 74.6% claiming twice-daily brushing, compared with 68.5% in the sealant group.
TABLE 6 The status of FPMs by quadrant at baseline for the 1015 children randomised to the trial
Status
FPM
UR (N= 1015),
n (%)
UL (N= 1015),
n (%)
LR (N= 1015),
n (%)
LL (N= 1015),
n (%)
Unerupted 93 (9.2) 95 (9.4) 60 (5.9) 48 (4.7)
D1–3T 114 (11.2) 120 (11.8) 109 (10.7) 107 (10.5)
D4–6T 11 (1.1) 10 (1.0) 24 (2.4) 12 (1.2)
MT 0 (0) 0 (0) 0 (0) 0 (0)
FT 1 (0.1) 5 (0.5) 5 (0.5) 5 (0.5)
D1–3MFT 115 (11.3) 125 (12.4) 114 (11.2) 112 (11.0)
D4–6MFT 12 (1.2) 15 (1.5) 29 (2.9) 17 (1.7)
D1–3S 115 (11.3) 123 (12.1) 114 (11.2) 111 (10.9)
D4–6S 11 (1.1) 10 (1.0) 24 (2.4) 12 (1.2)
MS 0 (0) 0 (0) 0 (0) 0 (0)
FS 1 (0.1) 6 (0.6) 5 (0.5) 5 (0.5)
D1–3MFS 116 (11.4) 128 (12.6) 118 (11.6) 116 (11.4)
D4–6MFS 12 (1.2) 15 (1.5) 29 (2.9) 17 (1.7)
Free of caries (D1–6MFT = 0) 796 (78.4) 785 (77.3) 817 (80.5) 843 (83.1)
Free of caries into dentine (D4–6MFT = 0) 910 (89.7) 905 (89.2) 926 (91.3) 950 (93.5)
FT, filled tooth; LL, lower left; LR, lower right; UL, upper left; UR, upper right.
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A greater proportion (55.3%) of parents in the FS arm than in the FV arm (48.9%) reported that their child
used family toothpaste to clean their teeth. The amount of toothpaste used on toothbrushes was broadly
similar between the trial arms. In both trial arms, 91% of the participants were lifetime residents of
non-fluoridated South Wales.
TABLE 8 Reported exposure to fluoride at baseline by intervention arm
Variable Scoring
FS (N= 314),
n (%)
FV (N= 283),
n (%)
Total (N= 597),
n (%)
Frequency of tooth brushing Never 0 (0.0) 0 (0.0) 0 (0.0)
Less than once a day 4 (1.3) 4 (1.4) 8 (1.4)
Once a day 77 (25.0) 48 (17.4) 125 (21.4)
Twice a day 221 (68.5) 206 (74.6) 417 (71.4)
More than twice a day 16 (5.2) 18 (6.5) 34 (5.8)
Toothpaste type Family toothpaste 168 (55.3) 134 (48.9) 302 (52.2)
Children’s toothpaste 131 (43.1) 133 (48.5) 264 (45.7)
Other 5 (1.6) 7 (2.6) 12 (2.1)
Amount of toothpaste A smear 24 (7.8) 23 (8.3) 47 (8.0)
A pea-sized amount 250 (81.4) 222 (80.1) 472 (80.8)
Cover the bristles 33 (10.7) 32 (11.6) 65 (11.1)
Use of mouthwash 97 (32.1) 82 (30.3) 179 (31.2)
Use of fluoride tablets 2 (0.9) 0 (0.0) 2 (0.5)
Use of fluoride drops 0 (0.0) 0 (0.0) 0 (0.0)
Use of FV 51 (16.6) 35 (12.6) 86 (14.7)
Lifetime resident in South Wales 238 (90.8) 215 (91.9) 453 (91.3)
TABLE 7 The distribution of FPMs included and excluded from the trial, together with reasons for exclusion
FPM
Total (N= 4060)UR (N= 1015) UL (N= 1015) LR (N= 1015) LL (N= 1015)
n % n % n % n % n %
Teeth included 978 96.4 983 96.8 962 94.8 976 96.2 3899 96.0
Teeth excluded 37 3.6 32 32.2 53 5.2 39 3.8 161 4.0
Reason for exclusion (n, % excluded)
Sealed 20 54.1 14 43.8 20 37.7 17 43.6 71 44.1
Filled 1 2.7 6 18.8 5 9.4 5 12.8 17 10.5
Caries at into dentine (D4–6) 11 29.7 9 28.1 24 45.3 12 30.8 56 34.9
PEBa 5 13.5 3 9.4 4 7.5 5 12.8 17 10.5
LL, lower left; LR, lower right; UL, upper left; UR, upper right.
a The PEB category is not necessarily mutually exclusive of other categories.
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Global oral hygiene regimen
The combined global rating scale of fluoride use and tooth brushing regimen, calculated as described in
Chapter 2, is shown in Table 9. This shows that the global oral hygiene score increased in both trial arms from
baseline to 12 months and was marginally higher in the FV arm than in the FS arm at 12, 24 and 36 months.
Diet
Reported dietary intake at baseline is shown in Table 10 and summarised in Table 11.
Cariogenic score
The cariogenic score, derived as described in Chapter 2, gives a summary measure of exposure to
cariogenic dietary items and is reported in Table 11. This shows that, although the score reduced between
the baseline and the 12-month examinations, it remained relatively constant thereafter and differed little
between the intervention arms.
Dental attendance
On the topic of dental attendance, 92.6% of children in the FS arm and 90.9% of children in the FV arm
were reported as being regular dental attenders, with the remainder described by their parents as
attending only when they were in pain.
Participation and retention
Of the 1016 children randomised to the trial, 835 (82.2%) underwent a final clinical examination at
36 months. The number completing the FS arm was 418 and the number completing the FV arm was 417.
The most common reason that children did not complete the trial was that they had moved away from the
area or to a school that was not participating in the trial; this was reported as lost to follow-up (see Figure 2).
The number of children who withdrew from the trial was five in the FS arm and seven in the FV arm.
It can be seen from the CONSORT diagram (see Figure 2) that the proportion of missing primary outcome
in each arm is evenly distributed by reason. Only 21 out of 514 (4.1%) participants in the FS arm and 22
out of 502 (4.4%) participants in the FV arm were a result of absence on the day of the final examination
or study withdrawal. Missing data attributable to participants moving out of the SoV area and a change
in medical circumstances were deemed to be unrelated to the treatments and, therefore, a completely
random mechanism. Moreover, the number of missing data that may possibly be related to treatment was
very low; therefore, imputation was not carried out and a complete case analysis is appropriate. Estimates
or treatment effect from these analyses will be unbiased with regard to missing data.
TABLE 9 Global oral hygiene regimen: summary score of reported oral hygiene habits during the trial by
intervention arm
Intervention
OverallFS FV
n Mean (SD) n Mean (SD) n Mean (SD)
Global oral hygiene regimen
Baseline 309 2.50 (1.083) 280 2.47 (1.018) 589 2.49 (1.052)
12 months 296 2.72 (1.136) 270 2.81 (1.183) 566 2.76 (1.159)
24 months 312 2.71 (1.204) 292 2.78 (1.130) 604 2.74 (1.169)
36 months 269 2.70 (1.035) 254 2.83 (1.090) 523 2.76 (1.063)
SD, standard deviation.
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TABLE 10 Reported dietary intake at baseline by intervention arm
Variable Scoring
Intervention arm
Total, n (%)FS, n (%) FV, n (%)
Milk Never and up to 4–6 times per week 102 (33.6) 93 (34.1) 195 (33.8)
1 per day to 2–3 times per day 202 (66.4) 180 (65.9) 382 (66.2)
Water Never and up to 4–6 times per week 88 (29.4) 69 (25.3) 157 (27.4)
1 per day to 2–3 times per day 211 (70.6) 204 (74.7) 415 (72.6)
Fizzy drinks Never and up to 4–6 times per week 264 (88.6) 233 (87.3) 497 (88.0)
1 per day to 2–3 times per day 34 (11.4) 34 (12.7) 68 (12.0)
Squash Never and up to 4–6 times per week 174 (60.0) 135 (51.5) 309 (56.0)
1 per day to 2–3 times per day 116 (40.0) 127 (48.5) 243 (44.0)
Fruit juice Never and up to 4–6 times per week 210 (72.2) 186 (70.3) 395 (71.3)
1 per day to 2–3 times per day 81 (27.8) 78 (29.7) 159 (28.7)
Diet/light drinks Never and up to 4–6 times per week 202 (69.9) 167 (63.5) 369 (66.8)
1 per day to 2–3 times per day 87 (30.1) 96 (36.5) 183 (33.2)
Sweets/confectionery Never and up to 4–6 times per week 236 (77.4) 214 (79.6) 450 (78.4)
1 per day to 2–3 times per day 69 (22.6) 55 (20.4) 124 (21.6)
Chocolate Never and up to 4–6 times per week 242 (79.1) 214 (79.3) 456 (79.2)
1 per day to 2–3 times per day 64 (20.9) 56 (20.7) 120 (20.8)
Crisps Never and up to 4–6 times per week 235 (76.5) 205 (75.9) 440 (76.3)
1 per day to 2–3 times per day 72 (23.5) 65 (24.1) 137 (23.7)
Fruit Never and up to 4–6 times per week 93 (30.5) 67 (24.6) 160 (27.7)
1 per day to 2–3 times per day 212 (69.5) 205 (75.4) 417 (72.3)
Biscuits and cakes Never and up to 4–6 times per week 231 (75.7) 210 (76.9) 441 (76.3)
1 per day to 2–3 times per day 74 (24.3) 63 (23.1) 137 (23.7)
High-fibre cereals Never and up to 4–6 times per week 189 (62.0) 159 (58.5) 348 (60.3)
1 per day to 2–3 times per day 116 (38.0) 113 (41.5) 229 (39.7)
Other cereals Never and up to 4–6 times per week 220 (73.1) 192 (71.1) 412 (72.2)
1 per day to 2–3 times per day 81 (26.9) 78 (28.9) 159 (27.8)
TABLE 11 Cariogenic score: summary score of reported dietary habits during the trial by intervention arm
Intervention arm
OverallFS FV
n Mean (SD) n Mean (SD) n Mean (SD)
Cariogenic score
Baseline 307 45.079 (15.3528) 275 46.188 (14.3435) 582 45.603 (14.8820)
12 months 299 44.997 (16.3388) 268 43.996 (14.5916) 567 44.524 (15.5320)
24 months 308 43.929 (14.2771) 289 43.053 (14.1149) 597 43.505 (14.1936)
36 months 266 42.097 (14.1395) 254 42.980 (14.5780) 520 42.528 (14.3483)
SD, standard deviation.
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The number of children who missed treatment at each of the 6-month intervals was small; for example, at the
12-month treatment session, 22 out of 484 (4.5%) missed treatment in the FS arm, and the corresponding
figure in the FV arm was 18 out of 474 (3.8%). This was because the children had been absent from school
on the day the MDC visited. As shown in Table 12, in both arms of the study 95% of participants received
the treatment on five or six of the six scheduled treatment visits, indicating extremely high fidelity in the study.
At the final assessment (36 months), the clinical team visited the schools on a second occasion to pick up
any absentees. Of the 866 children remaining in the trial and eligible for clinical assessment, 835 (94.6%)
were examined.
Participation rates across the trial by arm and by assessment and treatment visits are shown in Figure 4.
It is clear that, although there was a gradual loss of participants throughout the trial, the loss was equal
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FIGURE 4 Participation rates across the trial by arms and by assessment and treatment visits.
TABLE 12 Number of individual treatment visits by arm
Treatment visits attended
Intervention arm, n (%)
FS (N= 418) FV (N= 417)
0 0 (0) 0 (0)
1 1 (0.2) 0 (0)
2 0 (0) 1 (0.2)
3 2 (0.5) 4 (1.0)
4 16 (3.8) 15 (3.6)
5 92 (22.0) 96 (23.0)
6 307 (73.4) 301 (72.2)
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between the arms, and numbers of children remaining, at 418 and 417, were well in excess of the
required 313 per arm as determined in the power calculation (see Chapter 2, Sample size).
Clinical results
The proportion of children developing caries into dentine, having a
restoration or extraction on at least one first permanent molar at 36 months
The primary outcome measure of the trial was the proportion of children developing new caries into
dentine on any one of up to four treated FPMs (Table 13 and Figure 5). The proportion of children with
dentine caries (D4–6MFT) on any one of their FPMs was compared between those who had sealant and
those who had FV.
The proportion of children who developed dentine caries (D4–6MFT) on at least one FPM at 36 months was
broadly similar in the FS (19.6%) and the FV (17.5%) arms.
The OR for developing caries in the FV arm (when compared with the FS arm) was 0.87 (95% CI 0.61 to
1.23) in the unadjusted model, that is, children who received FV were slightly less likely to develop caries
than those who received FS, but the difference was not statistically significant (Table 14).
TABLE 13 The proportion of children with dentine caries (D4–6MFT) on any FPM in the trial at 36-month follow-up
by trial arm
Intervention arm, n (%)
Total (N= 835), n (%)FS (N= 418) FV (N= 417)
No dentine caries on any FPM 336 (80.4) 344 (82.5) 680 (81.4)
Dentine caries (D4–6MFT) on at least one FPM 82 (19.6) 73 (17.5) 155 (18.6)
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FIGURE 5 The proportion of children with dentine caries (D4–6MFT) on any FPM in the trial at 36-month follow-up
by trial arm.
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As sex and baseline caries prevalence were used to balance the randomisation, an adjusted model was
also performed, and this was taken as the primary analysis. The OR for developing caries in the FV arm
was 0.84 (95% CI 0.59 to 1.21) in the adjusted model.
In summary, the final model (see Table 14) shows that there was no significant difference in the proportion
of children with dentine caries (D4–6MFT) on any FPM in the trial at 36 months regardless of whether the
children received FS or FV. Children who had more than three carious primary teeth at baseline were
significantly more likely to develop caries into dentine on a FPM at 36 months. There was no difference
between the proportion of boys and girls developing caries into dentine on at least one FPM.
The influence of treating dental hygienist
Two trained experienced dental hygienists delivered the intervention. When the treating hygienist at baseline
was added to the single-level primary analysis as a factor, this was not significant (p = 0.981) and did not
change the primary outcome. When the primary outcome was modelled adjusted for treating hygienist
using a two-level logistic regression model, the outcome was unchanged compared with the unadjusted
result. The ICC for hygienist was zero, and so there was no clustering by staff delivering the intervention.
The influence of school attended
To determine if there was any clustering in the primary outcome at school level, a two-level multilevel
logistic regression was carried out. The results from the two-level model did not differ from the primary
model to any significant degree (Table 15) and school was dropped as level for subsequent analyses.
The ICC for school was 0.029 in the unadjusted model and 0.024 in the adjusted model.
The influence of cohort and baseline caries experience
To examine the influence of two prespecified subgroups on the primary outcome, an exploratory analysis
was undertaken. The children were recruited to the trial in two cohorts (see Chapters 2 and 6) over two
school years. The purpose of this analysis was to examine whether or not there were significant differences
in the primary outcome measures between the trial cohorts. The second analysis examined the effect of
caries in the primary dentition at the baseline examination on subsequent development of caries on FPMs.
The number of children developing D4–6MFT at 36 months related to the trial cohort and to the number of
decayed primary teeth at baseline is shown in Table 16.
TABLE 14 Primary analysis of the proportion of children with dentine caries, a restoration or extraction (D4–6MFT)
on any FPM in the trial by trial arm at 36 months
Unadjusted OR
(95% CI) p-value
Adjusteda OR
(95% CI) p-value
FS Reference Reference
FV 0.87 (0.61 to 1.23) 0.433 0.84 (0.59 to 1.21) 0.351
Baseline caries prevalence
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.58 (0.83 to 3.00) 0.165
≥ 3 primary teeth with caries into dentine 4.57 (2.83 to 7.39) < 0.001
Sex
Female Reference
Male 1.06 (0.74 to 1.52) 0.756
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
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TABLE 15 Analysis of the proportion of children with dentine caries, a restoration or tooth extracted because of
caries (D4–6MFT) on any FPM in the trial by trial arm at 36 months, adjusted for school attended
Unadjusted OR
(95% CI) p-value
Adjusteda OR
(95% CI) p-value
FS Reference Reference
FV 0.87 (0.61 to 1.23) 0.426 0.84 (0.59 to 1.21) 0.358
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.61 (0.84 to 3.07) 0.150
≥ 3 primary teeth with caries into dentine 4.56 (2.81 to 7.40) < 0.001
Sex
Female Reference
Male 1.06 (0.74 to 1.53) 0.747
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
TABLE 16 The development of dentine caries (D4–6MFT) on any FPM at 36 months by cohort and baseline caries
experience in the primary dentition at baseline
Intervention arm, n (%)
Total (N= 835), n (%)FS (N= 418) FV (N= 417)
No dentine caries in FPMs at 36 months
Cohort 1 173 (51.5) 180 (52.3) 353 (51.9)
Cohort 2 163 (48.5) 164 (47.7) 327 (48.1)
At least one FPM with dentine caries at 36 months
Cohort 1 41 (50.0) 46 (63.0) 87 (56.1)
Cohort 2 41 (50.0) 27 (37.0) 68 (43.9)
Total
Cohort 1 214 (51.2) 226 (54.2) 440 (52.7)
Cohort 2 204 (48.8) 191 (45.8) 395 (47.3)
No dentine caries in FPMs at 36 months
Baseline caries
Primary dentition free of caries into dentine 130 (38.7) 131 (38.1) 261 (38.4)
1–2 primary teeth with caries into dentine 68 (20.2) 69 (20.1) 137 (20.1)
≥ 3 primary teeth with caries into dentine 138 (41.1) 144 (41.9) 282 (41.5)
At least one FPM with dentine caries at 36 months
Baseline caries
Primary dentition free of caries into dentine 17 (20.7) 6 (8.2) 23 (14.8)
1–2 primary teeth with caries into dentine 8 (9.8) 11 (15.1) 19 (12.3)
≥ 3 primary teeth with caries into dentine 57 (69.5) 56 (76.7) 113 (72.9)
Total
Baseline caries
Primary dentition free of caries into dentine 147 (35.2) 137 (32.9) 284 (34.0)
1–2 primary teeth with caries into dentine 76 (18.2) 80 (19.2) 156 (18.7)
≥ 3 primary teeth with caries into dentine 195 (46.7) 200 (48.0) 395 (47.3)
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Children in cohort 2 experienced less diseased teeth. Children in the FV arm with dentine caries on one or
two primary teeth experienced more dentine caries in their FPMs than those in the FS arm. Those receiving
FV who had more than three primary teeth with dentine caries were also marginally more likely to
experience dentine caries in their FPMs than those receiving FS (48% vs. 46.7%).
The interaction between cohort and intervention arm is reported in Table 17. From this it is apparent that
the interaction of arm and cohort is not statistically significant.
The interaction of baseline caries risk with trial arm does not quite reach conventional levels of statistical
significance, as shown in Table 18. Those children treated with FV who had more caries at baseline in
their primary dentition were more likely to develop caries at 36 months than those who received FS.
However, caution should be used for the interpretation of these effects, as the subgroup sizes for baseline
caries risk were small.
Secondary analysis for the primary outcome: proportion of children developing
dentine caries (D4–6MFT) on any first permanent molar at 36 months
To determine the impact of potential confounding factors, a covariate analysis of the primary outcome was
undertaken from two perspectives: child level (Table 19) and school level (Table 20).
The numbers for the child-level covariate analyses were substantially lower than those for the primary
outcome because of questionnaire non-responses. The only covariates that were significantly associated
with outcome were frequency of tooth brushing (OR 0.36, 95% CI 0.21 to 0.60) and toothpaste type
(OR 0.45, 95% CI 0.27 to 0.75). Those brushing twice or more a day were less likely to develop caries on
their FPMs than those brushing once or less a day. Those using children’s or other toothpaste were less
likely to develop caries on their FPMs at 36 months. None of the covariates altered the main effect for arm.
Two further potential influencing factors on the primary outcome were examined: the size of the school, in
terms of the number of children enrolled, and the socioeconomic level of the locality in which the school
was situated, as determined by the WIMD.36
TABLE 17 Subgroup analysis of the proportion of children with dentine caries (D4–6MFT) on any FPM in the trial:
differential intervention effect by cohort
Adjusteda OR (95% CI) p-value
FS Reference
FV 1.07 (0.66 to 1.74) 0.790
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.62 (0.85 to 3.09) 0.140
≥ 3 primary teeth with caries into dentine 4.60 (2.84 to 7.44) < 0.001
Sex
Female Reference
Male 1.04 (0.73 to 1.50) 0.824
Cohort 1 Reference
Cohort 2 1.19 (0.72 to 1.96) 0.500
Reference
Cohort 2 × FV arm 0.58 (0.28 to 1.21) 0.147
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
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TABLE 19 The impact of child-level covariates between intervention arms on dentine caries (D4–6MFT)
Covariate Total N FS or FV Adjusteda OR (95% CI) p-value
Global oral hygiene regimen FS Reference
493 FV 0.90 (0.55 to 1.45) 0.652
Additional fluoride FS Reference
471 FV 0.93 (0.57 to 1.50) 0.753
Cariogenic global score FS Reference
487 FV 0.85 (0.53 to 1.39) 0.526
Socioeconomic group FS Reference
460 FV 0.85 (0.51 to 1.41) 0.524
Frequency of tooth brushing FS Reference
489 FV 0.97 (0.59 to 1.59) 0.904
Toothpaste type FS Reference
484 FV 0.88 (0.54 to 1.44) 0.616
Length of time brushing tooth FS Reference
467 FV 0.99 (0.55 to 1.47) 0.666
WIMD child FS Reference
834 FV 0.85 (0.59 to 1.22) 0.371
a Adjusted for sex and baseline caries risk.
TABLE 18 Subgroup analysis of the proportion of children with ICDAS caries (levels 4–6) on any FPM in the trial:
differential intervention effect by baseline caries risk group
Adjusteda OR (95% CI) p-value
FS Reference
FV 0.35 (0.13 to 0.92) 0.032
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 0.90 (0.37 to 2.19) 0.811
≥ 3 primary teeth with caries into dentine 3.16 (1.75 to 5.72) < 0.001
Sex
Female Reference
Male 1.05 (0.73 to 1.50) 0.808
Reference
FV × 1–2 primary teeth with caries into dentine 3.89 (0.99 to 15.28) 0.051
FV ×≥ 3 primary teeth with caries into dentine 2.69 (0.93 to 7.72) 0.067
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
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When modelled using a two-level logistic model of child within school, neither school size nor the WIMD
of the locality in which the school was located was significantly associated with the caries outcome at
36 months, and including them did not alter the main effect of intervention arm.
The effect of fissure sealant and fluoride varnish on caries
prevention by tooth
The proportion of first permanent molar teeth caries-free at 36 months
The analyses reported above relate to the proportion of children developing new caries on any one of up
to four treated FPMs, that is, a child-level outcome. The second main objective in this clinical trial was:
l the number of treated FPM teeth that were caries free at 36 months.
In both the FS and the FV arms of the trial, 120 FPM teeth (7.5% of all teeth) developed caries into dentine,
required a restoration or were extracted (Table 21). A multilevel model (Table 22), adjusted for the number
of decayed primary teeth at baseline and sex, confirmed that the difference between children receiving FS
and children receiving FV was not statistically significant (OR 0.97, 95% CI 0.73 to 1.28; p = 0.83). A
preliminary analysis showed that there was no significant differences between quadrants (upper right, upper
left, lower right and lower left), but quadrant was retained in the model as a cluster level (ICC = 0.12).
This means that there was no difference in the proportion of FPM teeth developing decay into dentine
between the arms of the trial.
A further analysis examined the severity of caries attack as determined by the number of teeth becoming
carious per child. The proportion of children with dentine caries (D4–6MFT) at 36 months by the number of
FPMs by intervention arm is shown in Table 23. The proportion of FPMs per child developing dentine caries
differed marginally between the intervention arms.
The significance of the difference between the intervention arms was tested using ordinal regression modelling
(Table 24). Those children with three or four FPMs with caries into dentine were grouped together. A marginally
smaller proportion of children who received FV developed caries into dentine in their FPMs at 36 months,
although the difference from the FS arm was not statistically significant (OR 0.87, 95% CI 0.64 to 1.20).
‘Threshold’ represents the response variable in the ordered logistic regression.
TABLE 20 The impact of school-level covariates between intervention arms on dentine caries (D4–6MFT)
Covariate n FS or FV Adjusteda OR (95% CI) p-value ICC
School size 835 FS Reference
FV 0.85 (0.59 to 1.22) 0.364 0.022
WIMD school 835 FS Reference
FV 0.84 (0.58 to 1.21) 0.348 0.032
a Adjusted for sex and baseline caries risk.
TABLE 21 The proportion of FPM teeth with dentine caries (D4–6MFT) at 36 months by intervention arm
Intervention arm, n (%)
Total (N= 3205), n (%)FS (N= 1609) FV (N= 1596)
No caries 1489 (92.5) 1476 (92.5) 2965 (92.5)
Caries on FPM surface 120 (7.5) 120 (7.5) 240 (7.5)
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TABLE 22 Multilevel model of quadrant within child for FPM caries at D4–6MFT
Unadjusted OR
(95% CI) p-value
Adjusteda OR
(95% CI) p-value
FS Reference Reference
FV 1.03 (0.79 to 1.35) 0.825 0.97 (0.73 to 1.28) 0.830
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.57 (0.90 to 2.74) 0.111
≥ 3 primary teeth with caries into dentine 5.66 (3.76 to 8.51) < 0.001
Sex
Female Reference
Male 1.00 (0.75 to 1.32) 0.972
a Adjusted for sex and baseline caries risk.
ICC for quadrant= 0.120.
TABLE 23 The proportion of children developing dentine caries (D4–6MFT) at 36 months by number of FPM by trial arm
Intervention arm, n (%)
Total (N= 835), n (%)FS (N= 418) FV (N= 417)
No caries on any FPM 336 (80.4) 344 (82.5) 680 (81.4)
Caries on one FPM 53 (12.7) 43 (10.3) 96 (11.5)
Caries on two FPM 22 (5.3) 17 (4.1) 39 (4.7)
Caries on three FPM 5 (1.2) 9 (2.2) 14 (1.7)
Caries on four FPM 2 (0.5) 4 (1.0) 6 (0.7)
TABLE 24 Ordinal regression analysis of the number of FPMs with dentine caries, a restoration or extracted
because of caries (D4–6MFT) at 36 months by trial intervention arm
Unadjusted OR
(95% CI) p-value
Adjusteda OR
(95% CI) p-value
FS Reference Reference
FV 0.89 (0.65 to 1.22) 0.465 0.87 (0.64 to 1.20) 0.399
Threshold
0 to 1 11.31 (7.16 to 17.86) < 0.001
1 to 2 32.38 (19.60 to 55.51) < 0.001
2 to 3 98.87 (53.37 to 183.14) < 0.001
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.54 (0.84 to 2.83) 0.167
≥ 3 primary teeth with caries into dentine 4.05 (2.59 to 6.35) < 0.001
Sex
Female Reference
Male 1.03 (0.75 to 1.41) 0.866
a FV compared with FS. Analysis adjusted for baseline caries risk group, sex and number of FPMs in the trial.
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The threshold estimates are the cut-off points that differentiate between ordered categories of the outcome.
The OR for trial arm is not statistically significant (and no different from the logistic model), indicating no
difference between the arms for the ordinal outcome of number of FPMs with caries per child.
The effect of fissure sealant and fluoride varnish by tooth surfaces
Because of its mode of action, FS can afford protection only to the occlusal tooth surface. By contrast,
FV can afford protection to the occlusal and the mesial, buccal, lingual and distal (smooth) tooth surfaces.
It was, therefore, important to determine if there was a difference between the intervention arms in the
number of tooth surfaces affected.
Looking first at the proportion of tooth surfaces that developed caries into dentine or that were restored or
extracted because of caries at 36 months (Table 25), the number of such surfaces affected was 169 (2.1%)
in the FS arm and 181 (2.3%) in the FV arm.
Table 26 reports a multilevel model that examines the proportion of tooth surfaces affected by dentine
caries (D4–6MFS) within quadrant within child. There was no significant difference between the intervention
arms in the number of FPM tooth surfaces developing caries (OR 1.06, 95% CI 0.84 to 1.33; p = 0.619).
TABLE 26 Multilevel model of surfaces within quadrant within child for FPM dentine caries, restored or extracted
tooth surfaces (D4–6MFS)
Unadjusted OR
(95% CI) p-value
Adjusteda OR
(95% CI) p-value
FS Reference Reference
FV 1.17 (0.93 to 1.46) 0.177 1.06 (0.84 to 1.33) 0.619
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.41 (0.86 to 2.33) 0.173
≥ 3 primary teeth with caries into dentine 6.50 (4.56 to 9.27) < 0.001
Sex
Female Reference
Male 1.38 (1.09 to 1.74) 0.007
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
ICC for quadrant= 0.197 and ICC for surface= 0.058.
TABLE 25 The number of surfaces with dentine caries, restored or that had been extracted (D4–6MFS) at 36 months
by intervention arm
Status
Intervention arm, n (%)
Total (N= 16,016), n (%)FS (N= 8041) FV (N= 7975)
Free of caries into dentine 7872 (97.9) 7794 (97.7) 15,666 (97.8)
D4–6MFS 169 (2.1) 181 (2.3) 350 (2.2)
DOI: 10.3310/hta21210 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 21
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chestnutt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
Table 27 further reports on the severity of caries experience on the FPMs, as represented by the number of
surfaces with caries into dentine as a proportion of the total number of surfaces affected. This shows the
severity of caries experience within the trial arms.
Ordinal regression modelling was undertaken on the number of FPM surfaces per child developing caries.
Those children with between 5 and 20 affected surfaces were combined into one group, owing to the
small numbers in these categories. As shown in Table 28, there was no statistically significant difference
between those receiving FS and those receiving FV, the model having been adjusted to account for the
number of surfaces with caries per child (OR 0.87, 95% CI 0.64 to 1.19; p = 0.385), the number of
decayed primary teeth at baseline and sex.
This means that there was no difference in the severity of the caries experience between the FS- and
FV-treated children.
Caries experience on occlusal and non-occlusal surfaces
Although there was no difference between arms in the proportion or the total number of tooth surfaces
affected by dentine caries, or in the severity of attack, it was necessary to check if there was a difference in
treatment effect by type of surface. Table 29 shows the distribution of caries-affected occlusal and non-occlusal
surfaces by trial arm. Although, overall, a significantly greater proportion of occlusal surfaces than smooth
surfaces had developed caries into dentine at 36 months (6.4% vs. 1.1%), it is clear that the proportion of
occlusal surfaces affected by dentine caries was remarkably similar in the FS and FV arms of the trial, at 6.5%
and 6.3%, respectively. Minimal differences between the intervention arms in the proportion of smooth
surfaces of FPMs developing caries were observed at 36 months (1.0% vs. 1.3%). A multilevel model that
accounted for quadrant and surface-level clustering, adjusted to account for caries prevalence in the primary
dentition at baseline, sex, surface type and surface by arm interactions, is reported in Table 30. As previously,
children with three or more affected primary teeth at baseline were significantly more likely to develop dentine
caries on a FPM by 36 months and, overall, there was a significant difference between the proportion of
occlusal surfaces developing dentine caries and the proportion of non-occlusal surfaces developing dentine
caries (OR 7.72, 95% CI 5.57 to 10.69). However, no significant difference was observed between the trial
arms for the main effect or for the interaction of arm with surface type, indicating no differential effect of
treatment on occlusal and non-occlusal surfaces.
TABLE 27 The number of FPM surfaces per participant developing dentine caries (D4–6MFS) at 36 months by
intervention arm
Intervention arm, n (%)
Total (N= 835), n (%)FS (N= 418) FV (N= 417)
D4–6MFS = 0 336 (80.4) 344 (82.5) 680 (81.4)
1 with caries 46 (11.0) 36 (8.6) 82 (9.8)
2 with caries 14 (3.3) 17 (4.1) 31 (3.7)
3 with caries 11 (2.6) 7 (1.7) 18 (2.2)
4 with caries 3 (0.7) 6 (1.4) 9 (1.1)
5 with caries 4 (1.0) 4 (1.0) 8 (1.0)
6 with caries 1 (0.2) 1 (0.2) 2 (0.2)
7 with caries 2 (0.5) 0 2 (0.2)
10 with caries 1 (0.2) 0 1 (0.1)
20 with caries 0 2 (0.5) 2 (0.2)
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Complier average causal effect analysis
In a trial such as that reported here, compliance with the intended treatment regimen is an important
consideration. Children participating in the trial were scheduled to be seen by the dental hygienist every
6 months, meaning a maximum of six times (at 0, 6, 12, 18, 24 and 30 months) during the course of the trial.
The number of treatment visits attended by each child who also underwent a final clinical examination at
36 months is shown in Table 31. It is apparent that fidelity in this trial was excellent, with in excess of 70% of
children attending all six treatment visits and 95% of children in the FS and FV arms of the trial attending at
least five treatment visits. The association of treatment visits and final outcome by trial arm is shown in Table 31.
From Table 31, it is clear that there was little association between the number of treatment visits and the
development of caries in either trial arm.
To determine the effects of adherence to the scheduled number of treatment visits, a CACE analysis was
carried out (Table 32). As FS was the standard treatment in the Designed to Smile programme prior to the
implementation of this trial, a CACE analysis was carried out, assuming FS as the ‘control’ with treatment
visits set to a constant (zero) and FV as the active treatment. In this way it can be established if the number
of FV treatment visits had any significant impact on the main treatment effect.
TABLE 29 The proportion of dentine caries, restored or extracted (D4–6MFS) at 36 months by occlusal and
non-occlusal surfaces by intervention arm
Status
Intervention arm, n/N (%)
Total (N= 16,016)FS (N= 8041) FV (N= 7975)
Caries on non-occlusal surface 64/6432 (1.0) 81/6380 (1.3) 145/12,812 (1.1)
Caries on occlusal surface 105/1609 (6.5) 100/1595 (6.3) 205/3204 (6.4)
TABLE 28 Ordinal regression analysis of the number of FPM surfaces with dentine caries (D4–6MFS) at 36 months by
trial arm
Unadjusted OR
(95% CI) p-value
Adjusteda OR
(95% CI) p-value
FS Reference Reference
FV 0.89 (0.65 to 1.22) 0.456 0.87 (0.64 to 1.19) 0.385
Threshold 0 to 1 11.38 (7.20 to 17.98) < 0.001
1 to 2 26.00 (15.93 to 42.42) < 0.001
2 to 3 46.43 (27.37 to 78.75) < 0.001
3 to 4 82.56 (45.76 to 148.94) < 0.001
4 to 5 133.16 (63.37 to 259.34) < 0.001
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.54 (0.83 to 2.82) 0.166
≥ 3 primary teeth with caries into dentine 4.05 (2.58 to 6.34) < 0.001
Sex
Female Reference
Male 1.05 (0.76 to 1.43) 0.782
a FV compared with FS. Analysis adjusted for baseline caries risk group, sex and number of FPMs in the trial.
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The coefficient for the number of treatment visits for FV was non-significant, indicating that increasing the
number of visits does not have an impact on the proportion of children experiencing caries on their FPMs.
The efficacy per visit was –0.005, indicating only a small decrease in the proportion of children with caries
on any FPM for additional FV visits. This small effect is attributable to the high proportion of children
attending at least five visits out of a maximum of six.
From this, it is concluded that adherence to the treatment protocol was not an influencing factor in the
results obtained at 36 months.
TABLE 31 The association of treatment visits and the primary outcome (D4–6MFT) on any FPM by intervention arm
Treatment visits
Intervention arm, n (%)
FS FV
No FPM with
D4–6MFT (N= 336)
At least one FPM with
D4–6MFT (N= 82)
No FPM with
D4–6MFT (N= 344)
At least one FPM with
D4–6MFT (N= 73)
1 1 (0.3) 0 (0) 0 0
2 0 0 0 1 (1.4)
3 1 (0.3) 1 (1.4) 4 (1.2) 0
4 13 (3.9) 3 (3.7) 11 (3.2) 4 (5.5)
5 75 (22.3) 17 (20.7) 80 (23.3) 16 (21.9)
6 246 (73.2) 61 (74.4) 249 (72.4) 52 (71.2)
TABLE 30 Two-level multilevel model of surfaces within quadrant within child for FPM dentine caries (D4–6MFT)
including interaction with surface type
Adjusteda OR (95% CI) p-value
FS Reference
FV 1.25 (0.89 to 1.77) 0.202
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.42 (0.86 to 2.36) 0.174
≥ 3 primary teeth with caries into dentine 6.96 (4.85 to 9.98) < 0.001
Sex
Female Reference
Male 1.38 (1.10 to 1.76) 0.007
Surface type
Non-occlusal Reference
Occlusal 7.72 (5.57 to 10.69) < 0.001
Surface by arm interaction Reference
(FV × occlusal surface) 0.75 (0.48 to 1.18) 0.217
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
ICC for quadrant= 0.213 and ICC for surface = 0.075.
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Adherence to the prespecified treatment window
The study protocol dictated that treatment visits should be scheduled within a 4-week window either side
of the due 6-month treatment schedule. Adherence to this schedule is shown in Table 33. Overall, 71.6%
of treatments were within the treatment window throughout the trial, and a further 26.1% were outside
the schedule on only one occasion, a further indicator of the fidelity of the trial.
To test for the effect of adherence to the treatment window, a binary indicator was added to the primary
model that categorised the participants as having received all of their treatment visits within the time window
stated in the study protocol or having had at least one visit outside the treatment window. The likelihood of
developing D4–6MFT on any FPM was lower for those who received at least one treatment outside the study
treatment window (OR 0.66, 0.43 to 1.00; p = 0.052). Although this effect was of borderline significance, the
main effect of FS versus FV remained unchanged compared with the primary analysis (Table 34).
This demonstrates that any deviation from the scheduled treatment window did not impact on the overall
results of the trial.
TABLE 32 Complier average causal effect analysis
Efficacy coefficient (95% CI) p-value
Number of FV treatment visits –0.005 (–0.014 to 0.004) 0.303
OR (95% CI) p-value
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.37 (0.97 to 1.10) 0.310
≥ 3 primary teeth with caries into dentine 1.22 (1.16 to 1.30) < 0.001
Sex
Female Reference
Male 1.00 (0.95 to 1.05) 0.961
TABLE 33 The proportion of children with treatments outside the specified treatment window by intervention arm
Number of treatments outside window
Intervention arm, n (%)
Total (N= 835), n (%)FS (N= 418) FV (N= 417)
0 302 (72.2) 296 (71.0) 598 (71.6)
1 106 (25.4) 112 (26.9) 218 (26.1)
2 7 (1.7) 5 (1.2) 12 (1.4)
3 1 (0.2) 3 (0.7) 4 (0.5)
4 2 (0.5) 0 2 (0.2)
5 0 1 (0.2) 1 (0.1)
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The effect of including enamel caries on trial outcome
The analysis reported in Complier average causal effect analysis at the D4–6MFT level is in line with
conventional reporting of dental clinical trials. In this study, dental caries was recorded using the ICDAS.26
This index includes the recording of enamel caries. This section reports the effects of including enamel
caries in the trial outcome data.
Table 35 shows the proportion of children developing enamel and dentine caries at the D1–6MFT level at
36 months. The proportion of children who developed dental caries was higher in the FS arm (77.3%)
than in the FV arm (67.6%). Adjusting for the number of decayed primary teeth at baseline and sex,
a significant treatment effect between arms was apparent (Table 36). The OR for developing caries when
enamel caries was included in the outcome measure was significant (OR 0.56, 95% CI 0.41 to 0.78),
indicating a possible protective effect of FV for enamel caries lesions. This suggests that, although there
was no difference between the trial arms in terms of caries into dentine prevented, the same does not
hold true when enamel caries is included in the outcome measure. A significantly greater proportion of
children did not develop either dentine or enamel caries on any FPM included in the trial when treated
with FV (32.4% vs. 22.7%).
The consequences of including enamel caries were further explored to examine the effect by occlusal versus
non-occlusal surfaces. In the FS arm of the trial, 6.7% of non-occlusal surfaces developed caries at the
D1–6MFS level, compared with 5.6% in the FV arm. On occlusal surfaces, the figures for the development of
either enamel or dentine caries were 39.2% and 40.5% in the case of FS and FV, respectively (Table 37).
TABLE 34 The effect of treatment window on the development of D4–6MFT on any FPM at 36 months
Adjusteda OR (95% CI) p-value
FS Reference
FV 0.84 (0.58 to 1.21) 0.341
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 1.61 (0.84 to 3.06) 0.140
≥ 3 primary teeth with caries into dentine 4.61 (2.85 to 7.45) < 0.001
Sex
Female Reference
Male 1.05 (0.73 to 1.50) 0.811
All treatment within window Reference
At least one outside window 0.66 (0.43 to 1.00) 0.052
a Adjusted for sex and baseline caries risk group.
TABLE 35 The proportion of children with (D1–6MFT) on any FPM in the trial, at 36 months by trial arm
Intervention arm, n (%)
Total (N= 835), n (%)FS (N= 418) FV (N= 417)
No caries on any FPM 95 (22.7) 135 (32.4) 230 (27.5)
Caries at D1–6MFT level on at least one FPM 323 (77.3) 282 (67.6) 605 (72.5)
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A multilevel model confirmed a statistically significant difference in favour of the FV-treated surfaces. The clinical
significance of this finding is unclear. It possibly shows FV to be protective for early-phase caries compared with
FS (Table 38). However, this does not translate into a protective effect for dentine caries compared with FS.
To further explore the effect of including enamel caries, analyses were conducted for enamel and dentine
caries at the D2–6MFT and D3–6MFT levels. Using both of these caries levels as the cut-off point for
determining the clinical outcome, children in the FV arm were significantly less likely to develop caries
experience on at least one FPM than those in the FS group: D2–6MFT (OR 0.65, 95% CI 0.49 to 0.88) and
D3–6MFT (OR 0.66, 95% CI 0.48 to 0.90).
Whole-mouth caries experience at 36 months
Although the caries-preventative effect of FS is limited to the occlusal surface of the treated tooth, it is
possible that, by elevating the general intraoral fluoride concentration, there may be a ‘wash-over’ effect
as a result of applying FV to the FPMs. To examine this possible difference between the treatments, the
caries increment on all permanent teeth present at the 36-month assessment was examined.
Table 39 shows the proportion of children with caries (D4–6MFT) on any permanent tooth at 36 months.
To examine the difference in the number of affected teeth, Poisson and binomial distribution modelling were
carried out. Furthermore, to account for the excess of non-affected individuals, zero inflated models were
conducted to improve model fit. The results are shown in Table 40. No significant differences were observed
between intervention arms. This means that no wash-over effect was observed. A similar analysis was carried
out on the D4–6MFS scores. No significant difference was observed between FS- and FV-treated children.
TABLE 37 The proportion of caries experience D1–6MFS at 36 months by occlusal and non-occlusal surfaces by
intervention arm
Intervention arm, n/N (%)
Total (N= 16,016), n/N (%)FS (N= 8041) FV (N= 7975)
Caries on non-occlusal surface 429/6432 (6.7) 360/6380 (5.6) 789/12812 (6.2)
Caries on occlusal surface 631/1609 (39.2) 646/1595 (40.5) 1277/3204 (39.9)
TABLE 36 The proportion of children with (D1–6MFT) on any FPM in the trial by intervention arm at 36 months
Unadjusted OR
(95% CI) p-value
Adjusteda OR
(95% CI) p-value
FS Reference Reference
FV 0.61 (0.45 to 0.84) 0.002 0.56 (0.41 to 0.78) 0.001
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 2.37 (1.54 to 3.64) < 0.001
≥ 3 primary teeth with caries into dentine 5.12 (3.54 to 7.40) < 0.001
Sex
Female Reference
Male 0.81 (0.58 to 1.11) 0.187
a FV compared with FS. Analysis adjusted for number of decayed primary teeth at baseline and sex.
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TABLE 39 The total number of permanent teeth affected by D4–6MFT by intervention arm
Number of permanent teeth with D4–6MFT
Intervention arm, n (%)
FS (N= 418) FV (N= 417)
0 326 (78.0) 334 (80.1)
1 56 (13.4) 42 (10.1)
2 27 (6.5) 26 (6.2)
3 5 (1.2) 11 (2.6)
4 3 (0.7) 4 (1.0)
6 1 (0.2) 0
TABLE 38 Multilevel model of surfaces within quadrant within child caries experience D1–6MFS at 36 months
including interaction with surface type
Adjusteda OR (95% CI) p-value
FS Reference
FV 0.80 (0.68 to 0.93) 0.004
Baseline caries
Primary dentition free of caries into dentine Reference
1–2 primary teeth with caries into dentine 2.00 (1.69 to 2.36) < 0.001
≥ 3 primary teeth with caries into dentine 4.37 (3.82 to 4.99) < 0.001
Sex
Female Reference
Male 0.92 (0.83 to 1.03) 0.148
Surface type
Non-occlusal Reference
Occlusal 19.44 (5.78 to 65.43) < 0.001
Surface by arm interaction Reference
(Varnish × occlusal surface) 1.29 (1.04 to 1.60) 0.019
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
ICC for quadrant= 0 and ICC for surface= 0.268.
TABLE 40 Analysis of the impact of FS and FV on all permanent teeth at 36 months
Adjusteda incidence rate ratio (95% CI) p-value Akaike information criterion
Poisson 0.94 (0.74 to 1.20) 0.624 1171
Negative binomial 0.93 (0.82 to 1.46) 0.549 1104
Zero inflated Poisson 1.01 (0.76 to 1.35) 0.920 1091
Zero inflated negative binomial 1.01 (0.75 to 1.35) 0.924 1093
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
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The effect of trial interventions at 12 and 24 months
All of the analyses reported above relate to the clinical outcome at 36 months, the a priori time period
agreed for the determination of the primary clinical outcome. Although no significant difference was
observed between FS and FV at 36 months, the question arises as to whether the outcome would have
been different had the trial terminated at 12 or 24 months.
At the 12-month examination, 36 (8%) children who had received FS experienced dental decay in at least
one FPM at the D4–6MFT level, compared with 37 (8.3%) of those treated with FV. By 24 months, the
numbers similarly affected had increased to 61 (13.9%) and 63 (14.9%) in the FS and FV arms of the trial,
respectively (Table 41).
A repeated measures analysis was carried out using the proportion of children experiencing caries D4–6MFT
on any FPM at 12, 24 and 36 months. Although the proportion of children experiencing caries was
significantly higher at 24 months than at 12 months and at 36 months than at 12 months, there were no
significant differential effects of treatment by time, and the interaction effect was dropped from the model
(Table 42).
It can, therefore, be concluded that there was no statistically significant difference between the treatments
under investigation at any of the annual examinations.
Sealant retention
The effectiveness of FS is influenced by retention,40 and complete sealants are known to be more effective
than partial sealants.41
TABLE 41 The proportion of children with caries (D4–6MFT) on any treated FPM in the trial at each annual
examination by intervention arm
Time point (months), n (%)
12 24 36
FS (N= 450) FV (N= 444) FS (N= 439) FV (N= 424) FS (N= 418) FV (N= 417)
No caries on any FPM 414 (92.0) 407 (91.7) 378 (86.1) 361 (85.1) 336 (80.4) 344 (82.5)
Caries on at least one FPM 36 (8.0) 37 (8.3) 61 (13.9) 63 (14.9) 82 (19.6) 73 (17.5)
TABLE 42 A repeated measures logistic regression of the proportion of children with caries (D4–6MFT) on any
treated FPM
Treatment effect
(sealant is reference)
Examination (time point, months) (12 months
is reference)
24 36
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Proportion with caries at ICDAS 4–6 0.96
(0.76 to 1.21)
0.878 1.92
(1.41 to 2.62)
< 0.001 2.64
(1.95 to 3.56)
< 0.001
Model is adjusted for sex and baseline caries risk.
DOI: 10.3310/hta21210 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 21
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chestnutt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
In this trial, children were examined at 6-month intervals and any deficient sealants were repaired. Policy
was to seal teeth as soon as sufficient tooth surface had erupted, so, particularly in the case of upper
molars, teeth were on occasion sealed over two visits as the tooth erupted. The status of the sealants as
recorded by the dental hygienists is shown in Table 43.
TABLE 43 Sealant status at each treatment visit
Time point (months), n (%)
6 12 18 24 30
UR intact 198 (44.7) 269 (68.3) 298 (76.4) 300 (76.7) 275 (74.5)
Partial 111 (25.1) 70 (17.8) 72 (18.5) 78 (19.9) 86 (23.3)
Lost 2 (0.5) 5 (1.3) 2 (0.5) 7 (1.8) 2 (0.5)
Tooth unerupted 40 (9.0) 7 (1.8) 3 (0.8) 2 (0.5) 1 (0.3)
Tooth extracted 0 0 0 0 0
Tooth previously unerupted 92 (20.8) 43 (10.9) 16 (4.1) 4 (1.0) 5 (1.4)
N 443 394 391 391 369
Missing 9 6 1
UL intact 172 (40.2) 259 (64.3) 298 (74.5) 285 (72.5) 275 (73.7)
Partial 130 (30.4) 90 (22.3) 82 (20.5) 93 (23.7) 84 (22.5)
Lost 4 (0.9) 10 (2.5) 5 (1.2) 10 (2.5) 9 (2.4)
Tooth unerupted 22 (5.1) 6 (1.5) 0 1 (0.3) 1 (0.3)
Tooth extracted 0 0 0 0 1 (0.3)
Tooth previously unerupted 100 (23.4) 38 (9.4) 15 (3.8) 4 (1.0) 3 (0.8)
N 428 403 398 393 373
Missing 2 7 5 2 2
LR intact 274 (62.3) 311 (78.1) 339 (85.8) 350 (88.4) 324 (88.0)
Partial 33 (7.5) 22 (5.5) 23 (5.8) 20 (5.1) 32 (8.7)
Lost 1 (0.2) 1 (0.3) 2 (0.5) 5 (1.3) 2 (0.5)
Tooth unerupted 41 (9.3) 16 (4.0) 10 (2.5) 3 (0.8) 2 (0.5)
Tooth extracted 0 0 0 0 0
Tooth previously unerupted 91 (20.7) 48 (12.1) 21 (5.3) 18 (4.5) 8 (2.2)
N 440 398 395 396 368
Missing 6 7 1 3
LL intact 262 (59.4) 314 (78.1) 346 (87.2) 347 (87.8) 340 (91.4)
Partial 30 (6.8) 24 (6.0) 17 (4.3) 28 (7.1) 19 (5.1)
Lost 4 (0.9) 2 (0.5) 2 (0.5) 4 (1.0) 3 (0.8)
Tooth unerupted 32 (7.3) 16 (4.0) 9 (2.3) 5 (1.3) 2 (0.5)
Tooth extracted 0 0 0 0 0
Tooth previously unerupted 113 (25.6) 46 (11.4) 23 (5.8) 11 (2.8) 8 (2.2)
N 441 402 397 395 372
Missing 8 8 4 2
LL, lower left; LR, lower right; UL, upper left; UR, upper right.
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Examiner reproducibility
The kappa statistics for agreement with the gold standard examiner are shown in Table 44. Based on
Landis and Koch,42 all of the examiners show substantial agreement (0.69–0.8) or excellent agreement
(0.81–1) throughout the study. Calibration was at the d/D0–3:d/D4–6 level.
To determine intra-examiner reproducibility, 5% of participants were re-examined. The resultant kappa
values (DMFT sound surfaces excluded) are shown in Table 45.
Treatment time
The time taken to provide the FS and FV treatments, recorded as time spent in the dental chair by each
child at the baseline and 30-month examinations, is recorded in Table 46.
At baseline, the mean treatment time was higher for the FS arm than for the FV arm, whereas at 30 months
the mean treatment time was slightly lower for the FS arm. This is because, as the trial progressed, fewer
FSs needed to be placed in the FS arm, although some time was needed to repair FS when deficient. At
baseline, 1301 FSs were placed, whereas at 12 months only 313 top-up treatments were performed. By
24 months, the number of top-up treatments had dropped to 178, and this dropped further to 130 at the
30-month time point, which was the final treatment.
Data were transformed using a natural log for regression analyses and, hence, effects are interpreted as
percentage difference between arms.
TABLE 44 Calibration (inter-examiner reproducibility)
Assessment
Examiner
1 2 3 4 5 6
2011 0.754 0.819 0.749
2012 0.830 0.883 0.914
2013 0.754 0.915 0.768
2014 0.938 0.801 0.690
2015 0.931 0.740
TABLE 45 Intra-examiner reproducibility
Assessment
Examiner
1 2 3 4 5 6
2011 0.929 0.908 0.818
2012 0.939 0.928 0.657
2013 0.925 0.946 0.909
2014 0.8500 0.960 0.830
2015 0.972
DOI: 10.3310/hta21210 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 21
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chestnutt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
At both time points, the addition of school as a level in a two-level regression (model 1) does not change
the effect compared with the single-level model (model 2). At baseline, times were significantly lower in
the FV arm, but at 30 months the difference was in the opposite direction (Table 47). These findings are in
line with clinical expectations. At baseline, it takes much longer to place the FS because of the more
involved clinical nature of the procedure, compared with the less complex method of FV placement.
Adverse effects
Throughout the trial adverse effects either during treatment or in the period thereafter were recorded as
described in Chapter 2. For the entire duration of the trial, no adverse effects were reported.
Summary
This chapter has reported the clinical findings of the trial. The main findings are as follows.
l Children were recruited to the trial in two cohorts over successive school years and followed for
36 months. Of the 514 and 502 children randomised to the FS and FV treatments, respectively, 418 and
417 remained at 36 months [more than the 313 required per trial arm, as detailed in the power calculation
(see Chapter 2)]. The majority of those not completing the trial moved to a non-participating school.
l There were no significant differences in participant characteristics between trial arms at baseline in those
randomised, those who withdrew or were lost to follow-up and in those who completed the trial.
l The OR of developing caries in the FV arm compared with the FS arm was 0.87 (95% CI 0.61 to 1.23) in
the unadjusted model, that is, the proportion of children who received FV who were likely to develop
caries into dentine was lower than the proportion of those developing dentine caries in the FS arm, but
this difference was not statistically significant. As sex and baseline caries risk group were used to balance
the randomisation, an adjusted model was also performed and was taken as the primary analysis. The OR
for developing caries in the FV arm was 0.84 (95% CI 0.59 to 1.21) in the adjusted model.
TABLE 47 Linear regression of treatment time at baseline and 30 months
Effect (percentage difference) (95% CI) p-value ICC
Baseline, model 1 0.37 (0.36 to 0.39) < 0.001 0.142
Baseline, model 2 0.37 (0.35 to 0.39) < 0.001 n/a
30 months, model 1 1.66 (1.52 to 1.80) < 0.001 0.117
30 months, model 2 1.64 (1.50 to 1.79) < 0.001 n/a
n/a, not applicable.
TABLE 46 Mean treatment time (seconds) for FS and FV at baseline and 30 months
Intervention arm
OverallFS FV
n Mean (SD) n Mean (SD) n Mean (SD)
Baseline 467 533.0 (189.90) 463 190.5 (57.68) 930 362.5 (221.58)
30 months 424 130.0 (119.75) 418 151.1 (46.38) 842 140.5 (91.60)
SD, standard deviation.
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l Adjusting for baseline caries experience in the primary dentition, school attended (size and deprivation
score) did not affect the primary outcome of the trial.
l None of the covariates examined (fluoride use, oral hygiene regime, diet or deprivation) made any
difference to the primary outcome of no significant difference between trial arms.
l A subsequent analysis examining differences between intervention arms at tooth level did not show
any difference in the number of teeth developing decay into dentine between the arms of the trial.
l Examining the outcome at tooth-surface level showed that, although a significantly greater proportion
of caries experience occurred on occlusal surfaces, there were no significant differences by trial arm.
l Fidelity in the trial was excellent, with 95% of the children receiving treatment at five or six of the six
scheduled treatment sessions over the 36 months. Overall, 71.6% of treatments were within the
treatment window throughout the trial, and a further 26.1% were outside the schedule on only
one occasion.
l As per the trial protocol, and in line with convention, decay into dentine, as a cavity, restoration or
tooth extracted because of caries, was taken as the caries level for the primary reported outcome.
As the ICDAS was used to record caries, the effect of including enamel caries in the analysis was also
determined. This resulted in the only analysis to suggest a significant difference between trial arms.
The percentage of children in the FV arm of the study who developed decay at the D1–6MFT level was
67.6%, compared with 77.3% of FS-treated children (adjusted OR 0.56, 95% CI 0.41 to 0.78).
l There was no evidence of any ‘wash-over’ effect on caries prevention in those treated with FV.
l There were no significant differences in caries outcome between trial intervention arms at the 12- or
24-month time points.
Chapter 4 reports on the economic aspects of the trial.
DOI: 10.3310/hta21210 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 21
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chestnutt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49

Chapter 4 Health economic evaluation: methods
and results
Introduction
The recently updated Cochrane review16 highlighted the scarcity and clinical diversity of data, making it
difficult to draw clear conclusions on the effectiveness of FS versus FV in preventing dental caries. This
review did not undertake a review of the relative cost-effectiveness of these two technologies and neither
could any comparable economic evaluations be found in a rapid review of the health economics literature
conducted as part of the health economic analysis plan. This chapter reports on the methods and results
of the economic evaluation conducted alongside the trial. The objectives were to establish the:
l costs and budget impact of FS and FV delivered in a community/school setting
l relative cost-effectiveness of these technologies.
Health economic methods for the within-trial analysis
Assessment of costs
Costs were considered from the perspective of the NHS (i.e. direct health-care costs associated with the
interventions) and from a partial societal perspective that considered the costs to the family and school
(education sector).
The intervention costs were obtained from discussion with the trial team and MDC staff and from data
collected as part of the trial case report forms. Research costs (such as the costs of the calibration training
or costs of storing the technologies to be compliant with MHRA guidelines) were not included. With the
technologies for both interventions being delivered in an established MDC, the costs of the clinic in the
base case (e.g. costs of the van, running costs or equipment costs) were not included, as these are
equivalent. However, to illustrate the costs associated with the delivery of the technologies within a MDC
setting, we reported a separate cost with the MDC included.
The main intervention costs were (1) acquisition costs for FS and FV and (2) costs associated with the
delivery of the technologies (including the clinical assessments). The costs of the FS and FV were taken
from the trial protocol, that is, it was assumed that a standard dosage was applied to all trial participants
and, when required, the costs of any reapplication were also calculated when they were recorded. The
costs of delivery were calculated from ‘time in chair’ information contained within the case report form for
each participant visit. The skill mix and grade of staff involved in the visit were obtained from the clinical
staff providing the interventions. In addition, any specific materials or equipment used in the application
of the FS or FV were obtained from the clinical staff. These costs were aggregated and an average
intervention cost per participant in each trial arm was calculated (Table 48).
Information about the other health-care visits associated with dental-related problems for each trial
participant was obtained from a parent resource utilisation questionnaire (the DHQ; see Appendix 13).
This captured information on dental health-care visits (e.g. to the family dentist), other health-care
contacts (e.g. general practitioner or hospital) as a result of dental health problems and any prescriptions
(e.g. painkillers or antibiotics) for dental health problems. As it would have been implausible to ask the
parent/carer precise information about which tooth was affected, information was collected from the
parent/carer on all dental health visits and events related to his or her child. The DHQ was completed by
the main parent/carer at baseline and at 12, 24 and 36 months.
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Additional costs incurred by the family were also captured in the DHQ. This included any travel time and
time off work/other activities associated with a health-care contact. The cost of caring for the child was
also considered as a result of a dental health problem (e.g. day off work to care for the child). The main
parent/carer was asked to estimate the time the child had off school as a result of a dental health problem.
Cost associated with travel time (using published government mileage rates) and time off work to attend
health-care appointments with the child or the time taken to care for a child off school was calculated
using a human capital approach. The value of work as well as leisure time was estimated by applying
hourly rates, according to the parents’ professions, to the time expended because of dental health
problems during the trial period. Hourly rates of household/domestic help were used to cost the time of
unemployed parents.
To capture the costs to the school, a series of questions were given to the head teacher as part of the
process evaluation. These questions asked the head teacher to estimate the time the child had away from
school activities in order to receive the interventions, any time required by the teacher or other support
staff (e.g. to settle a child back into the classroom) and any other costs incurred by the school to support
(e.g. administration time).
Prior to commencement of the trial, the DHQ, alongside the CHU-9D, was piloted for comprehensiveness,
ease of completion, recall and accuracy in a primary school in South Wales, which was not included in the
trial, with a similar sociodemographic to the trial population. A protocol was developed (available from the
chapter author on request), with ethics approval given by Swansea University School of Human and Health
Sciences prior to the pilot evaluation. Of 30 children who were given a pack to take home, six responses
were obtained (20% response rate). All parents completed a postal questionnaire, with all responses
indicating that their child had no difficulties understanding or completing the CHU-9D. In addition, the PPI
representative on the TSC reviewed both questionnaires to check for readability and comprehension.
When possible, unit costs for the UK were applied [e.g. Personal and Social Services Research Unit,44
British National Formulary (BNF),45 NHS reference costs46] to increase generalisability. However, to ensure
that the skill mix of the MDC was fully considered in the analysis, local salary scales from NHS Wales47 were
obtained, and these were fully agreed with the trial team prior to analysis. These are reported in Table 48.
A summary of the other resource items, unit costs and sources is given in Table 49.
TABLE 48 Summary of intervention resource, unit costs and source
Basis of estimate Unit cost (£) Per hour (£) Data sources
Dentistry staff band 3 × 1 – 9.20 NHS Staff Agenda for Change43
Dentistry staff band 4 × 1 – 10.58 NHS Staff Agenda for Change43
Dentistry staff band 5 × 0.65 – 12.62 NHS Staff Agenda for Change43
Administration staff (band 3) × 1 – 9.20 NHS Staff Agenda for Change43
Administration staff (band 4) × 1 – 10.58 NHS Staff Agenda for Change43
FV (Duraphat) 2.00 – Dental suppliera
Sealant (Delton) 2.50 – Dental suppliera
Clinical disposables (e.g. gloves, cotton wool, bib, etc.) 2.50 – Dental suppliera
Sterilisation costs 1.75 – Cardiff and Vale UHBb
a www.henryschein.co.uk (accessed in March 2016).
b www.cardiffandvaleuhb.wales.nhs.uk/home (accessed in March 2016).
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The intervention costs and health-care utilisation costs were summated to give the total cost per
participant for each arm (NHS costs), with the wider costs to the family and school reported separately
(see Table 54).
Valuation of costs
All data were valued in monetary terms (£), and the price year of 2015 was applied to costs (representing
the end point of the trial). As follow-up was beyond 12 months, discounting of 3.5% was applied, in line
with the National Institute for Health and Care Excellence (NICE) reference case for health technologies57
for the base-case costs. All costs were summarised into the different cost categories, with means and
standard deviations (SDs) produced. A total cost (means and 95% CIs) was calculated for each trial arm,
with differences reported using a Levene’s test for equality t-test and with statistical significance accepted
at the 5% level. When missing data existed, a simple weighted average cost based on known cost histories
based on accepted methods was used.49
To take into account the possible impact of skewness in cost data, the distribution of costs for normality
were examined, as was the impact of removing extreme outliers from the analysis. When required,
the sensitivity of the results was checked by considering appropriate transformation.50
Outcomes used in the health economic analysis
Caries avoided
The data from the main trial were used to calculate the percentage of dentine caries (D4–6MFT) avoided at
36 months.
Quality-adjusted life-years using the Child Health Utility Index 9D
The CHU-9D is a child-specific generic preference-based measure of HRQoL. It consists of a descriptive
system of nine questions and a set of preference weights based on five levels with a recall period of
today/last night. The CHU-9D allows the generation of utility values for each health state to enable the
calculation of QALYs.51,52
The CHU-9D was originally intended for use in a population aged 7–11 years. Prior to commencement of
the trial, the original developer (Dr Katherine Stevens) was contacted to discuss whether or not it could be
used in a younger age group, and there were no major concerns with regard to the trial’s slightly younger
age group. The trial team were mindful of the trial population and the potential variance in ability to
self-complete the CHU-9D. The CHU-9D was piloted in a non-participating school in South Wales, with a
debriefing interview completed by the parent/carer to assess any problems in its use. No issues were
identified. Since the commencement of the trial, further studies have reported the use of the CHU-9D in a
comparable age group to the trial population at study entry.53,54
TABLE 49 Summary of other resource items, unit costs and sources
Health service resource utilisation Unit cost (£) Source
Dentist 110 Average weighted NHS Reference
Cost 2014/15,46 M01a-3b
Socioeconomic classification wages per hour Various Office for National Statistics, 201548
Cost to schools attributed to absence Various GOV.uka
Medicines Various BNF, 201545
a www.gov.uk/school-attendance-absence/overview (accessed on 1 June 2015).
DOI: 10.3310/hta21210 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 21
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chestnutt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
The CHU-9D was delivered to the child’s home address with instructions given to complete at 12, 24 and
36 months. The instruction given was that either the child should self-complete or that the parent/carer
would read the questions aloud to the child who would give his or her response. Owing to the practicalities
of the trial, it was deemed unfeasible to collect the CHU-9D from the child, for example in school. Thus, the
administration of the CHU-9D in this context may have resulted in under-/over-estimation of QoL, as it was
not possible to verify whether or not this had been reported by the child himself/herself. However, this is
expected to be similar across both study arms. The CHU-9D scores were computed for each time point and
the QALY was calculated to obtain the difference in QALYs between the two trial arms at 36 months. In
accordance with good practice, appropriate methods were explored to take into account missing data on
the CHU-9D and subsequent QALY calculation.
Quality-adjusted tooth-year
Published utilities and clinical data used to derive the tooth-year were derived in order to generate a
QATY. A QATY will estimate the production of additional years of life (tooth-year) of each tooth adjusted
for the quality of that tooth. An unrestored tooth has a QATY of 1 in the year it was restoration free,
although a restored, crowned or root canal-treated tooth has a QATY of less than perfect (i.e. less than 1)
in the year that it was restored and in subsequent years. The QATY for an extracted tooth is equal to 0 in
that year and subsequent years.
Although the QATY is seen as potentially useful in providing a more dental-specific analogy to the QALY,
it has had limited use within the literature because of the limitations of being compared across different
interventions and the lack of robust methodological work in deriving suitable utilities in order to populate
the ‘Q’ element of the QATY. Owing to the lack of resources to undertake necessary methodological work
to derive precise estimates of dental-specific utilities in children, this was intended to be an exploratory
analysis only. Thus, only a one-way sensitivity analysis was undertaken.
The trial data were used to provide a series of health states associated with the tooth state of the four
index teeth in the trial, based on the caries status. Published utilities were assigned from the published
utilities from the Fyffe and Kay55 study and from an economic analysis on the cost-effectiveness of oral
health programmes56 and were agreed with the trial team (Table 50).
A combined ‘FPM utility’ from the scores using the mean of the four tooth state utilities is as follows:
∑4i=1
Ui
n
. (1)
TABLE 50 Quality-adjusted tooth-year tooth utility reasoning
State Utility Comments
Sound tooth or sound and sealed
tooth (completely caries free)
1 As per Fyfe and Kay55
Unerupted tooth 1 As per Fyfe and Kay55
Tooth with enamel caries (D1–3)
either sealed or unsealed
0.95 A tooth in this condition can be ‘healed’ or the lesion stopped
from progressing, so although in the early disease stages and not
as desirable as a totally sound tooth, this state is more desirable
than a filled tooth. Fyfe and Kay have no utility for this state
Filled tooth (FT) 0.90 As per Fyfe and Kay55
Tooth with dentine caries (D4–6) 0.81 D4–6 is the equivalent to Fyfe and Kay’s
55 decayed and non-painful
posterior tooth
Extracted tooth 0 As per Fyfe and Kay55
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Analysis
Within-trial analysis
A series of incremental cost-effectiveness analyses were planned: (1) an incremental cost per caries avoided
at 36 months and (2) an incremental cost per QALY (cost–utility). As part of a secondary analysis, costs and
QATYs were examined. If one technology was both more effective and less costly, it would be considered
to dominate the other technology and, as such, an ICER would not be reported. When there was no such
dominance, an ICER would be calculated.
Univariate sensitivity analyses for all ICERs were recalculated after changing the value of a range of
parameters individually to examine the uncertainty around the ICER (Table 51).
A probabilistic sensitivity analysis undertaken for the cost–utility analysis (CUA), with changes to the
values of all chosen parameters (usually within the 95% CI or a reasonable, defined range), calculated
the probability that the intervention was cost-effective in accordance with commonly accepted norms
(£20,000–30,000 per incremental QALY gained).57 Uncertainty associated with the individual parameters
was considered.
Bootstrapping was used to construct data sets of the same trial population size by sampling at random
with replacement over 1000 times. Cost-effectiveness acceptability curves (CEACs) were produced.
TABLE 51 Parameters assessed in the univariate sensitivity analysis
Parameter
Intervention arm (£)
Analysis Justification/source
FS FV
Base
case
Lower
range
Upper
range
Base
case
Lower
range
Upper
range
Costs (£)
Staff costs of delivering
the technology
74.12 51.88 96.36 64.16 44.91 83.41 BI ± 30% from trial data
One-off application of FS 14.24 9.97 18.51 – – – BI ± 30% from trial data
FV application in school
by dental hygienist
– – – 11.48 8.04 14.92 BI ± 30% from trial data
Delivery within school
with MDC
95.73 67.01 124.45 86.33 60.43 112.23 BI ± 30% from trial data
Health-care resource
usage for dental health
problems (95% CI)
–68.13 (–5.63 to –130.63) ICER Based on 95% CIs
from trial data
Clinical effects
Caries avoided (95% CI) 0.021 (–0.0317 to 0.0738) ICER Based on 95% CIs
from trial data
Health outcomes
Changes in QALY
estimates (95% CI)
0.002 (–0.010 to 0.005) ICER Based on 95% CIs
from trial data
Changes in QATY
estimates (95% CI)
0.007 (–0.068 to 0.011) ICER Based on 95% CIs
from trial data
BI, budget impact.
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Budget impact analysis
A budget impact analysis to compare the costs to the NHS of FS versus FV was undertaken using the
estimations of costs of the two interventions derived from the trial. The total budget impact for all patients
within the trial population was calculated and examined the potential cost saving on a per-patient basis
based on being treated with FS versus FV within the current intervention mix (based on the MDC). The
impact to NHS budgets was estimated at 3 years. No discounting was applied to the budget impact analysis.
Model-based analysis
Deterministic sensitivity analyses were conducted to estimate the worst- and best-case scenarios of the budget
impact of FS versus FV by using the lower and upper costs derived from the trial. The different scenarios that
could impact on NHS budgets were (1) the cost of the intervention using a best-case/worst-case scenario;
(2) the inclusion of the costs of the MDC; (3) the delivery of FV by a community dental nurse in a ‘classroom’
setting (i.e. not requiring a MDC but reflecting the potential for this technology to be delivered in a single
application with minimal equipment/resources); and (4) the application of FV by a dental hygienist alone
within a classroom/school medical room setting).
To assess the longer-term cost-effectiveness of FS versus FV in preventing dental caries in children,
post-trial modelling was undertaken. As no suitable model could be identified from the literature search
for adaptation, a de novo decision-analytic model was constructed. A UK NHS and Personal Social Services
perspective was adopted in the analysis, in line with NICE methodological recommendations.57 In the base
case, costs and benefits were discounted at a rate of 3.5%.
Model structure
A Markov cohort simulation model, written in Microsoft Excel® 2013, version 15 (Microsoft Corporation,
Redmond, WA, USA), was developed, with a 3-month time cycle employed in order to reflect an appropriate
time point for caries progression to occur. Half-cycle corrections were applied. The time horizon of 5 and
10 years was chosen as sufficient to reflect potential changes in the change of progression of dental caries
as a result of FS and FV in children up until the onset of adulthood. Although a lifetime horizon was
considered, the lack of suitable evidence to make plausible assumptions about the longer-term effects of FS
and FV resulted in an amendment to the original protocol plan. This was agreed with the trial team.
For FS and FV utilisation, Markov modelling allows for the construction of an arbitrary complex chain of
events that represents the natural history of sealant retention, caries formation and their associated health
states.58 A sealed tooth may lose its seal and remain sound, may be resealed or may transition to caries.
Caries may be restored. A restored tooth may develop further caries and this may finally lead to the tooth
being lost. Varnished teeth represented the second intervention arm. A varnished tooth may develop
caries, after which the pathway is the same as that for a tooth that develops caries after losing its seal.
A lost/removed tooth was the absorbing state in the model.
A model structure was developed outlining the disease pathways and validated with the trial team before
the model was built in Microsoft Excel. An outline of the model structure is given in Figure 6.
Key model assumptions
The model assumed that the population was the same as the trial population in terms of baseline
characteristics at entry into the model. Children would be eligible to receive FS and FV as specified in the
trial. After trial completion, children would no longer be in the Designed to Smile programme (i.e. they
would have entered secondary school). It was assumed that all children would be entitled to NHS dental
care until the age of 16 or 17 years, which would represent the ages of children up until the 10-year
time horizon.59
We assumed that children would continue to receive their original intervention (i.e. they would not receive
both interventions) and that the same products would be applied in a similar way to that in the trial. The
standard of application and the efficacy of the staff administering the intervention would be commensurate
HEALTH ECONOMIC EVALUATION: METHODS AND RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
c[
h
ea
lt
h
 s
ta
te
]
u
[h
ea
lt
h
 s
ta
te
]
p
[t
ra
n
si
ti
o
n
 s
ta
te
]
C
o
st
s
U
ti
lit
ie
s
Tr
an
si
ti
o
n
 p
ro
b
ab
ili
ti
es
Se
al
ed
p
Se
al
Lo
ss
p
Se
al
R
es
to
re
d
cC
ar
ie
s
u
C
ar
ie
s
u
R
es
to
re
d
cR
es
to
re
d
u
Se
al
cS
ea
l
cS
R
es
to
re
cV
ar
n
is
h
u
V
ar
n
is
h
u
Lo
ss
Se
al
p
C
av
Se
al p
C
av
V
ar
n
is
h
p
Lo
st
To
o
th
cL
o
st
To
o
th
p
C
av
2
p
C
av
R
es
to
re
d
C
ar
ie
s:
C
1
C
2
C
3
C
4
Lo
st
 s
ea
l
V
ar
n
is
h
Lo
st
 t
o
o
th
R
es
to
re
d
:
R
1
R
2
R
3
R
4
FI
G
U
R
E
6
M
ar
ko
v
st
at
e
d
ia
g
ra
m
:o
u
tl
in
e
o
f
m
o
d
el
le
d
in
te
rv
en
ti
o
n
p
at
h
w
ay
s
fo
r
FS
vs
.F
V
.
Th
e
st
at
es
ar
e
re
p
re
se
n
te
d
b
y
o
va
ls
an
d
p
o
ss
ib
le
tr
an
si
ti
o
n
s
b
et
w
ee
n
st
at
es
ar
e
re
p
re
se
n
te
d
b
y
ar
ro
w
s.
DOI: 10.3310/hta21210 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 21
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chestnutt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
with the trial, as would the accuracy in diagnosing and appropriately treating the tooth. For the base case,
we assumed that children would visit a NHS community dentist and receive the intervention in accordance
with standard practice, including, when required, the reapplication of FV or resealing of FS.
The trial permitted the child’s tooth to be assessed to ensure that the FPMs were sufficiently erupted to be
treated, as part of the early detection of caries risk provided by the MDC. The same dental recall periods
were used within the first 5 years of the model, that is, periods of 6 months, as the child would still be in
the Designed to Smile programme. Between 5 and 10 years, it would be assumed that the recall period
would be based on an individual risk-based assessment for each child and thus it would be problematic to
provide a precise estimate of the time interval. NICE guidance60 recommended that the shortest interval for
oral health reviews for all patients should be 3 months, and, for patients < 18 years old, the longest
interval should be 12 months. The health economic analysis undertaken for this guideline used Markov-
based modelling to assess the cost-effectiveness of different dental recall periods, emphasising that, with
considerable uncertainty around model parameters (particularly clinical efficacy), conclusions about the
relative cost-effectiveness of different recall times could not be drawn.
On the basis of the trial outcomes, and as agreed with the trial team, it was assumed that all children
attended a dental visit every 6 months. This was assumed to be the same for both trial arms.
Within this model, no assumptions were made regarding the accuracy of clinical assessments or the impact of
different clinical reversal rates and it was assumed that a similar reversal rate could be achieved as that in the
trial results on caries progression. The possible impact of dental health problems (e.g. caries progression in
other teeth) or other oral health interventions on the subsequent health states of the FPMs was not considered.
Base-case inputs
As this was a model developed from the SoV trial, when possible and appropriate, the clinical evidence
from the trial, alongside the costs and outcomes used in the within-trial health economic analysis, were
used to provide data inputs. The FS was the base case, with incremental cost-effectiveness reported for FV
compared with FS.
Although the trial provided estimates of the incidence of caries at baseline and the rate of caries
progression as a result of the two technologies up until 36 months’ follow-up, it was problematic to
estimate precise estimates of progression beyond the trial duration.
The strongest clinical evidence would be derived from the updated Cochrane review that evaluated the
relative clinical effectiveness of FS versus FV (and FS + FV vs. FV alone) for preventing dental caries in
the occlusal surfaces of permanent teeth of children and adolescents.16 From this review, only one study
provided longer-term outcome data,61 which was assessed to have both an unclear risk of bias because no
information was provided at 48 months, and a high risk of bias as only 33% of trial participants were
included at 9 years’ follow-up. This trial was also assessed as having a high risk of bias for four key
domains (outcome assessment, incomplete outcome data, selective reporting and baseline comparability).
The model was therefore constrained by using evidence from the trial, and discussions with the clinical trial
team were used to make assumptions, when necessary. All data inputs underwent full validation by the
trial team, and uncertainty was considered within the sensitivity analysis.
Clinical data
The trial data were used to inform the probability of the different progression into caries through the model.
Costs
It was assumed that modelled patients accrued costs associated with any assessment and intervention and
that they continued to receive interventions to prevent/manage caries progression in the FPMs. The costs
reflected a NHS and Personal and Social Services perspective, that is, drug costs, intervention costs and any
other resource use that may be required (e.g. adverse events).
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The same costing approach was used from the within-trial analysis of costs, valued in monetary (£) terms
at 2015 prices from unit costs from published sources, for example BNF, Personal and Social Services
Research Unit and NHS reference costs and, when applicable, local financial records from Cardiff and Vale
UHB. Tables 48 and 49 reported the costs utilised in the model.
Health utilities
The following estimates of QoL were used (Table 52), using the trial data to estimate utility decrements.
One-way sensitivity analysis
Table 51 presented the range of parameter estimates applied to the comparison of FS with FV in the
one-way sensitivity analysis of the CUA, and these were applied to the model.
Probabilistic sensitivity analysis
A probabilistic sensitivity analysis was performed to test the robustness of the modelling conclusions in the
face of uncertainty surrounding the choice of modelling inputs. Parameter values were varied within a
reasonable range in each of 1000 runs and the results averaged across runs. Costs were sampled from
gamma distributions, utilities from beta distributions, and rates and probabilities from log-normal or beta
distributions. A CEAC was generated to depict the probability of the intervention being cost-effective at
different willingness-to-pay (WTP) thresholds.
Results: within-trial analysis
Intervention costs
The interventions costs for FS versus FV are shown in Table 53. The overall intervention costs were
aggregated across all the treatment and clinical assessment time points, as per the trial protocol. For the
base case, the overall mean costs were lower for FV than for FS (£32,146.50 vs. £38,098.71, respectively).
These were mainly attributed to the difference in time receiving treatment (in chair) between the two
treatments. The overall time in chair across the trial period was 24 minutes for FS and 16 minutes for FV;
even taking into account the reapplication of FV over the trial period, this cost of treatment remained
lower (£74.12 per FS patient vs. £64.16 per FV patient). When the costs of the MDC were added, this
increased the mean per-patient cost in each arm, but the incremental difference was small (£95.73 vs.
£86.33 for FS vs. FV, respectively).
Dental visits
The DHQ was used to estimate the resource use over the 3 years based on all available data for the two
interventions. Children in the FV arm had, on average, fewer visits to the dentist (outside the MDC) than
children in the FS arm (3.5 vs. 3.9, respectively). However, there were small differences in the reasons
documented for these visits, with more children in the FS arm than in the FV arm attending for ‘check-ups’
(3 vs. 2.7, respectively), which equates to a difference of £28 per patient across the arms. The estimated
TABLE 52 Base-case utility values used in the model-based analysis
Value
QoL weight for one cycle of sealed tooth 0.002
QoL weight for one cycle of lost seal 0.002
QoL weight for one cycle of varnished tooth 1E–12
QoL weight for one cycle with dental caries 0.05
QoL weight for one cycle of restored tooth affected by dental caries 0.05
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mean cost per patient associated with additional dental visits in the FS was £426, compared with £368 in
the FV (£58.17, 95% CI –£4.33 to £120.67). The results are shown in Table 54.
An important cost driver to assess differences between the two technologies would be the treatment
required as a result of caries within the FPMs, for example the cost of filling or removing the index tooth.
One of the limitations of the DHQ is that it would not be precise enough to estimate direct costs attributed
to the FPMs. Thus, the clinical trial data were examined to give a more accurate estimation of the costs of
treating caries, assigning a cost to each event based on the unit cost of treatment. These were used as the
primary source of data for these key cost drivers, with the DHQ providing information of other dental
health-related events.
With regard to hospital visits (e.g. hospital-based dental outpatients) and hospital admissions associated
with dental health problems, there were no recorded events across both treatment groups. No other
health-care attendances were recorded (e.g. accident and emergency department attendance or
out-of-hours service).
Prescription costs
Parents were asked to estimate the prescriptions given by a dentist or other health-care professional given to
treat dental health problems during the trial. On examining the data, there were some anomalies noted,
insofar as a prescription was recorded but not the prescribing health-care professional (e.g. dentist or
general practitioner). This was discussed by the trial team and it was assumed that a community dentist
would have prescribed. Painkillers and antibiotics were the only medications prescribed. It was assumed this
was done as part of a dental visit already counted.
TABLE 53 Intervention costs of FS vs. FV
Basis of estimate
Unit
cost (£)
Per
hour (£)
Per full treatment
(FS= 24 minutes), (£)
Per full treatment
(FV= 16 minutes), (£) Data sources
Dentistry staff band
3 × 1
9.20 3.68 2.45 NHS Staff Agenda
for Change43
Dentistry staff band
4 × 1
10.58 4.23 2.82 NHS Staff Agenda
for Change43
Dentistry staff band
5 × 0.65
12.62 5.05 3.37 NHS Staff Agenda
for Change43
Administration staff
(band 3) × 1
9.20 3.68 2.45 NHS Staff Agenda
for Change43
Administration staff
(band 4) × 1
10.58 4.23 2.82 NHS Staff Agenda
for Change43
FV (Duraphat) 2.00 12.00 Dental suppliera
FS (Delton) 2.50 15.00 Dental suppliera
Clinical disposables
(e.g. gloves, cotton
wool, bib, etc.)
2.50 22.50 22.50 Dental suppliera
Sterilisation costs 1.75 15.75 15.75 Cardiff and Vale
UHBb
Intervention costs total 38,098.71 32,146.50 –
Number of eligible
pupils
514 501 –
Cost per eligible pupil 74.12 64.16 –
a www.henryschein.co.uk (accessed in March 2016).
b www.cardiffandvaleuhb.wales.nhs.uk/home (accessed in March 2016).
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The estimated mean per-patient cost for medications prescribed in the FS arm was £0.28, compared with
£0.44 in the FV arm (–£0.17, 95% CI –£0.36 to £0.03). This was seen as a non-statistically significant
difference (see Table 53; p = 0.091).
The base-case analysis shows that the children randomised to the FS arm accumulated more costs, overall,
than children in the FV arm. Table 54 also shows the comparison of total mean health-care costs between
the two technologies. These results were used in the subsequent cost-effectiveness analyses and budget
impact analysis.
Costs to the family
The costs to the family were estimated from the DHQ. With regard to over-the-counter medications, the
total costs were £12.54 for FS versus £13.49 for FV. In terms of carer time as a result of taking time off to
attend dental health appointment with the participating child or time to look after the child, the mean
per-carer cost was estimated to be £29 versus £25 for FS versus FV, respectively. Table 54 shows the costs
to the family regarding the costs resulting from time off.
Cost of hosting mobile dental clinic to the school
The schools questionnaire was returned by 30% of the participating schools. In their responses, all schools
stated that there were negligible costs associated with the school’s participation related to the MDC, with
little disruption to classroom time for the teacher or administrative tasks. Thus, the costs to the school of
hosting the service were not formally analysed.
Overall NHS costs
Table 54 shows the health-care contacts across the trial arms from the NHS perspective. Non-statistically
significant differences were seen in the contacts, that is, £425 versus £367 (FS vs. FV, respectively), with a
difference of £58.17 (95% CI –£4.33 to £120.67; p = 0.068).
Total combined NHS and family costs
Table 54 shows the health-care contacts across the trial arms from the perspective of the NHS and a partial
societal (family) perspective. Statistically significant differences were seen in the ‘total cost of time off
work’ contacts, that is, £28.79 versus £24.97 (FS vs. FV, respectively), a difference of £3.83 (95% CI £0.55
to £7.10; p = 0.022).
The costs of the two technologies showed small but statistically significant differences; the mean cost to
the NHS (including intervention costs) per child was £500 for FS, compared with £432 for FV, a difference
of £68.13 (95% CI £5.63 to £130.63; p = 0.033) in favour of FV.
When costs to the family were included (with NHS costs), the costs were £529 for FS and £457 for FV,
with a difference of £71.96 (95% CI £7.21 to £136.71; p = 0.029) in favour of FV.
Health outcomes
Dentine caries avoided at 36 months
The data presented in Table 13 were used to estimate the cost of each 1% reduction in the proportion of
children who at 36 months had developed dental cares.
Health utilities and quality-adjusted life-years
The mean utility values derived from the CHU-9D at each of the follow-up points were similar (p-values
greater than 0.05) for both technologies (Table 55). In the FS arm, the mean utility value (and resultant
QALY) was 0.928 at 12 months and this increased to 0.933 at 36 months. In the FV arm, the mean utility
value (and resultant QALY) was 0.931 at 12 months and this increased to 0.933 at 36 months.
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The effects of these very small changes in the CHU-9D (both within and across the two arms) are reflected
in the negligible utilities lost/gained and subsequent QALYs from 12 to 36 months. Overall, there was a
small and non-statistically significant difference in QALYs at 36 months in the FV arm (0.931) compared
with the FS arm (0.929) (difference 0.002, 95% CI –0.010 to 0.005). However, the very small difference
and the 95% CIs indicate that these data should be treated with some caution (Table 56). In effect, there
is a non-statistically significant difference and negligible clinically significant difference in QALYs, which
was a similar result to the clinical outcomes reported in the trial.
Tooth utilities and quality-adjusted tooth-years
Table 57 reports the tooth utilities associated with the two technologies and QATY differences. The mean
tooth utility at 36 months was 0.932 in the FS arm and 0.925 in the FV arm. The overall QATY difference
was 0.007 in favour of the FS arm, a small and non-significant numerical difference. The clinical significance
of this result is negligible and thus should be regarded with caution.
Cost-effectiveness analysis
Incremental cost per child with dentine caries avoided
The base case of the analysis for the incremental cost per child with dentine caries avoided is presented in
Table 58.
TABLE 55 Health utilities and QALYs by treatment arm
Treatment allocation n Mean (SD) 95% CI of the difference p-value
CHU-9D 12 months
FS 262 0.928 (0.072) –0.003 (–0.015 to 0.009) 0.624
FV 248 0.931 (0.061)
CHU-9D 24 months
FS 272 0.926 (0.074) –0.002 (–0.015 to 0.010) 0.720
FV 252 0.928 (0.069)
CHU-9D 36 months
FS 236 0.933 (0.066) 0.000 (–0.012 to 0.013) 0.956
FV 219 0.933 (0.066)
TABLE 56 Health utilities and QALYs
Time period
Intervention arm
QALY difference
FS FV
CHU-9D score
Change
over time CHU-9D score
Change
over time
12 months 0.928 – 0.931 – –
24 months 0.926 –0.001 0.928 –0.001 –
36 months 0.933 0.004 0.933 0.002 –
QALY gain at 3 years – 0.003 – 0.001 0.002 (–0.010 to 0.005)
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With very small numerical differences in dental caries between the two trial arms, the ICER computed that
FV was dominant over FS. However, appropriate caution should be exercised in using and interpreting the
term ‘dominant’ in the context of these results.
Sensitivity analysis
As shown in Table 58, the results remained consistent when adjusted around the upper and lower range
(95% CI) for costs and outcome. The CEAC for the incremental cost per child with dentine caries avoided
is shown in Figure 7. Although there is no formal threshold, this illustrates the probability of FV being
cost-effective at different monetary WTP thresholds.
Incremental cost per quality-adjusted life-year
Table 59 shows the incremental cost per QALY.
Figure 8 presents the CEAC.
TABLE 57 Tooth utilities and QATYs
Intervention
QATY difference
FS FV
Tooth Tooth utility Tooth Tooth utility
UR6 0.925 UR6 0.937 –
UL6 0.927 UL6 0.938 –
LR6 0.933 LR6 0.906 –
LL6 0.944 LL6 0.920 –
Overall FPM utility 0.932 Overall FPM utility 0.925 0.007 (–0.068 to 0.011)
LL, lower left; LR, lower right; UL, upper left; UR, upper right.
TABLE 58 Incremental cost per 1% of proportion of children with dentine caries prevented
Parameter
Incremental cost of
intervention (£)
Proportion of children
without dentine caries
ICER (using % dentine
caries free scores)
Base case –68.13 (–5.63 to –130.63) 0.021 (–0.0317 to 0.0738) FV is dominanta
Upper 95% bound of net cost –130.63 0.0738 FV is dominanta
Upper 95% bound caries free (%)
Upper 95% bound of net cost –130.63 –0.0317 FV is dominanta
Lower 5% bound of caries free (%)
Lower 5% bound of net cost –5.63 –0.0317 FV is dominanta
Lower 5% bound of caries free (%)
Lower 5% bound of net cost –5.63 0.0738 FV is dominanta
Upper 95% bound caries free (%)
a With very small numerical differences in effect in favour of FV and FV being less costly than FS, the ICER is calculated as
dominant. However, this calculation is based on non-statistically significant differences in outcomes between FS and FV.
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For the cost per QALY, the probability of FV being cost-effective is 70% at a NICE societal WTP threshold
of £20,000 per additional QALY.
Incremental cost per quality-adjusted tooth-year
The base case of the analysis of the incremental cost per QATY is presented in Table 60. It can be seen
that, in comparison with FV, FS generated slightly more QATYs. However, when the ICER calculation is
performed, FV was dominant.
This is a result consistent with the previous ICERs, and the same caution is applied in the interpretation of
these results. This remained consistent when a one-way sensitivity analysis was performed. As this was an
exploratory analysis, no CEAC is presented.
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FIGURE 7 The CEAC for incremental cost per child with dentine caries avoided.
TABLE 59 Incremental cost per QALY
Parameter
Incremental cost of
intervention (£)
Incremental CHU-9D
utility
ICER (using CHU-9D
utility scores)
Base case –68.13 (–5.63 to –130.63) 0.002 (–0.010 to 0.005) FV is dominanta
Upper 95% bound of net cost –130.63 0.005 FV is dominanta
Upper 95% bound of net utility
Upper 95% bound of net cost –130.63 –0.010 FV is dominanta
Lower 5% bound of net utility
Lower 5% bound of net cost –5.63 –0.010 FV is dominanta
Lower 5% bound of net utility
Lower 5% bound of net cost –5.63 0.005 FV is dominanta
Upper 5% bound of net utility
a With very small numerical differences in effect in favour of FV and FV being less costly than FS, the ICER is calculated as
dominant. However, this calculation is based on non-statistically significant differences in outcomes between FS and FV.
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Budget impact analysis
The budget impact analysis (Table 61) was calculated on the trial population patients at 3 years (n = 1015).
The total cost of FS treatment was £38,098 and the total cost of FV treatment was calculated at £32,144
(or £74.12 per patient in the FS arm and £64.16 per patient in the FV arm). The NHS costs associated with
dental appointments (other than those administered in the intervention) totalled £218,822 for the FS arm
and £184,143 for the FV arm. When the costs of implementation and the resource usage costs are
combined and compared between arms, there is a –£35,021 cost-saving difference in favour of FV over
the trial period. The results show that there is an overall per-patient cost saving of £68.13 (95% CI £5.63
to £130.63; p = 0.033) in favour of the FV arm compared with the FS arm.
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FIGURE 8 The CEAC (CUA).
TABLE 60 Incremental cost per QATY
Parameter
Incremental cost of
intervention (£)
Incremental tooth
utility
ICER (using tooth
utility scores)
Base case –68.13 (–5.63 to –130.63) 0.007 (–0.068 to 0.011) FV is dominanta
Upper 95% bound of net cost –130.63 0.011 FV is dominanta
Upper 95% bound of net utility
Upper 95% bound of net cost –130.63 –0.068 FV is dominanta
Lower 5% bound of net utility
Lower 5% bound of net cost –5.63 –0.068 FV is dominanta
Lower 5% bound of net utility
Lower 5% bound of net cost –5.63 0.011 FV is dominanta
Upper 5% bound of net utility
a With very small numerical differences in effect in favour of FV and FV being less costly than FS, the ICER is calculated as
dominant. However, this calculation is based on non-statistically significant differences in outcomes between FS and FV.
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Sensitivity analysis of the budget impact analysis
Deterministic sensitivity analyses were conducted to estimate the worst-case and best-case scenarios of the
budget impact of FS versus FV by using the lower and upper costs derived from the trial. To examine
different scenarios that could impact on NHS budgets, three additional scenarios were explored: (1) the
budget impact when the costs of the MDC are included, (2) the budget impact of a community dental
nurse delivering FV in a ‘classroom’ setting (i.e. not requiring a MDC but reflecting potential for this
technology to be delivered in a single application with minimal equipment/resources), and (3) the budget
impact when a dental hygienist alone applies FV within a classroom/school medical room setting.
Table 62 shows the different cost scenarios for the intervention over a 3-year period as seen in the trial. It
can be seen that the deterministic sensitivity analysis is unchanged in most of the modelled scenarios, that
is, FV is dominant and is seen to be the optimal strategy. However, when the best-case cost scenario of
£51.88 for FS is compared with the worst-case cost scenario of £83.41 for FV, FS technology dominates.
That FS could cost as little as this in a real-life setting is questionable, and so caution should be exercised
with regard to this. Further work would be required to explore the plausibility of this scenario.
TABLE 61 Budget impact analysis at 3 years based on trial population
Baseline
Intervention arm
FS FV
Cost of implementation (£) 38,098 32,144
Number of patients 514 501
Cost of implementation per patient (£) 74.12 64.16
Total cost of dental appointments (£) 218,822 184,143
Mean cost of dental appointments per patient (SD) 425.7 (523.0) 367.5 (490.6)
Difference (95% CI) –58.17 (–4.33 to 120.67)
Overall cost differences between the interventions (£) –35,021
Cost saving per patient (£) –68.13
TABLE 62 Base-case and sensitivity analysis of the cost of delivering the technologies in the school setting using
best-case/worst-case scenarios
Parameter
Intervention arm
Budget impactFS FV
Base case (lower ranges, upper ranges) 74.12 (51.88, 96.36) 64.16 (44.91, 83.41) FV is dominant
Upper range FS 96.36 83.41 FV is dominant
Upper range FV
Upper range FS 96.36 44.91 FV is dominant
Lower range FV
Lower range FS 51.88 44.91 FV is dominant
Lower range FV
Lower range FS 51.88 83.41 FS is dominant
Upper range FV
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Table 63 shows the different cost scenarios for the intervention to be administered if the costs of the MDC
are included. It can be seen that the deterministic sensitivity analysis is unchanged in most of the modelled
scenarios, that is, FV is dominant and is seen to be the optimal strategy. However, when the best-case cost
scenario of £67.01 for FS is compared with the worst-case cost scenario of £112.23 for FV, FS dominates.
The plausibility of this scenario reflecting a real-life cost needs further discussion.
Table 64 represents the analysis of one FV application by a dental nurse in the school. It can be seen that, by
reducing the costs of the FV technology, it becomes dominant and is seen to be the optimal strategy across
all the scenarios. The plausibility of this scenario reflecting a real-life cost would need further investigation.
Finally, Table 65 represents the analysis of one FV application by a dental hygienist in the school. Again, it
can be seen that, by reducing the costs of the FV technology, it becomes dominant and is seen to be the
optimal strategy across all of the scenarios. Again, the plausibility of this scenario reflecting a real-life cost
would need further investigation.
TABLE 63 Base-case and sensitivity analysis of the cost of delivering the technologies in the school setting
(with additional MDC costs included) using best-/worst-case scenarios
Parameter
Intervention arm
Budget impactFS FV
Base case (lower ranges, upper ranges) 95.73 (67.01, 124.45) 86.33 (60.43, 112.23) FV is dominant
Upper range FS 124.45 112.23 FV is dominant
Upper range FV
Upper range FS 124.45 60.43 FV is dominant
Lower range FV
Lower range FS 67.01 60.43 FV is dominant
Lower range FV
Lower range FS 67.01 112.23 FS is dominant
Upper range FV
TABLE 64 Deterministic sensitivity analysis of the FV application by a dental nurse in the school (classroom or
medical/school nurse room setting)
Parameter
Intervention arm
Budget impactFS FV
Base case (lower ranges, upper ranges) 74.12 (51.88, 96.36) 11.48 (8.04, 14.92) FV is dominant
Upper range FS 96.36 14.92 FV is dominant
Upper range FV
Upper range FS 96.36 8.04 FV is dominant
Lower range FV
Lower range FS 51.88 8.04 FV is dominant
Lower range FV
Lower range FS 51.88 14.92 FV is dominant
Upper range FV
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Additional scenario analysis
To provide further illustration of the practical implications of the findings, an additional scenario analysis
was undertaken to provide a hypothetical illustration of the time savings that could be achieved in
delivering FS versus FV. As shown in the results, one of the resources attributed to costs is the ‘time in
chair’ and another is the skill mix of staff that would be needed to deliver the technologies and how these
findings can be used to optimise capacity and the number of children treated within the service. The ideal
service configuration of preventative dental health for a population of children at high risk of caries is
informed by translating the time savings gained from using FV with a dental care team that, compared
with FS, needs to be less highly trained and does not include a qualified dentist. Table 66 presents an
illustrative scenario (using time to treat each child gathered from the trial) in which, compared with FS,
using FV allows 93 more children to be treated within the same time (assuming a day’s session, based on
the school working day of 9 a.m. to 3 p.m., at a school that has this number of children).
Post-trial modelling
Table 67 reports the estimations of the incremental cost per QALY at 5 and 10 years. These base-case
results estimate that FV continues to be dominant over FS because of lower costs and slightly more
QALY gains.
The results of the univariate sensitivity analysis estimated that FV remained dominant.
Figures 9 and 10 show the CEACs generated for 5 and 10 years, respectively. They show that, at a NICE
societal WTP threshold of < £20,000 per QALY gained, FV is 99% (at 5 years) and 96% (at 10 years) likely
to be cost-effective.
TABLE 65 Deterministic sensitivity analysis of the FV application by a dental hygienist in the school (classroom or
medical/school nurse room setting)
Parameter
Intervention arm
Budget impactFS FV
Base case (lower ranges, upper ranges) 74.12 (51.88, 96.36) 10.91 (7.64, 14.18) FV is dominant
Upper range FS 96.36 14.18 FV is dominant
Upper range FV
Upper range FS 96.36 7.64 FV is dominant
Lower range FV
Lower range FS 51.88 7.64 FV is dominant
Lower range FV
Lower range FS 51.88 14.18 FV is dominant
Upper range FV
TABLE 66 Illustrative scenario of hypothetical time savings that could be achieved between delivering FS versus FV
Intervention arm
DifferenceFS FV
Average time of one application of FV (minutes) – 2.7 –
Average time per patient for one-off treatment of FS (with no top-ups) 8.9 – –
Number of minutes in a session (9 a.m. to 3 p.m.) 360 360 –
Theoretical number of patients to be seen per session 40 133 93
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TABLE 67 Incremental cost per QALY at 5- and 10-year horizons
Cost (£)
Incremental cost (£)
QALY
Incremental QALY ICERFS FV FS FV
5 years 1055 663 391 0.03 0.15 –0.12 FV is dominant
10 years 1580 822 0.05 0.31 –0.26 FV is dominant
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FIGURE 9 The CEACs for a 5-year time horizon.
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FIGURE 10 The CEACs for a 10-year time horizon.
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Summary of health economic results
This chapter has reported the health economic methods and findings of the trial. The main findings are
as follows.
l It is feasible to undertake a comprehensive health economic evaluation alongside a randomised
controlled trial of preventative health technologies within in the context of a MDC setting.
l The intervention costs of the two technologies were £74.12 (FS) and £64.16 (FV) per child over the
course of the trial.
l The costs of the two technologies showed small but statistically significant differences between arms;
the mean cost to the NHS (including intervention costs) per child was £500 for FS compared with £432
for FV, a difference of £68.13 (95% CI £5.63 to £130.63; p = 0.033) in favour of FV.
l When a partial societal perspective was included (with intervention costs), the mean cost per child was
£529 for FS and £457 for FV, a difference of £71.96 (95% CI £7.21 to £136.71; p = 0.029) in favour
of FV.
l The budget impact analysis at 3 years showed that FV had a cost saving of £68.13 (95% CI £5.63 to
£130.63; p = 0.033) compared with FS. In addition, when three different scenarios were examined,
the results did not change and FV remained dominant.
l As numerical differences in outcomes were non-significant, the ICER was very sensitive to very small
numerical differences in outcomes. For all outcomes, differences between FS and FV were neither
statistically significant nor clinically important, and so the ICER calculation should be treated with
appropriate caution. However, results remained consistent across all three outcomes used in the health
economic analysis, that is, FV was less costly than FS, with similar outcomes achieved.
l The CEAC showed that there was a 70% probability of FV being cost-effective at a societal WTP
threshold of £20,000 per QALY.
l The results of model-based analysis to estimate the incremental cost per QALY over longer-term
horizons were consistent with the results of the in-trial analysis, with FV being associated with lower
costs and small QALY gains achieved, leading to FV being dominant in the ICER calculation. The
CEACs showed that there was a 99% (over 5 years) and 96% (over 10 years) probability of FV being
cost-effective within a societal WTP threshold of £20,000 per QALY. However, there are a number of
uncertainties in the model, particularly the dearth of evidence on longer-term costs and outcomes
associated with FV and FS within a preventative dental health context.
Chapter 5 describes the process evaluation.
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Chapter 5 Acceptability of the Seal or Varnish?
intervention and trial
Introduction
An important element of the clinical trial was determining the acceptability of the interventions provided,
and the setting in which they were being provided, from the perspective of the participating children, their
parents, schools/school staff and clinical staff. In addition, parents’ decisions and perceptions of their child
participating or not participating in the trial were investigated. A mixed-methods approach was used.
Treatment acceptability was assessed in three ways:
1. Acceptability scales were completed by clinical staff.
2. Acceptability scales also were completed by the children participating in the trial.
3. Qualitative interviews were conducted with a subsample of children.
A longitudinal process evaluation for the trial was conducted to assess how the FS/FV intervention was
implemented for children in a school-based setting in a socioeconomically deprived area and to facilitate
the interpretation of outcome effects to establish what works for whom and in what circumstances. The
process evaluation focused on implementation and acceptability, as these were factors likely to influence
the effectiveness of the trial, in addition to treatment efficacy. The research questions addressed and the
mode of data collection are shown in Table 68.
The methods used were, briefly, the completion of acceptability scales by treating clinicians and the
participating children, interviews conducted with participating children and their parents, interviews with
head teachers of schools participating in the study and interviews with CDS staff delivering treatment.
Parents who were not participating in the trial were also interviewed. In addition, a school staff questionnaire
was sent to schools, and a short questionnaire about reasons for non-participation was included in the
second recruitment mailing to parents for completion by parents who did not want to take part in SoV.
The methodology used is described in detail in Methodology. Findings on the acceptability of the intervention
to children, parents, staff and schools are then reported. Any changes in oral health behaviour were also
noted, to assess whether or not there were differences between trial arms that might affect outcomes.
Reasons for parents consenting or not consenting for the children to participate in SoV are then described.
Methodology
Data collection
Acceptability as determined by observed signs of distress during treatment
An observation scale (see Appendix 16) was completed independently by the dental hygienist and dental
nurse for each child immediately following application of the FS or FV. This scale recorded five items of
children’s behaviour: vomiting, crying, gagging, excessive arm/leg movements and other signs of distress.29
Acceptability as reported by participants immediately following treatment
A DTF scale27,28 was used to assess the acceptability of the treatment for children, both for overall acceptability
(how they felt during treatment and how they would feel if they had to have the treatment the following day)
and for three specific aspects of treatment: taste, length of treatment and feeling sick (see Appendix 12).
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As there are few scales designed for acceptability of dental treatment, and as none was available for very
young children, the DTF scale was selected, but it was adapted by graphic artists to enhance visual appeal, as
the original scale was designed for slightly older children. The DTF scale was completed by children in the
MDC immediately following the initial application of FS/FV and at each follow-up visit. Answers were given on
a five-point Likert scale, on which children could mark a picture of a face, which ranged from smiling to sad,
to indicate how they felt about different aspects of treatment. The protocol for completion of the scale was
for the child to sit apart from other children, to avoid children discussing or influencing each other’s answers.
Interviews with children
School sampling
A subsample of schools participating in the trial was selected for acceptability interviews with children.
All schools were in Communities First areas, which were characterised by deprivation; however, within
this category there was a range of deprivation levels in schools. As the impact of preventative dental
interventions in deprived areas was an area of interest for the study, the impact of level of deprivation was
also of interest.5,6 Schools were selected from the highest and lowest deprivation quartiles of schools in the
SoV trial, measured by the percentage of pupils in a school receiving free school meals (FSMs). Data were
used from the StatsWales website of the Welsh Assembly Government,62 and the measure used was the
percentage of 5- to 15- year-olds eligible for FSMs in 2010. The overall range of children receiving FSMs in
TABLE 68 Summary of process evaluation research questions and data collection methods
Research question Data collection method
Year of study in which
data were collected
1 2 3
Acceptability: are FV and FS treatments acceptable to
children aged 6–10 years, what factors influence
acceptability and are there differences between trial
arms? Includes:
Did the children display signs of distress during the
treatment?
Did the children feel happy or sad after the treatment
was completed?
Hygienist/nurse observation ✗ ✗ ✗
DTF scale ✗ ✗ ✗
Child interviews ✗ ✗
Parent interviews ✗ ✗
Clinician interviews ✗ ✗ ✗
Implementation: is the delivery of this type of
preventative treatment acceptable to children, their
parents, clinicians and the schools where the
treatments take place; what are the factors affecting
implementation of treatment in a school setting?
Child interviews ✗ ✗
Parent interviews ✗ ✗
Clinician interviews ✗ ✗ ✗
School staff questionnaire ✗
School staff interviews ✗
What factors affect whether parents consent or do not
consent to take part in an intervention and trial such
as SoV?
Parent interviews ✗ ✗
Parent questionnaire ✗
School staff questionnaire ✗
School staff interviews ✗
Does treatment with FV or FS affect (self-reported)
subsequent oral health behaviour, and, if so, are there
differences between trial arms?
Child interviews ✗ ✗
Parent interviews ✗ ✗
What is the effect of the trial on recruitment or
acceptability to parents, dental staff and schools?
Parent interviews ✗ ✗
Clinician interviews ✗ ✗ ✗
School staff interviews ✗
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participating SoV schools was 3–75%. The high-deprivation quartile schools had an average FSM rate
of 58%, while the low-deprivation quartile schools had an average FSM rate of 18%. In the UK, the
proportion of children receiving FSMs averages 15% across all schools, while the Welsh average is 18%.
The sampled ‘low-deprivation schools’ in the SoV trial were, therefore, similar to the Welsh average, while
the high-deprivation schools within the SoV trial had much higher levels of children receiving FSMs, at
58%, more than three times the average level of FSMs in Wales.
In year 1 of the study, schools with more study participants (either larger schools or smaller schools with
high study consent rates) in each selected quartile were sampled for interviews. Schools were selected in
this way to allow for large enough groups of children in each school to be paired by trial arm and also by
children’s choice of interview partner (see below). When numbers did not reach 24 for each trial arm,
additional schools were added until at least 24 children had been interviewed in each trial arm. Because of
problems contacting parents to gain consent for follow-up interviews in year 3, additional schools were
sampled in year 3 to increase the sample size. The attempts to recruit for interview were stopped when
around 30 children and parents had been interviewed. As respondents were providing similar answers and
no new data were emerging from subsequent interviews, it was concluded that data saturation had been
reached. Four schools were sampled in year 1 of the study; seven schools (including the four from year 1)
were sampled for follow-up in year 3.
Child interview pairings
Children were interviewed in pairs, or occasionally singly or in threes, so that they would feel more
comfortable in the interview environment.63 The intention was also to facilitate the collection of more,
and better-quality, data. Teachers and classroom assistants, and sometimes head teachers and school
administrators, assisted with pairing children. Lists of children (identified by unique ID study number)
participating in treatment for each school were divided by trial arm and, whenever possible, children from the
same trial arm were interviewed together in order that children would be able to report on the same type
of treatment in an interview. Within the trial arm groups, children were given the option to choose their
interview partner (or teachers were asked to pair children with a friend). In some cases, the requirements of
teachers or classroom activities also dictated which children would accompany each other, particularly when
a year group was split over two or three classrooms. Originally, children were also to be purposively sampled
from each trial arm for a range of acceptability scores, and children in each trial arm with similar acceptability
scores were to be interviewed together, to ensure a maximum difference of acceptability across the sample.
However, this proved impossible, as the sample sizes for each trial arm in each school were too small to
divide the children into further groups; it would have disrupted classes too much to create a very rigid list of
pairings of children, and it would have prevented children from being able to choose their interview partner.
Child interviews
Face-to-face paired interviews were conducted with children in a school setting ≤ 2 weeks after their first
treatment and ≤ 2 weeks after their final treatment, to ensure that children’s recall of their experience of
treatment was reasonably accurate. Most children were interviewed within a few days of their treatment.
Interviews lasted for around 15–20 minutes each and most children appeared relaxed and confident in
interviews. Written parental consent to interview children was included in the main study consent; in
addition, a reminder telephone call was made to parents in years 1 and 3 of the study to confirm consent
before the researcher visited schools. Interviews were undertaken by one of the coauthors (SMT) and took
place in spare classrooms, head teacher offices, staff rooms, school libraries and school halls. All interviews
took place where school staff or other children could not hear the content of an interview (although,
to comply with safeguarding requirements, all spaces were also visible) and it was explained to the
interviewed children that the data collected were confidential. Assent to be interviewed was also verbally
checked with children at the beginning of the interview. The interview topics included acceptability of
treatment and the treatment setting, social influences on attitudes towards treatment and treatment
settings (such as prior experience of dental treatment), changes in the child’s oral hygiene behaviour and
perceptions of treatment impact. See Appendix 17 for the children’s interview schedule. Fifty children were
interviewed in year 1 of the study. Thirty-two follow-up interviews were conducted with children in year 3.
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Methodological issues in child interviews
The children, especially in year 1 of the study when they were aged 6 or 7 years and at a relatively early
developmental and educational stage, were limited in what they were able to report in interviews. Not all
of the children were able to understand or to answer all of the questions posed in the interviews, and
when the children were unable to answer a question, further probing questions were used in a very
limited way to avoid causing anxiety. Several common limitations emerged across the group. First, some
of the children’s concepts of time were distorted; for example, one child in the final year of the study
(when the children were 8 or 9 years old and the study was in its third year) thought that he had been
receiving the treatment for about 8 years and then corrected himself and said it was only about 5 or 6 years.
Most children in the first year of the study struggled with describing behaviour before and after a past event
(e.g. ‘have you changed how you brush your teeth since your last visit to the dental van?’). Their awareness
of factors such as family and friends’ dental habits was also limited, so social influences on their attitudes
towards dental treatment were not always clear. They were not always able to be clear about the FS/FV
treatment visits to the MDC, other visits to a MDC (e.g. examination visits for the study were also held in
the MDC) and visits to a community dentist in town, especially in year 1 of the study. For example, children
occasionally described a dental examination visit or having their teeth removed rather than a FS/FV treatment
visit. They were also sometimes unable to consolidate or clearly articulate their feelings about an aspect of
treatment, giving contradictory answers in interviews; this is not uncommon in qualitative interviews, but it
occurred to a greater degree in the child interviews. Some children may have contradicted themselves in
order to agree with their interview partner. When contradictory comments were made, data are not
reported, as the child’s preferences or views were not clear. Therefore, the number of unambiguous answers
for each question or theme (such as whether or not children liked the taste of the treatment) reported here
is lower than the number of children interviewed.
Interviews with participating parents
The interviews with parents were conducted by telephone 4–6 weeks after their child’s first and last
treatments, in years 1 and 3 of the study. Parents were interviewed after their children had been interviewed.
The interview schedule was piloted with parents at a local community centre in South Wales in an area
that was not part of the trial. The following comments were received.
l The term ‘interview’ was perceived as intimidating. Parents preferred the terms ‘courtesy call’ or ‘chat’.
However, because there was a need to be clear to study participants that data were going to be
collected and analysed, the term ‘interview’ was retained, but simpler language was used when
parents were contacted. For example, parents were told that the purpose of the interview was to find
out what they thought about SoV.
l Similarly, parents thought that ‘recorded’ sounded less ominous than ‘tape-recorded’, because
‘recorded’ sounded similar to the phrase ‘your call may be recorded for training purposes’, which
people were used to hearing.
l Parents also suggested clarifying that interviews would take place by telephone; they said that this
would encourage more parents to consent, as it was perceived as easier to participate in a telephone
interview than in a face-to-face interview.
l Parents also made recommendations about recruiting other parents, suggesting that schools could be
more involved in this. They suggested using posters with pictures to remind parents about the study
and to increase trust because recruitment would be through the school. They also suggested enabling
parents to collect and return forms directly to the school rather than by a postbox, especially to class
teachers, as they are particularly trusted. Using plain English on posters and advertising, and clarifying
that assistance from staff was available for parents with low literacy/English language skills, were also
suggested as ways to increase accessibility.
Schools were not asked to assist further with recruitment as there were concerns about the research
burden. Nevertheless, some schools did assist with recruiting. For example, one school inserted a
reminder about study recruitment into the school newsletter, and one head teacher spoke to parents
as a group about the trial, as he thought that the parents would not understand the paperwork.
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Forty-nine parents were interviewed in year 1 of the study and 30 parents were interviewed in year 3.
The aim of the interviews in year 3 was to follow up all interviewees from year 1; attempts were made
to follow up as many children and parents from year 1 as possible, even if the child and parent could
not be interviewed. The most common reason for not following up a child or parent was that the parent
had changed their telephone number or did not answer the telephone despite several calls (the initial
telephone call was partly to reconfirm consent, so if the parent was not contactable then their child was
not interviewed). Another problem was the poor coverage of mobile phone reception in some areas of the
South Wales valleys (many parents did not have landlines). Furthermore, telephone calls from the university
were routed through the university switchboard; this resulted in the recipients of calls not being able
to identify the caller number, which probably resulted in some parents not answering. A mobile phone
was not a viable alternative because it could not be used in conjunction with a voice recorder for the
interviews, and the reception/quality of the line tended to be poor. Three parents were followed up after
the school was contacted for an up-to-date telephone number (permission to do this had been obtained
in the study consent forms). Secondary reasons for not following up were that a few children were absent
on the day of the interview at the school or had been withdrawn from the trial. As a result of the absent
children and the various problems recontacting parents, follow-up in year 3 of the study with some parents
and children was not possible. The intention was to interview the same pairs of parents and children in
years 1 and 3; this was achieved for 17 child–parent pairs. To increase the overall number of interviews,
additional schools were sampled and children and parents from these schools were also interviewed.
The interviews with parents were relatively short, lasting approximately 10–15 minutes, owing to parents’
brief answers and often busy schedules; on some occasions, during the interviews, young children could
be heard in the background. The interview topics included the acceptability of the treatment and the
treatment setting, social influences on attitudes towards treatment and treatment settings (such as
prior experience of dental treatment), changes in the child’s oral hygiene behaviour, the perceptions of
treatment impact and the acceptability and impact of the trial processes. See Appendix 18 for the parent
interview schedule.
Questionnaire and interviews with school staff
In year 1, a questionnaire was sent by e-mail to all 65 schools participating in the study. A second e-mail
was sent to non-responding schools and, if required, further contact was made by sending postal
questionnaires to any schools that had still not responded. The questionnaire included both closed and
open questions about schools’ experiences of the implementation of SoV (both the treatment programme
and the trial) and acceptability of the intervention. Twenty-four questionnaires (37%) were returned.
In the third year of the trial, at the end of the school year, the 24 schools that had returned a questionnaire
in year 1 were contacted by telephone to request their participation in an interview; those that agreed were
sent consent forms to complete. Of the 24 schools contacted, five agreed to take part in an interview,
and four interviews were actually conducted (one was cancelled because of sickness). Three interviewees
were head teachers and one was a class teacher. The interviewees were asked about the impact of the
trial and treatment delivery in the school, contextual factors that affected the feasibility and acceptability
of delivering preventative treatment in a school setting, the acceptability of treatments and the recruitment
of hard-to-reach parents for interventions. The interview schedule is in Appendix 19. The original intention
had been to purposively sample schools based on their questionnaire responses; however, as only
24 questionnaires were returned in year 1, and as the sample of teachers or head teachers willing or
able to spare time for an interview was likely to be only a fraction of this figure, all 24 schools were
contacted so that the number of staff interviewed would not be too small.
Interviews with community dental unit staff
The dental team delivering the treatment was interviewed annually; this took place at the end of the
school year. These interviews were conducted face to face at the CDS offices in Cardiff. Nine staff
were interviewed in the first year and 12 staff were interviewed in both the second and the third years.
This group included hygienists, dental nurses and the staff members who collected children from the
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classrooms. The staff makeup of the groups was largely the same each time, but there were occasional
omissions or additions because of staff leaving or joining, or because a staff member was unavailable
(e.g. through sickness) on the days of the interviews. The interviews explored the feasibility and acceptability
of delivery in a school setting, perceptions of acceptability of the treatment for children, child co-operation
and perceptions of parent recruitment issues. The interview schedule is in Appendix 20.
Questionnaire and interviews with non-participating parents
For the first and second cohorts, the interviews with parents who did not participate in the trial were
conducted after the trial recruitment periods had ended; this was to avoid any confusion or perceptions
of harassment about recruitment to the trial itself rather than to a research interview. Two recruitment
methods were used; the intention was to recruit up to 20 parents by each method. In the first method, if
parents had not responded to the initial SoV recruitment attempt, they were sent information about the trial
a second time. This information included a consent form for a telephone interview to discuss their reasons
for non-participation, and a one-page questionnaire about their reasons, for those parents who did not
wish to participate in the SoV study but were willing to take part in research about non-participation. The
parents were invited to return the questionnaire, the consent form or both if they did not wish to participate
in the trial. Those who returned the consent form were followed up with a telephone interview.
The second recruitment method was speaking to parents who had not returned any paperwork for the
SoV trial itself and had also not returned the questionnaire or consent form for the interview about
non-participation. This was done to collect data from parents who may have been willing to take part in
the research but were unlikely to respond via a written invitation. Direct contact, including face to face, is
likely to be effective for recruitment for interviews for hard-to-reach groups that have difficulty with literacy
or paperwork and has the added benefit that a researcher visiting schools in person can familiarise people
with a study and reduce anxiety about particular elements. It was also expected that teacher and school
staff support for an intervention would have a positive influence on recruitment rates.64 Seven schools
were visited to recruit this group of parents and these were sampled by identifying schools that had lower
than average recruitment rates for SoV, although very small schools were excluded as there were too few
potential interviewees. The initial plan was to recruit parents from a parents’ evening at a sample of
schools, at which teachers and school staff would introduce the researcher to groups of parents and
request participation in a research interview, but the research team was advised by several schools that it
would be difficult because of how busy these events are and that parents would have limited time for
interviews. Therefore, a second approach was devised.
In this second approach, a researcher waited with the year 2 class teacher by the exit door at the end
of the school day, a time when a direct handover of the child to the parent or carer is required. The
researcher and teacher/teaching assistant handed out information sheets directly to parents. This helped to
associate the researcher with the school and with the class teacher, which it was hoped would build trust,
and meant that the researcher was available for parents to ask any questions about the research. The
researcher did not approach parents, except to give them the information sheet, to avoid parents feeling
harassed to take part. This recruitment was conducted after the first child dental examination to establish
trial eligibility had been carried out, so there was no possibility that this approach could be identified
with trial recruitment, which had finished by this point. The information sheet made it clear that the trial
recruitment had finished and that the current recruitment was for a research interview only, to find out
why some parents decided not to take part in dental studies and programmes to inform future
interventions. Information sheets were given only to parents who had not returned any paperwork to the
trial. Parents were told that the researcher would be in the school (accessible via the school reception desk)
one day during the following week, when parents could drop in to do an interview if they wanted. The
interviews were set up on a ‘drop-in’ basis to make it easy and flexible for parents, rather than arranging
an appointment time, and to further avoid parents feeling harassed to take part in the research. Year 2
class teachers were asked to remind parents about the interviews the day before. The information sheet
also included the researcher’s telephone number in case parents had any queries about the interviews.
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This recruitment was carried out in years 1 and 2 of the study (for cohorts 1 and 2), and for cohort 2 an
incentive of a £10 shopping voucher was offered for a completed interview.
Parents who withdrew their children from the trial were also sent a letter inviting them for a telephone
interview about their reasons for deciding to no longer take part. The target for the study was to recruit up
to 20 withdrawing parents and to compare data by trial arm.
The results of these recruitment efforts and the data collected on reasons for non-participation are discussed
in detail in Findings.
Data analysis
Treatment acceptability as measured by observed signs of distress
A ‘signs of distress’ scale independently measured by both the dental nurse and dental hygienist was
calculated as the mean of the valid item responses (scored 1 for yes and 0 for no; see Appendix 16).
When three or more of the items were missing, the score was set as ‘missing’.
Treatment acceptability as determined using the Delighted–Terrible Faces scale
Child-rated treatment acceptability at each treatment visit used the DTF scale. Faces were scored 1–5
(happy to sad) and a mean score calculated over the five items. The distribution of this score precluded
linear regression analysis and the results were categorised into a binary outcome as follows (scores 1–2.49
as ‘happy’ and scores 2.5–5 as ‘sad’). When three or more of the items were missing, the DTF score was
set as missing.
The determination of acceptability between intervention arms of the trial is reported as unadjusted and
adjusted ORs, calculated as described in Chapter 2.
Qualitative data
All interviews were digitally recorded and fully transcribed. Transcriptions were then uploaded to NVivo
version 9 (QSR International, Warrington, UK) and analysis was conducted in three stages. First, data were
analysed by means of framework analysis, using NVivo version 9 software.65 Framework analysis is a method
that organises responses by respondent and interview content, and allows analysis by case or theme so that
they can be compared easily.65 The research questions and interview schedule questions formed the initial
categories for the framework; any additional categories for other themes that emerged from the data were
added to the framework. For example, children tended to discuss not only the FS or FV treatment itself,
but also the chair, protective glasses, air/water sprays and so on, and so these were recorded as separate
factors affecting acceptability. Separate frameworks were produced for each trial arm, interviewee group
(child, parent, CDS staff, school staff), time point (first, second and third year of trial) and school deprivation
level (high/low). This was to facilitate reporting by each interviewee group and comparison between trial
arms, deprivation level and across time. Most of the categories in each framework were similar (e.g. all
interviewees were asked about treatment acceptability), but a few varied (e.g. only the CDS staff framework
had a thematic category for child co-operation). Each category in each of the frameworks was summarised
in a short list of bullet points in summary tables; this enabled a summary of each theme to be produced, but
also contained sufficient detail about variance between responses to avoid bias in the reporting.
The qualitative data analysis took a postpositivist approach (compared with the constructivist paradigm that
is often adopted in qualitative research). This was primarily because the research questions for the process
evaluation were very specific to particular aspects of the treatment and setting, rather than being an
exploratory or in-depth study of behaviours. Furthermore, the child and parent interviews were relatively
short, and answers tended to be brief and to the point. The children were too young to provide very
elaborate answers and parents were often very busy (young children or infants were frequently heard in the
background of telephone interviews). The data collected therefore matched all interview schedule categories
very closely and did not elaborate beyond brief facts or opinions. This made a framework analysis
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appropriate for analysing this type of data, rather than the multilevel interpretive coding that would be
appropriate for more in-depth data. For the same reason, only one researcher (SMT) analysed the data.
Reflexivity in terms of the interview schedule or interpretation of the data was also not conducted, as the
interpretative nature of data analysis is not emphasised in postpositivist research. However, potential
influences on the data were noted when appropriate (e.g. a probable social desirability bias in reporting oral
hygiene and dietary behaviours, as noted in Impact of treatment and trial on oral health behaviour).
In the second stage of analysis, the framework summaries were compared by trial arm, deprivation level
and time points (years 1 and 3 of the trial).
Findings
Overall acceptability of FS/FV treatment in a school setting was high for children, CDS staff, school staff
and parents. Factors influencing acceptability were largely non-FS/non-FV aspects of treatment or aspects
of the wider treatment or school setting. These are discussed separately in the following sections. First, the
acceptability is described as it was observed during treatment and reported by the children immediately
post treatment. Next, the acceptability of the actual FS/FV treatments for children is reported, before global
acceptability for children is reported, which often depended on wider aspects of the dental treatment. The
section after this describes the acceptability of the treatment setting to children, parents, CDS staff and
schools. Finally, the impact of the SoV trial on oral hygiene behaviour and the reasons for participation and
non-participation in SoV are discussed.
Acceptability of treatment
Signs of distress
Immediately after treatment in the MDC, the dental hygienist and the dental nurse recorded signs of
adverse behaviour during FS or FV placement. Observations during the baseline examination are reported
in Tables 69 and 70. The equivalent data at the 30-month treatment visit are shown in Tables 71 and 72.
Overall, the proportion of children displaying adverse behaviours or showing signs of distress during
treatment at baseline, as observed by the dental hygienist, was small: 97 of the 468 children in the sealant
treatment arm and 40 out of 464 children in the FV arm of the study. Children in the FS arm were more
likely to gag and to cry. There was good agreement between the observations made by the dental
hygienist and the accompanying dental nurse, although the nurses were more likely to observe and report
excess movement of arms and legs during treatment.
TABLE 69 Dental hygienist observation of behaviour during baseline treatment, by trial arm
Behaviour
Intervention arm
Total (N= 932), n (%)FS (N= 468), n (%) FV (N= 464), n (%)
Vomiting 4 (0.9) 3 (0.7) 7 (0.8)
Gagging 39 (8.4) 16 (3.5) 55 (6.0)
Crying 16 (3.5) 3 (0.7) 19 (2.1)
Excessive arm movements 22 (4.8) 8 (1.7) 30 (3.3)
Excessive leg movements 2 (0.4) 5 (1.1) 7 (0.8)
Other signs of distress 67 (14.6) 20 (4.4) 87 (9.5)
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To facilitate analysis, the adverse outcomes over the course of the trial as observed by the dental hygienist
and the dental nurse were dichotomised (any adverse outcome vs. no adverse outcomes recorded) for
analysis (Tables 73 and 74). The behaviours observed differed across the intervention arms of the study.
At baseline, 21% of participants displayed some form of adverse behaviour, but this fell steadily at
subsequent treatment visits up to the final treatment visit at 30 months, at which only 2.6% of the
participants were observed to have some form of adverse behaviour during treatment. In contrast, the
proportion of children showing signs of adverse behaviour during the application of FV remained more
constant in the course of the trial, ranging from 8.7% at baseline to 3.8% and 4.1% at the 24- and
30-month visits, respectively. During the trial, increased familiarity with the treatment process and
increased ability to cope as the children got older are probable influences on these findings.
TABLE 70 Dental nurse observation of behaviour during baseline treatment, by trial arm
Behaviour
Intervention arm
Total (N= 931), n (%)FS (N= 467), n (%) FV (N= 464), n (%)
Vomiting 2 (0.4) 1 (0.2) 3 (0.3)
Gagging 35 (7.6) 13 (2.8) 48 (5.2)
Crying 17 (3.7) 4 (0.9) 21 (2.3)
Excessive arm movements 24 (5.2) 12 (2.6) 36 (3.9)
Excessive leg movements 12 (2.6) 3 (0.7) 15 (1.6)
Other signs of distress 52 (11.4) 20 (4.4) 72 (7.9)
TABLE 71 Dental hygienist observation of behaviour during 30-month treatment, by trial arm
Behaviour
Intervention arm
Total, n (%)FS, n (%) FV, n (%)
Vomiting 0 (0) 0 (0) 0 (0)
Gagging 6 (1.4) 7 (1.7) 13 (1.5)
Crying 3 (0.7) 2 (0.5) 5 (0.6)
Excessive arm movements 0 (0) 2 (0.5) 2 (0.2)
Excessive leg movements 0 (0) 0 (0) 0 (0)
Other signs of distress 7 (1.7) 12 (2.9) 19 (2.3)
TABLE 72 Dental nurse observation of behaviour during 30-month treatment, by trial arm
Behaviour
Intervention arm
Total, n (%)FS, n (%) FV, n (%)
Vomiting 0 (0) 1 (0.2) 1 (0.1)
Gagging 4 (1.0) 10 (2.4) 14 (1.7)
Crying 3 (0.7) 3 (0.7) 6 (0.7)
Excessive arm movements 1 (0.2) 1 (0.2) 2 (0.2)
Excessive leg movements 0 (0) 0 (0) 0 (0)
Other signs of distress 8 (1.9) 14 (3.3) 22 (2.6)
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The difference between trial arms at baseline as observed by the dental hygienists at the baseline
examination was subject to two-level and single-level logistic regression (Tables 75 and 76).
Model 1 is a two-level logistic model of child within school, whereas model 2 is a single child-level model
for the dichotomised adverse outcome scale. It can be seen that the addition of school as a level does
not alter the main conclusion that a significantly higher proportion of children in the FS arm experienced
adverse outcomes at baseline. Both models adjust for the balancing variables from the randomisation
(sex and baseline caries).
A similar analysis was of the behaviours observed by the treating dental hygienist conducted at the
30-month treatment visit (Table 77). Slightly more adverse events were recorded in the FV arm at 30 months,
although the number of events was low in both intervention arms.
TABLE 73 Trends in signs of distress as observed by the dental hygienists at baseline and at 6, 12, 18, 24 and
30 months
Time point
Intervention arm
Overall, n (%)FS, n (%) FV, n (%)
Dichotomised hygienist-rated adverse outcome scale (yes)
Baseline 97 (21.0) 40 (8.7) 137 (14.9)
6 months 72 (15.4) 35 (7.9) 107 (11.7)
12 months 40 (8.7) 24 (5.3) 64 (7.0)
18 months 20 (4.4) 23 (5.2) 43 (4.8)
24 months 18 (4.1) 16 (3.8) 34 (3.9)
30 months 11 (2.6) 17 (4.1) 28 (3.3)
TABLE 74 Trends in signs of distress as observed by the dental nurse at baseline and at 6, 12, 18, 24 and 30 months
Time point
Intervention arm
Overall, n (%)FS, n (%) FV, n (%)
Dichotomised nurse-rated adverse outcome scale (yes)
Baseline 92 (20.0) 36 (7.8) 128 (13.9)
6 months 56 (12.0) 32 (7.2) 88 (9.7)
12 months 23 (5.0) 24 (5.3) 47 (5.2)
18 months 16 (3.5) 26 (5.9) 42 (4.7)
24 months 15 (3.4) 15 (3.6) 30 (3.5)
30 months 14 (3.3) 25 (5.9) 39 (4.6)
TABLE 75 Summary data for the dichotomised hygienist-rated adverse outcome scale at baseline
Adverse outcome
Intervention arm
Overall, n (%)FS, n (%) FV, n (%)
No 365 (79.0) 420 (91.3) 785 (85.1)
Yes 97 (21.0) 40 (8.7) 137 (14.9)
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Again, model 1 is a two-level logistic model of child within school, whereas model 2 is a single child-level
model for the dichotomised adverse outcome scale. It can be seen that the addition of school as a level did
not alter the main conclusion that the proportion of children experiencing adverse outcomes at 30 months
was slightly higher in the FV arm than in the FS arm, but the difference was not significant (Table 78). Both
models adjust for the balancing variables from the randomisation (sex and baseline caries).
Acceptability of fissure sealant/fluoride varnish treatment
for children
Participants’ perception of treatment acceptability
Treatment acceptability was assessed from the child’s perspective through a DTF scale (see Appendix 12),
completed by all children in the MDC immediately following the initial application of FS/FV and at each
follow-up visit. The scores recorded at the baseline treatment visit are recorded in Table 79. It is apparent
that time and taste were the dominant factors influencing acceptability. To facilitate analysis of the trends
observed over the course of the trial, the data were dichotomised to most happy/happy versus neither
happy nor sad/sad/most sad.
The proportion of children who opted for the neither happy nor sad face, the sad face or the very sad face
at baseline to describe their feelings on completion of treatment was much higher in the FS group than in
the FV group (49.2% vs. 27.1%). This proportion reduced during the course of the study so that by the
TABLE 76 Two-level and single-level logistic regression of the dichotomised hygienist-rated adverse outcome scale
at baseline
Model ORa 95% CI p-value ICC
Model 1 0.337 0.22 to 0.51 < 0.001 0.152
Model 2 0.357 0.24 to 0.53 < 0.001 n/a
n/a, not applicable.
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
TABLE 78 Two-level and single-level logistic regression of the dichotomised hygienist-rated adverse outcome scale
at 30 months
Model ORa 95% CI p-value ICC
Model 1 1.63 0.75 to 3.55 0.221 0.087
Model 2 1.59 0.74 to 3.45 0.238 n/a
n/a, not applicable.
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
TABLE 77 Summary data for the dichotomised hygienist-rated adverse outcome scale at 30 months
Adverse outcome
Intervention arm
Overall, n (%)FS, n (%) FV, n (%)
No 411 (97.4) 401 (95.9) 412 (96.7)
Yes 11 (2.6) 17 (4.1) 28 (3.3)
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30-month examination, only 16.8% of the FS-treated group reported that they were neutral or sad
immediately following treatment. This contrasts with the findings in the FV arm, in which there was a
gradual increase in the proportion of children opting for the neutral or sad options on the DTF scale
between baseline and 30 months (Table 80).
Two-level and single-level logistic regression models were constructed to determine the difference between
intervention arms at baseline and at 30 months (Tables 81–84).
TABLE 79 Delighted–Terrible Faces scale scores at baseline treatment visit
Score
Intervention arm
Total (N= 926), n (%)FS (N= 463), n (%) FV (N= 463), n (%)
How did you feel during the treatment?
1 – most happy 245 (53.1) 319 (69.0) 564 (61.1)
2 97 (21.0) 56 (12.1) 153 (16.6)
3 77 (16.7) 59 (12.8) 136 (14.7)
4 22 (4.8) 22 (4.8) 44 (4.8)
5 – most sad 20 (4.3) 6 (1.3) 26 (2.8)
If you had to have the treatment tomorrow how would you feel?
1 – most happy 180 (39.1) 212 (46.0) 392 (42.6)
2 104 (22.4) 116 (25.2) 217 (23.6)
3 85 (18.5) 62 (13.4) 147 (16.0)
4 43 (9.3) 43 (9.3) 86 (9.3)
5 – most sad 51 (11.1) 28 (6.1) 79 (8.6)
How do you feel about the time it took to have the treatment?
1 – most happy 161 (35.4) 273 (59.2) 434 (47.4)
2 65 (14.3) 86 (18.7) 151 (16.5)
3 95 (20.9) 56 (12.1) 151 (16.5)
4 64 (14.1) 24 (5.2) 88 (9.6)
5 – most sad 70 (15.4) 22 (4.8) 92 (10.0)
How did you feel about the taste of the treatment?
1 – most happy 75 (16.5) 184 (39.8) 259 (28.3)
2 39 (8.6) 48 (10.4) 87 (9.5)
3 47 (10.4) 53 (11.5) 100 (10.9)
4 116 (25.6) 78 (16.9) 194 (21.2)
5 – most sad 177 (39.0) 99 (21.4) 276 (30.1)
Did the treatment make you feel like you wanted to be sick?
1 – most happy 280 (61.5) 299 (64.7) 579 (63.1)
2 22 (4.8) 26 (5.6) 48 (5.2)
3 35 (7.7) 43 (9.3) 78 (8.5)
4 53 (11.6) 42 (9.1) 95 (10.4)
5 – most sad 65 (14.3) 52 (11.3) 117 (12.8)
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TABLE 80 The number of participants selecting ‘neither happy nor sad, sad or very sad’ at each of the time points
in the clinical trial by intervention arm
Time point
Intervention arm
Overall, n (%)FS, n (%) FV, n (%)
Dichotomised modified DTF scale (‘neither happy nor sad, sad or very sad’)
Baseline 224 (49.2) 125 (27.1) 349 (38.1)
6 months 131 (28.7) 134 (30.1) 265 (29.4)
12 months 92 (21.2) 148 (32.7) 240 (27.1)
18 months 77 (17.1) 140 (31.9) 217 (24.4)
24 months 81 (18.7) 159 (37.9) 240 (28.1)
30 months 71 (16.8) 171 (40.7) 242 (28.7)
TABLE 81 Summary data for the dichotomised modified DTF scale at baseline
Intervention arm
Overall, n (%)FS, n (%) FV, n (%)
Very happy or happy 231 (50.8) 337 (72.9) 568 (61.9)
Neither happy nor sad, sad or very sad 224 (49.2) 125 (27.1) 349 (38.1)
TABLE 82 Two-level and single-level logistic regression of the dichotomised modified DTF scale at baseline
Model ORa 95% CI p-value ICC
Model 1 0.38 0.29 to 0.50 < 0.001 0.012
Model 2 0.38 0.29 to 0.50 < 0.001 n/a
n/a, not applicable.
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
TABLE 83 Summary data for the dichotomised modified DTF scale at 30 months
Intervention arm
Overall, n (%)FS, n (%) FV, n (%)
Very happy or happy 351 (83.2) 249 (59.3) 600 (71.3)
Neither happy nor sad, sad or very sad 71 (16.8) 171 (40.7) 242 (28.7)
TABLE 84 Two-level and single-level logistic regression of the dichotomised modified DTF scale at 30 months
Model ORa 95% CI p-value ICC
Model 1 3.63 2.60 to 5.07 < 0.001 0.073
Model 2 3.44 2.19 to 4.75 < 0.001 n/a
n/a, not applicable.
a FV compared with FS. Analysis adjusted for baseline caries prevalence and sex.
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Model 1 is a two-level logistic model of child within school, whereas model 2 is a single child-level model
for the DTF scale. It can be seen that the addition of school as a level does not alter the main conclusion
that the proportion of children reporting that they were happy or very happy at baseline was significantly
higher in the FV arm than in the FS arm, and that the proportion of children reporting that they were
happy or very happy at 30 months was significantly higher in the FS arm than in the FV arm. Both models
adjust for the balancing variables from the randomisation (sex and baseline caries).
From the above, it is obvious that the acceptability of the technologies under test as judged by the children
immediately post treatment was different at different time points in the trial. There are two main issues:
1. At baseline, the children in the FV arm were significantly happier than those in the FS arm, this situation
being reversed at the final treatment at 30 months.
2. Those receiving FS became happier as the trial progressed; however, in contrast, in the FV arm there
was a modest decrease in the number of children who chose a happy face over the course of the trial.
These findings are in line with what might be expected from a clinical perspective. As the FSs were applied
at the beginning of the study as soon as the FPMs erupted, the treatment was more invasive and intense
and, as described in Chapter 3, took longer. The children receiving FV, however, had to experience
treatment of approximately the same intensity throughout the study.
Qualitative findings on treatment acceptability
In addition to the quantitative determination of treatment acceptability, treatment acceptability formed a
major component of the qualitative investigations. In the interviews, the children largely talked about the
actual FV or FS treatment in terms of taste. FV was variously described as ‘banana jam/gel/paste’, tasting like
‘candy floss’, ‘oranges’ or ‘apple’, being ‘burny’ and tasting ‘a bit funny and a bit nice’. FS was described as
tasting like water, tasting like ‘sour apples’ and being ‘very horrible’ or ‘disgusting’ (although some children
liked the taste). Children in year 1 of the study tended to think of the treatment as a ‘banana gel/paste’
and, as children were not always aware that there were two different treatments, children in both arms
talked about a banana flavour. Because CDS staff were aware that not all children liked banana flavour and
that this might make them reluctant to co-operate with further treatment, they referred to a ‘fruity taste’
when talking to children. In the final year interviews, children discussed different fruit flavours of the
treatment, and some children thought that different flavoured treatments were used or wanted to receive a
different flavoured ‘gel’ on each visit.
Children’s opinions were mixed in terms of whether or not they liked the taste; some had mild like/dislike,
whereas others had stronger positive or negative reactions:
Interviewer: All right, so you both don’t like the taste of it? Is it just a little bit disgusting or is it
really awful?
Child 1: Really awful.
Child 2: It’s really awful.
Paired child interview, one FS arm and one FV arm, year 3
Interviewer: And what do you think about having a dental van coming to the school?
Child 1: I like it, I feel happy I do.
Child 2: I feel happy too.
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Interviewer: And why do you like it and why do you feel happy?
Child 1: Because when like you have this banana stuff.
Child 2: Aw yeah, it tastes really nice.
Child 1: It tastes nice.
Interviewer: Is that what you like about it?
Child 1: Yeah.
Paired child interview, FV arm, year 3
I think the banana gel is a bit bleurgh.
Paired child interview, FV arm, year 3
It’s not the best taste but it’s not the worst taste.
Paired child interview, FS arm, year 3
Many children said that their experience of the treatment and of visiting the MDC was good, and said they
felt ‘OK’ or ‘fine’ about it, even if they did not like the taste:
Interviewer: So can you tell me what you thought about going to the dentist when you went?
Child 1: It was quite fun.
Child 2: It was quite fun and it tasted disgusting.
Interviewer: OK [to child 2] you thought it was disgusting and [to child 1] you thought it was
quite fun.
Child 1: I thought it was fun.
Child 2: It was fine but it tasted horrible.
Paired child interview, FS arm, year 1
Several clinical staff members thought that children did not always complete the DTF form in a way that
was internally consistent or consistent with what they expressed to staff during their treatment visit; this
may be because of the number of different factors driving acceptability for children, as reflected in the
previous quotation.
In year 1 of the study, in the FS arm, 13 of the 16 children who made clear statements about the taste of
treatment made negative comments about the taste, whereas in the FV arm children’s reactions to the
taste were more evenly spread. However, children in the FV arm who did not like the taste were more
likely to express negative feelings about having to have more treatment in the future, and half of these
children said nothing positive about the treatment experience at all. This may indicate that, although
children were less likely to dislike the FV, those who did dislike it had stronger reactions to the taste of the
treatment than did children in the FS arm. However, these results should be interpreted with caution, as
the sample sizes were small.
In year 3 of the study, there were far fewer very negative comments about having more treatment than
there had been in year 1. Children in the FV arm again made a fairly even spread of comments about the
taste, from positive to negative, whereas FS children were more likely to make ‘middling’ assessments.
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This may be because some FS arm children would not have been having further treatment at this stage,
unless the sealant needed to be reapplied. Two of the FS children thought that the process was quick, and
two others in this group mentioned the treatment visits not always being the same. Of the children who
made negative comments in the FV arm, all mentioned the taste and/or feeling sick, although only one
said that they would be nervous about going back for more treatment because of this. There were no
differences by deprivation level.
In the final year of the study, no child interviewed reported very negative overall attitudes towards having
treatment, even though some children still reported not liking the taste. For example, one FS child in year 3
said that they would be excited to go for treatment again, but also said that the taste was really awful.
Overall, most children were generally tolerant about having FS/FV treatment by this stage:
Interviewer: When you have to go and have your treatment in the dental van, what do you think
about that?
Child 1: It was all right but the taste was a little bit not that nice.
Interviewer: Not that nice.
Child 1: It tasted like bananas.
Interviewer: So you didn’t really like the taste but apart from that, it was all right you said?
Child 1: Yeah.
Interviewer: It was OK. And what about you [to child 2]? What do you think?
Child 2: The taste was not that nice and it tasted like oranges.
Interviewer: It tasted like oranges. OK. So not that nice but apart from the taste, how was it having to
go and have the treatment?
Child 2: Not that bad.
Paired child interview, FV arm, year 3
The qualitative data on treatment acceptability are similar to the findings from the DTF scales and co-operation
scales, in that the acceptability of FS treatment was low overall in year 1 but increased over time.
Other aspects of treatment were mentioned with less frequency than taste. Children very rarely
commented on the length of treatment unless they were prompted and seemed unconcerned by this
aspect of treatment. Perceptions of length of treatment depended more on the individual child than on
the trial arm. Children were more likely to comment on the time taken in terms of not liking to wait in
dentist waiting rooms (which they reported happened more commonly in community dentist offices than
in the MDC as part of the SoV trial). A very small number of children mentioned the texture of their teeth
afterwards as being sticky (FV) or ‘bumpy/dotty’ (FS). A few children mentioned feeling sick or vomiting:
one child in the FV arm and two in the FS arm mentioned feeling or being sick in year 1 and two children
in the FV arm in year 3 mentioned feeling sick. Most children did not notice discoloration, and the few
who did were not concerned by this. When asked whether or not their teeth had changed after treatment,
some children thought that the treatment had made their teeth stronger, whiter, cleaner or ‘fresh’. When
children commented on changes in their teeth, this tended to be in relation to normal changes such as
their adult teeth appearing, rather than any changes attributable to FS/FV.
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Parental reports of treatment acceptability
Parent accounts of child acceptability corroborated child reports. Parents said that children found it novel
and exciting to visit the MDC (known colloquially as ‘the van’) and that they liked various aspects of
treatment such as being with their friends and being given stickers:
Interviewer: Has he ever said anything about the taste or about how long it takes or anything
like that?
Parent: He said it’s banana taste.
Interviewer: Does he like that or does he not like that?
Parent: He likes that.
Interviewer: He likes the taste, OK. And does he say anything else about the van or going with his
friends or anything like that?
Parent: He just says he likes going on the van and having a sticker.
Interviewer: And he likes the sticker, do you know what he likes about going on the van?
Parent: I think it’s the chair, because they let him play with the chair.
Parent interview, FS arm, year 3
Many parents said that their children did not say much about the treatment but would have complained if
they had found the treatment very objectionable. A small number of children had reported to their parents
that they did not like the taste or another aspect of treatment (e.g. that it was ‘gluey’) but, again,
acceptability was often based on more than one factor:
Parent: She said that it tasted horrible.
Interviewer: OK.
Parent: That was it really just it didn’t taste very nice but she was delighted because she had stickers
[laughs] you know I was like ‘What was it like, what did they do?’ and she said ‘They put something in
my mouth and it didn’t taste very nice’.
Parent interview, FS arm, year 1
In year 1, children either did not say anything about the treatment to their parents or said that it tasted
funny or that they did not like the taste. In year 3, children still either said little or reported that they did
not like the treatment, but children at this stage also mentioned to parents aspects of the treatment that
they liked. There were no differences between trial arms or by deprivation level.
Parents in the high-deprivation schools in the first year of the study were most likely to report discoloration
of teeth from the treatment, in both trial arms. In the final year of the study, a very small number (n = 3)
of parents in the FV arm reported discolouration. If parents did notice discoloration, they were not always
sure that this was because of the treatment; other explanations were that it might be because of their
child’s age or inadequate brushing. No parent was concerned about discoloration, and perceptions did not
differ by trial arm.
A few parents thought that their child’s teeth were whiter or shinier; some were not sure about changes but
expressed a hope that the child’s teeth were stronger or more protected because of the treatment received.
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School staff reports of treatment acceptability
Staff reported that the MDC and CDS service was well liked in schools by children; one head teacher
commented that usually children were disappointed if they were not called to attend. One school staff
member commented that if children did not like an aspect of treatment they forgot about it soon after
returning to the classroom.
Community Dental Service staff reports of treatment acceptability
Throughout the study, CDS staff had mixed opinions about which treatment was more acceptable to
children. They observed varied reactions to the treatment and different aspects of treatment that were
more or less popular:
The children react differently to be honest. Some of them love the varnish or some of the hate the
varnish, some of them play up because their friends are there or whatever, they have a different
reaction and then some of them are good with the sealants as well.
CDS staff interview, year 2
Community Dental Service staff commented that children were generally tolerant and well behaved,
regardless of whether they liked the treatment.
In year 1, more staff thought that FV was better liked by children because it was quicker and did not
involve cotton wool rolls, and because some children did not like the taste of the FS fixer. In year 2, the
staff commented in more detail about the pros and cons of both treatments: FV was quicker and easier to
apply, but it was also sticky, could cause nausea and had a lingering taste, whereas children could rinse
after FS treatment; if children gagged easily it meant that applying FS could be difficult, and children
sometimes found it difficult to keep their mouth open for a long time, but FS usually required only
check-ups rather than reapplication. They also mentioned that FV was easier than FS for a difficult child
as it was the quicker treatment. Staff used various tactics to encourage children, such as bringing nervous
children back later in the day to retry treatment, treating a nervous child first (so that the child did not
have to wait) or last (so that the child could observe other children receiving treatment), and sitting a child
further upright to reduce gagging.
Staff in years 2 and 3 also said that children were very accepting of treatment and that refusals were rare,
but they did note that acceptability still varied and that some children liked the treatment or taste and
some did not. By this point, some children remembered not liking the treatment and could react negatively
when attending again, which could then affect the other children they were with. One staff member
thought that children from more deprived areas reacted more negatively when coming back for treatment.
However, some FS children were disappointed that they did not receive any treatment when other
children did.
Various CDS staff comments mirrored what children reported. One staff member commented that children
receiving FS disliked the cotton wool rolls more than they disliked the length of treatment. A number of
staff members reported that whether or not children found the treatment acceptable was largely driven by
taste, and also that some children thought the treatment was too quick and would have liked more time
out of the classroom. Staff also commented that children liked different aspects of treatment, particularly
laughing at each other wearing the protective glasses; preferring to be with their friends and being less
nervous if they were accompanied; and enjoying the novelty and excitement of being on the MDC:
Oh they love coming on the van. They love it. They always ask who drives it and where do people,
some, some think that they sleep there overnight and it turns into a caravan but they love it, they love
coming on. What’s this drawer for, you know, yeah, they love coming on.
CDS staff interview, year 2
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The CDS staff members’ comments that children were chattier and asked more questions in year 3 of the
study also corroborated some children’s reports that they felt more confident now that they were older.
Global intervention acceptability for children
Turning to the information analysed from the interviews with the participating children, the primary
finding on the overall acceptability of FS/FV treatment for children was that there were many factors that
contributed to whether or not children found the treatment acceptable. Most of these factors were related
not to the FS/FV aspects of the MDC visit but rather to more general aspects of treatment or to the context
in which the treatment was delivered.
Most children commented that ‘going to the van’ was ‘fun’, ‘brilliant’ and ‘good’ and that it was exciting
to go there (the ‘van’ is the term children used to describe the MDC). Receiving stickers was a very popular
aspect of MDC visit, and three children mentioned that they liked the CDS staff. When comparing a visit
to the MDC with a visit to a family/community dentist, most children also expressed their views in relation
to factors beyond the actual treatment received, such as being given stickers, the speed of the visit, which
visit was warmer and the van being fun. Some children also mentioned that they liked having their teeth
looked after or protected:
I like the dentist because they look after your teeth and keep them clean.
Child interview, FV arm, year 1
Fourteen children in year 1 of the study mentioned feeling scared or nervous about the treatment; of
these, 12 said that being with friends (children normally attended the MDC in groups of three) made them
less nervous or feel safer. In year 3 of the study, fewer children mentioned feeling nervous, and in the
low-deprivation schools four children commented that they felt more confident about being at the dentist
now that they were older and more used to the treatment visits:
Child 1: We did both say we were nervous when we went, when we were.
Child 2: Yeah, when we were younger, ‘cos it was our first time.
Child 1: Yeah ‘cos it was less.
Child 2: We were like . . . not confident.
Child 1: Yeah.
Child 2: ‘Cos we were just too young to go on our own, not like on our own like.
Interviewer: You were quite young when you started though.
Child 2: Yeah, I was talking about before.
Child 1: Because you’re like quite scared, because you haven’t been to the dentist oftenly[sic].
Child 2: Then you might need . . .
Child 1: So when you get older and older and . . .
Child 2: You’ll be more confident.
Child 1: Yeah.
Paired child interview, one FS arm and one FV arm, year 3
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Although the older children generally felt more relaxed and confident about a visit to the MDC, they were
also more aware of what was going on around them. In year 3 of the study, a small number of children
reported that the examination made them feel anxious because they did not understand the tooth-numbering
terminology the CDS hygienist used and were worried that there might be something wrong with their teeth:
Child 1: They say stuff like numbers and stuff and we don’t really know what that means.
Interviewer: You don’t know what that means, OK.
Child 1: So like, they could be saying that our teeth are really bad or really good but we don’t know.
Child 2: Like A2 and A3 and that.
Child 1: Yeah.
Interviewer: Yeah.
Child 2: AC.
Interviewer: Sounds funny doesn’t it?
Child 2: Yeah.
Child 1: Yeah.
Interviewer: So would you like to know more, you’d like to understand what they’re saying?
Child 1: Yeah.
Paired child interview, one FS arm and one FV arm, year 3
Children also frequently mentioned generic aspects of the dental treatment they liked, particularly the
moving dental chair and protective (and often coloured) glasses. Feelings about the three-in-one syringe
were mixed, as some children found it unpleasant but some liked it because it was ‘ticklish’. The cotton
wool rolls were the least popular aspect of treatment and a few children expressed a dislike of having
their teeth ‘scraped’/’poked’. There were no differences in preferences between the FS and FV trial arms.
Children’s responses to what they thought about the overall treatment often centred on these wider
factors rather than on the FS/FV itself:
Interviewer: So can you tell me, what did you think about going to the dentist earlier this week?
Child 1: It was good, I liked it.
Interviewer: It was good . . .
Child 2: It was fun.
Interviewer: And you thought it was fun [to child 2], OK. And what did you like about it? [Pause.]
Or are you not sure?
Child 1: Because you got to sit on the special chair.
Interviewer: The special chair, a magic chair?
Child 1: Yeah.
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Interviewer: What was special about it? Why was it a good chair?
Child 2: Because it can move.
Interviewer: Is that fun?
Child 1: Yeah, and I like the glasses.
Interviewer: What do you like about the glasses?
Child 1: Because they protect our eyes and face.
Interviewer: They protect your eyes. Are they a special colour?
Child 2: White.
Interviewer: White?
Child 2: Yeah.
Interviewer: OK. Is there anything else that you liked about going?
Child 1: Yeah, I was excited.
Interviewer: You were excited . . .
Child 1: And because you got to go in the van.
Interviewer: Oh right, what do you like about the van?
Child 1: Because um [pause] can’t remember.
Interviewer: You’re not sure, that’s OK. But it’s fun going in the van?
Child 1: Yeah.
Paired child interview, FV arm, year 1
Taste was the main aspect of the actual treatment acceptability mentioned by children, but it was one of
several factors:
Interviewer: If somebody said you’ve got to go and have that same treatment done again tomorrow,
how would you feel about that?
Child 1: I wouldn’t mind.
Interviewer: You wouldn’t mind [to child 1] and how about you [to child 2]?
Child 2: It would be OK.
Interviewer: It would be OK. So it wouldn’t be fantastic but it would be OK?
Child 1: It would be fantastic.
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Interviewer: Why would it be fantastic?
Child 1: Because I love the banana gel.
Interviewer: Is that the best thing about going?
Child 1: No.
Interviewer: What’s the best thing about going?
Child 1: Getting the sticker.
Paired child interview, FV arm, year 3
A small number of children were so enthusiastic about the treatment visits that they responded
(unprompted) that they would be happy to have the treatment done all day/every day:
Interviewer: If the van came back tomorrow and you had to have it done all over again, how would
you feel about that?
Child: It don’t matter, I’ll have it every day.
Interviewer: OK. Why would you have it every day?
Child: Because the chair is fun.
Interviewer: Is that your favourite thing?
Child: Yeah.
Paired child interview, FV arm, year 1
Children in both trial arms mentioned similar acceptability factors in year 1 and year 3 of the study, such as
liking being with their friends, treatment being good for their teeth, and liking the stickers and the moving
chair, and mixed attitudes towards different aspects of the treatment, such as the three-in-one syringe:
Interviewer: And what do you think about going there for the treatment?
Child 1: I think it’s really good idea.
Child 2: Mm hm.
Interviewer: And what’s good about it?
Child 1: It’s like, we can get to wear some glasses, we can get a sticker, stuff like that.
Interviewer: Mm hm.
Child 1: We don’t get bad teeth when we’re older.
Paired child interview, FV arm, year 3
In year 3 of the study, children reported that some people in their class liked treatment and some did not.
However, most children in year 3 were more likely to report that they were ‘fine’ or happy/excited to go
for treatment, even if they did not like all aspects of it.
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Acceptability of treatment setting
Acceptability of treatment setting for children
To elicit information about the acceptability of the FS/FV treatment, children were asked if they preferred
being in class or leaving class to visit the dentist at the MDC. In year 1 of the study, most children did not
express a clear preference or were indifferent. Children who did express a preference gave various reasons:
they thought that it was important to get dental care, they did not like doing schoolwork/they liked
missing class, or they liked going to the MDC. One child said that they preferred being in class because
they liked their teacher. There were no differences between the FS and FV trial arms.
In the final year of the study, children were more aware of having to catch up on schoolwork if they
missed part of a class to visit the MDC, although this was not a major problem, as children mentioned
receiving help from their friends or from the teacher to do this. The main reason that children preferred
staying in the classroom was avoiding having to catch up on work later. Two children were not sure about
their preference; three children said that, if the lesson was mathematics, they would prefer to go to
the dentist.
Acceptability of treatment setting for parents
Several parents thought that their children behaved better, made less fuss or were less nervous about
seeing a dental clinician in a school environment:
Parent: He will do it in school.
Interviewer: So he’s a bit better in school?
Parent: Yeah, as the teachers are there.
Interviewer: The teachers are around?
Parent: Yeah yeah.
Interviewer: And you’re not?
Parent: That’s right he’s a good boy in school see [laughs] it’s an awful thing to say but it’s true.
Interviewer: Right, so is it just mainly because of the teachers and because it’s a school environment
that he behaves better?
Parent: He’s never naughty in school.
Parent interview, year 1
Parents did not mind their children missing some class time to attend the MDC. Some pointed out that, as
the children were young, missing a small amount of time was not significant. A few also pointed out that
the children missed less class time going to the MDC than they would if they went to a community dentist.
Parents also appreciated not having to escort children to the appointments and commented that this was
very convenient for them. A small number commented that the intervention was good for children who
would not otherwise see a dental professional.
Acceptability of treatment setting for school staff
In response to the questionnaire in year 1, the majority of schools indicated that hosting SoV in their
school had been straightforward, the programme ran smoothly with minimal disruption to the school, the
information received was easy to understand and SoV was similar to existing dental programmes running
in schools. CDS communication and co-ordination was good and both CDS and schools were flexible
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(e.g. in response to each other’s timetables). Six also said that it was interesting to be part of a study and
two said that they were pleased to offer it to their children. One head teacher mentioned not knowing
details of the study, which would have been helpful in explaining the intervention in response to parent
queries. One support teacher had had problems with not being aware that the vans were coming and this
causing disruption. One class teacher said that some children did not like the taste of the treatment and
that staff had to comfort them when the vans arrived the next time. The only other problems were taking
time to explain the study to parents (four respondents mentioned this), explaining the study to teachers in
the school (two respondents) and finding the time to respond to requests for data (four respondents).
Some schools distributed letters for the study, although some also actively reminded parents to return
them, by telephoning or texting parents, reminding them in person and by displaying a poster (in one
case). Eleven schools agreed that SoV fitted in with other health programmes or initiatives they were
involved in; the most common were tooth-brushing programme and the Healthy Schools scheme. Some
schools were unsure whether or not SoV had changed dental behaviour, several thought it made children
more aware of the importance of looking after their teeth, although another respondent commented that
they did various dental programmes so it was hard to know the effect of SoV on behaviour.
Responses in telephone interviews with school staff (mainly school heads) in year 3 were similar to the
questionnaire findings. Two school staff mentioned minor disruption to classes when children left to visit
the MDC and a small amount of extra paperwork but said that this was not a problem. Overall, visits to
the MDC were not perceived as a problem because they were quick and efficient, and schools were very
used to their visits:
Very, very minimal impact really. I mean they come in they do their stuff and off they go again.
School staff interview, year 3
The preventative programme was also perceived as meaning that children would miss less school than they
would visiting a community dentist for dental problems later on:
Well I’m hoping, from the information that was provided when I took over the class room is that it
was going to protect the children’s teeth, that there was going to be less cavities, less absences with
them disappearing for full days when they have teeth removed and teeth repaired because they’re
going to be better protected.
School staff interview, year 3
One school head also commented that the service was very child-friendly, and, because of this, the
children were not stressed and their visit to the MDC did not disrupt the school day too much.
School staff were positive about having the CDS service in schools and regarded it as fitting in with their
promoting health agenda and also helping them engage with families, which was seen as part of
their remit:
Interviewer: What do you think about having the dental clinic on the school grounds?
School staff: Oh absolutely fine.
Interviewer: Mm hm.
School staff: Absolutely fine. I think it was nice for the parents to see.
Interviewer: Mm hm. Why is that?
School staff: Well, because I think a lot of them find dentists, doctors, even crossing the threshold of
the school quite intimidating.
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Interviewer: Mm hm.
School staff: It’s made it more accessible for the community.
School head interview, year 3
School staff thought that SoV, along with other dental programmes, had improved children’s awareness of
dental health and oral hygiene.
Feasibility and acceptability of treatment setting for Community Dental
Unit staff
Community Dental Service staff found the treatment setting unproblematic on the whole, largely because
SoV was integrated with the Designed to Smile dental programme for children in South Wales, which
already used MDCs to deliver dental treatment to school children and typically ran very smoothly. CDS
staff reported that being part of the SoV trial had created extra paperwork and that this took some extra
time, especially early in the trial when staff were still getting used to it but that they were generally
positive about being part of the trial and reported no significant impact on how treatment was delivered
compared with other CDS services. A small number of staff mentioned that they had little time with each
child, which could be a disadvantage as chatting to a child could reduce anxiety sometimes.
Minor difficulties noted included parking a MDC in tight spaces or driving one in bad weather, and
occasionally school administrators (the main liaison persons for the CDS in schools) complaining about
paperwork or not being as helpful as they might be. One SoV staff member commented that because of the
various dental programmes running in schools, each with their own paperwork, schools could get confused
between them sometimes. However, most school administrators were helpful; for example, one would assist
SoV with recruitment if numbers were low and another would text reminders to parents. Overall, CDS staff
found schools very helpful and found that they valued CDSs. CDS staff reciprocated, being careful to
organise themselves around the school timetable and events to minimise disruption. Two CDS staff
members thought that schools in the more deprived areas were particularly welcoming to the MDC.
Community Dental Service staff also mentioned several aspects of the school setting that made treating
children easier, including children being more likely to turn up for appointments:
CDS staff: In the schools we’ve got a captive audience.
Interviewer: Mm.
CDS staff: In the clinic we have horrendous, horrendous DNA [did not attend] rates.
CDS staff member, year 3 of study
The CDS staff were also able to treat larger numbers of children more quickly in a school setting.
Impact of treatment and trial on oral health behaviour
As discussed in Chapter 3, none of the potentially confounding covariates affected treatment outcome by
trial intervention arm (see Table 19). In the qualitative element of the study, children and parents were
asked about changes in oral health behaviour as a result of participating in the trial. Both child and parent
interviewees tended to describe low and declining levels of child sugar and fizzy drink consumption:
Child: Well, I know it’s really bad for my teeth and that’s why I stopped ‘cos I don’t want like my teeth
to rot and stuff.
Interviewer: Yes, you stopped what?
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Child: I stopped drinking fizzy drinks and eating sweets . . . I’ve stopped chocolate and sweet stuff.
Interviewer: And what made you change?
Child: Cos my mum told me to stop it and I never used to listen to her and now everybody is saying
it’s bad for your teeth.
Interviewer: Mm.
Child: And so I don’t eat it any more.
Interview, year 3
Some children also reported starting to use mouthwash or brushing their teeth more frequently. One child
commented that they brushed their teeth more ‘to make them grow’. A small number of parents also said
that they monitored their child’s brushing more closely. There were no differences by trial arm (the sample
size was very small to make comparisons in any case, as some children found the concept of change over
time difficult to grasp). Some parents and children reported improving the child’s diet or tooth-brushing
habits because of the input from SoV, sometimes just by acting as a reminder to look after the child’s
teeth. However, there is likely to be a social desirability bias in the data collected, especially as some
parents assumed that the researcher was a dental practitioner (several requests were made by parents to
inspect children’s or parents’ teeth during the study; parents were advised to see a dental practitioner).
Reasons for participating or not participating in Seal or Varnish?
Reasons for participation
Most parents were not fully aware of the details of the treatment or study but were participating to
generally benefit their children’s teeth and to feel that they had done as much as possible to promote their
child’s dental health:
I’m thinking myself there’s every chance now that I’ve given her the best chance to look after her
teeth then and she may not have decay.
Parent interview, year 3
Most made the decision about participation themselves, although some also consulted their spouse or the
child as well. A small number checked with their regular dentist first. Some parents were able to recall that
it was a protective treatment that was put on teeth, although not all remembered that it was treating only
molars or that there were two different treatments being used. Some thought that SoV included dental
education. Randomisation to trial arm was not always understood: one parent thought that their child
might receive no treatment, and another thought that their child was ‘lucky’ to be picked for treatment.
Few knew how long the study lasted, and many asked about this during research interviews. A few
parents had very little understanding or had completely forgotten the details of the study:
Interviewer: Do you understand what the study is about?
Parent: Not really no.
Interviewer: OK, is there anything, if you had to tell a friend about what Seal or Varnish? was what
would you say?
Parent: Well to be honest I don’t really know a lot about it.
Parent interview, year 1
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However, parents trusted the school and several said that they participated partly because of this:
It was with the school I was quite happy because it was recognised through the school.
Parent interview, year 1
I trust the school with everything.
Parent interview, year 1
Several parents also gave accounts of family members’ dental histories and experience of FS/FV, either their
own or that of the participating child or another of their children, both positive and negative, and gave
this as a reason for participation. Some parents liked that the programme would mean that their children
would have dental check-ups more regularly (even if they were already having 6-monthly check-ups at a
community dentist) because problems would get picked up more quickly.
A small number of parents (both participating and non-participating) also mentioned the value of doing
research and were also willing to participate for this reason (although it was not a primary reason).
Reasons for non-participation
Nineteen parents returned a consent form (including in the second trial recruitment package sent home with
children) to be interviewed about non-participation. When contacted by telephone, four said that they were
taking part in the trial or had signed up, so no interview was attempted. Five did not answer the telephone or
the number was wrong, two had a level of English that was too limited for an interview, two said that they
were not participating because they were moving house, one was too busy to do an interview because of
family illness and one said that they did not want to do an interview and also commented that they did not
participate because they already had a dentist in town. On subsequent cross-checking of the 19 consent
forms with trial records, it was found that only 8 of the 19 ‘non-consenter’ parents had not given consent.
Six had given consent but were ineligible and five were actually in the trial. It is likely that a majority of
parents had completed all the forms their child had brought home from school without checking the content
of the form thoroughly and did not realise that the consent forms for non-participation interviews were
different from the trial forms and completed and returned all the forms they received. CDS staff reported that
this was common in parents receiving paperwork about other dental programmes. Hence, the contacts made
with parents who returned these forms did not yield any data on reasons for non-participation, except that
parents had not always understood the paperwork they received or completed it correctly.
Twelve parents returned the questionnaire about reasons for non-participation (parents could give multiple
responses, and so the number of responses is > 12).
The responses indicate positive and negative reasons for non-participation. Some parents did not
participate because they just wanted to continue with existing dental care, some were unsure about SoV’s
benefit or acceptability to the child, and some were unwilling to take part because it was also a research
study (Table 85).
The questionnaire also asked about dental care and tooth-brushing habits, to determine whether children
with poor dental habits were more or less likely to take part in this type of intervention. According to their
parents, three children brushed their teeth at least twice a day, four children brushed their teeth once a
day and one child did so less frequently than once a day. All parents said that their child visited a dental
surgery regularly.
Face-to-face recruitment at the school handover at the end of the day, through distributing an invitation to
participate in a research interview, did not work well for the hardest to reach non-participating parents
(those who had never responded to any of the study recruitment materials they had received). This
recruitment effort was a second measure to try to collect data on why some parents did not participate in
the SoV intervention or study. During recruitment for non-participants at handover time at the end of the
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school day, no parents queried the researcher, although one or two made more general queries about
dental services available in relation to specific problems that their child was having. These parents were
given the telephone number for the CDS for information about appropriate dental services.
Five parents across three schools gave consent to be interviewed. One decided not to participate in SoV
because they were moving house but would have liked to otherwise and had attended the interview
primarily to find out about their own dental treatment. One was participating in the trial and two thought
that they had returned consent forms. One of these parents was familiar with FS because their child’s older
sibling had had this treatment, and they thought that they had consented and so did not know why they
were not taking part. Three did not remember receiving any information about SoV but were generally
positive about school dental programmes. Two commented that they thought that their child had probably
lost the letter sent out from the school and that this had happened with school letters before: ‘sometimes
she makes paper aeroplanes out of it’. None expressed any negative feelings about taking part in a trial.
Therefore, this set of interviews yielded no data on reasons for non-participation, as parents were generally
positive about the dental programme, except that, again, that there was confusion about or difficulties
with completing the paperwork. This recruitment effort was eventually abandoned, as these five interviews
yielded few useful data and had required 14 school visits (two visits each to seven schools) to achieve. The
addition of a shopping voucher as an incentive in year 2 increased the participation rate only very marginally.
The overall finding from the recruitment efforts and results from speaking to these ‘non-participating’
parents was that there was a lack of understanding of and engagement with the paperwork in various
respects. In the initial piloting of the materials, the paperwork such as the information sheet and consent
form was found to be very long, even though it had been shortened as much as possible and a graphic
design company had produced a very friendly format. Despite this, none of this group of parents could
articulate what the study was about in full or mentioned the comparative aspect of SoV, indicating that
the paperwork had not communicated the study to parents clearly or that the information had not been
retained. One had understood that it was to ‘seal their teeth’ but thought that it was to address existing
holes in children’s teeth and one thought that the SoV programme also handed out toothbrushes.
TABLE 85 Parents’ reasons for not participating in SoV
Response
Frequency of
responses
I wanted my child to continue with their current/normal dental treatment at a local dental surgery 7
I did not understand what the study would involve 3
I did not want to be interviewed for the study 3
I wanted my child to continue their normal treatment from the MDC and did not want them to receive
anything different
2
My child did not want the treatment and I did not want to make them have it 2
I was afraid my child might lose their place at the local NHS dentist if they went somewhere else for
treatment
1
I wasn’t confident that the treatment would be good for my child 1
I was worried about what a dental examination might find in my child’s teeth 1
I do not like the school being involved in or knowing too much about my child’s health care 1
I do not like taking part in research 1
I did not like being unable to choose which treatment my child received in the study 1
I did not want to have to fill out questionnaires for the study 1
Other: ‘My child don’t like the fact that he is not able to rinse his mouth after brushing in class, even though I know its
fine, but he does not like it. Funny really.’
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Another thought that it addressed tooth grinding and that it was a student research project. No negative
attitudes towards the SoV intervention or trial were expressed.
In interviews, both school and CDS staff discussed similar problems with contacting and recruiting parents
for programmes, and commented that they did not always get paperwork back from parents whatever the
programme. School and CDS staff thought that parents with little English would also have problems,
especially with long forms; of the five non-participating parents recruited for interview through school visits,
one had no English (a friend attended the interview to translate) and another spoke English as a second
language. CDS staff also mentioned that some parents had problems completing paperwork because of
literacy problems. One parent commented they would have preferred to receive information about SoV face
to face rather than in a ‘big booklet’. School staff thought that some parents needed face-to-face support in
order to understand the study and to complete recruitment forms correctly, and so would sometimes assist
parents with filling in paperwork. One school staff member commented that it would have been helpful
for teachers to know more about SoV so that they could have answered parents’ queries about it. Some of
the difficulty was also a result of the volume of paperwork and participation in other dental programmes
running in the school, leading parents to think that they were already taking part. CDS staff reported that
schools often found it a challenge themselves to keep track of the paperwork from different programmes
operating in the school, including several dental programmes. School and CDS staff also commented that
parents who were already engaged with health and dental services were another group that was less likely
to participate because they might not see a need beyond their existing dental visits. One parent commented
to the researcher in the playground that their child already saw a dentist and they did not want to use up
additional resources unnecessarily. Other families who tended not to engage, according to school staff, were
those who were nervous of school environments or who had chaotic lives or work/other commitments that
were difficult to juggle. Some school staff thought that parents needed reminders in person from school
staff to sign up for programmes. School staff sometimes made an effort to recruit those families, in person,
that they thought might be particularly in need of services, either to explain letters or to discuss any
potential barriers.
Summary
The work reported in this chapter set out to answer a series of questions (see Table 68) that related to the
acceptability of technologies under test and the setting in which they were being provided.
The first question related to the acceptability of the FV and FS treatments to the children, what factors
influenced acceptability and if there were any possible differences between the trial arms.
Overall, the acceptability of the treatments was very high, as judged by the fact that very few children
refused treatments or discontinued in the trial because of the lack of acceptability of the treatments (see
Chapter 3). When judging acceptability from the perspective of both the parents and the children, it was
apparent that this was influenced to a large degree by the wider factors rather than the actual treatments
being provided. This means that acceptability needs to be understood as a broad measure, as contextual
factors can make a significant difference to acceptability for children, parents and schools.
From the perspective of the children, the novelty of dental treatment in the MDC and MDC aspects such
as the provision of reward stickers both seemed to feature as highly in the issues raised in the qualitative
interviews as issues around the treatments provided. When pressed specifically on the treatments, the taste
of the interventions featured highly in the narratives.
There were significant differences in the acceptability of the FS and FV treatments with the preference
changing over the trial period. However, the more involved nature of the FS treatment in the early visits,
compared with the constant application of the FV at every treatment visit, is reflected in the results.
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The second question concerned implementation, whether or not the delivery of this type of preventative
treatment was acceptable to children, their parents, clinicians and the schools in which the treatments
took place and the factors affecting implementation of treatment in a school setting.
The answer to this question has to be yes, and it is clear that in deprived areas in which encouraging
at-risk children to attend services is key, this work has shown that the school context can be an effective
delivery organisation for preventative services. In the qualitative interviews, parents reported trust in the
school and convenience of access as important factors in utilising the service.
The child-friendly nature of the setting, the longer-term and ongoing relationship of the CDS with the
participating schools and the convenience of attending in school were all factors affecting the acceptability
of the treatment setting for parents, teachers and CDS staff.
The favourable reports from the school staff on the implementation of the study and the minimal
disruption to the running of the school caused by the CDS team visiting are positive features of the
feedback received.
The third question concerned the factors that affect whether or not parents consent to take part in an
intervention and trial such as SoV.
A clear and definitive answer to this question was not forthcoming, primarily because of the difficultly in
recruiting non-consenting parents. Those who did not want/were insufficiently organised to consent to
the trial were similarly difficult to consent to an interview about non-consenting. Trust in the CDS and
particularly in the school’s judgement about facilitating the trial were raised as important determinants of a
positive decision by parents to allow their children to participate in the trial. Tailored communication and
assistance with understanding materials and completing forms could help those with low literacy or levels
of English to access trial and intervention information to a greater degree.
The fourth question concerned whether or not treatment with FV or FS affects (self-reported) subsequent
oral health behaviour, and if so whether or not there differences between trial arms.
In the main clinical analysis of the study (see Table 13) and qualitative analysis, there were no significant
differences between trial intervention arms related to tooth brushing, diet or other oral health-related
habits. In the qualitative interviews, some parents reported that the fact that their child was participating in
the trial heightened their awareness of dental issues, but it is clear from the quantitative analysis that these
parameters did not impact significantly on trial outcomes.
What is the effect of the trial on recruitment or acceptability to parents, dental staff
and schools?
The reasons offered by parents for consenting their children to the trial included the perceived benefits.
However, it is clear that, on occasion, parents were not entirely clear about or could not fully recall the
purpose of the trial, again resorting to trust in the school and familiarity with the CDS.
The main trial findings and conclusions are discussed in Chapter 6.
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Chapter 6 Discussion and conclusions
Main trial findings
Clinical results
This trial found that the proportion of children who developed dentine caries or had a restoration or tooth
extracted because of caries (D4–6MFT) on any FPM after 36 months did not differ significantly between
those treated with FS and those treated with FV (OR 0.84, 95% CI 0.59 to 1.21; p = 0.351). Similarly,
when the proportion of teeth, the number of teeth or the number of tooth surfaces was studied as the
outcome measure, no significant difference was observed between treatments. However, across all of
these measures, marginally fewer teeth were affected in the FV-treated children.
This study was commissioned because the relative effectiveness of FS and FV was unknown. Cochrane
systematic reviews published just before17 this study started and immediately before it finished16 came
to the conclusion that, when comparing resin-based FS and FV application, there is some evidence to
suggest that FS is more effective. However, these studies reported that it is not possible to draw definitive
conclusions based on the four previous studies to have compared resin-based FS and FV. The authors
attributed this to scarce and clinically diverse data, and to the low quality of previously reported studies.
What other studies found
There have been four previous studies that have investigated whether resin-based FS or FV is the more
clinically effective.61,66–68 In their 2016 review of these studies, Ahovuo-Saloranta et al.16 said that it was not
possible to reach conclusions about whether to apply FS or FV to the occlusal surfaces of permanent
molars to best effect. The clinical outcomes from the current trial suggest that there is no significant
difference in the clinical outcome, irrespective of whether FS or FV is used.
In this study, care was taken to ensure that potential confounding factors were accounted for in the
analyses. These were adjusted to account for the deprivation score of the locality in which the schools
were located, the size of the school and individually reported oral hygiene regime, diet and dental
attendance. None impacted on the clinical finding of no significant difference between the FS and FV
treatments in terms of clinical effectiveness.
It is, therefore, necessary to take into account cost and patient acceptability considerations, as discussed in
Health economics and Treatment acceptability.
Other clinical findings
Beyond the primary and main clinical outcomes, some additional clinical parameters were explored.
Surfaces protected
Clearly, the only surfaces that could be protected by the FS were the occlusal surfaces, although the FV
had the potential to protect both the occlusal and the non-occlusal surfaces. When diagnosed at the caries
into dentine (D4–6MFT) level, there was, as would be expected, a significant difference in the proportion of
occlusal surfaces that experienced decay compared with non-occlusal surfaces. However, no significant
differences were observed between treatments in relation to the protection afforded to occlusal and
non-occlusal surfaces.
The effect of including enamel caries
All of the primary outcome data were based on the traditional caries detection threshold: caries into dentine.
In this study, the use of the ICDAS caries scoring system made data available at a lower diagnostic threshold,
thereby enabling an analysis that included both enamel and dentine caries. This was the only analysis that
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suggested a significant difference in outcome between the FS and FV arms of the trial in favour of the
FV-treated children. The inclusion of the D1–3 lesions resulted in a significantly lower proportion of caries
lesions in the FV arm than in the FS arm, a finding that may well reflect the caries-protective effect of FV on
smooth surfaces. However, this effect is negated by the overall finding of no difference in the proportion of
children or the number of teeth or tooth surfaces that developed D4–6MFT lesions, the primary outcome
measure.
‘Wash-over’ effect
It is also possible that a ‘wash-over’ effect was observed in the FV arm. In other words, the raised intra-oral
fluoride environment associated with the FV treatment may have exerted an effect on teeth distant from
the FPMs. However, this proved not to be the case, and no significant differences were observed between
treatments when whole-mouth D4–6MFT scores were analysed.
Trial duration
This trial took the traditional approach to the duration of caries clinical trials of 36 months’ follow-up in
the absence of radiographic examination. The question arose of whether or not a difference in primary
outcome would have been observed with a trial of shorter duration. It was not possible at either the
12-month or the 24-month clinical assessments to demonstrate any clinically significant difference between
the FS and FV treatments.
Failure to prevent dental caries
It should be noted that, irrespective of treatment received, around one in five children developed dental
caries that had progressed into dentine on at least one FPM. This probably reflects the high caries risk
status of the children participating in the trial.
Health economics
The health economics analysis indicated that, within the context of a MDC setting and under the trial
conditions, FV cost less than FS, even taking into account the repeated application of FV over the trial
period. A similar picture is shown when the costs to the patient and family are included. Although there
is no obvious single cost driver that accounts for this cost differential, it appears that the FV arm had
a consistent and cumulative pattern of fewer costs in intervention and health-care utilisation and,
subsequently, in costs attributed to the family.
When the costs are translated into estimating the impact of delivering FS or FV on NHS budgets,
this estimates that FV results in a cost saving of £68.13 per child treated compared with FS.
The clinical findings showed no statistically significant or clinically meaningful differences across the
majority of primary and secondary outcomes (including health utilities). In such a scenario, the health
economic analysis inevitably becomes a cost-minimisation analysis. Thus, the cost differences and
subsequent budget impact could be seen as one of the key findings of the economic analysis. In our
sensitivity analysis of the budget impact, changing individual parameters estimated that there could be
different results. This further examination of a range of scenarios was undertaken because of the need to
fully consider the potential impact of delivering the intervention in a different ‘real-world’ clinical context
rather than just under the trial conditions.
With such small and non-statistically significant differences in outcomes, any ICERs become extremely
sensitive to small changes in numerical values and should be treated with appropriate caution.
The base-case results show that because numerical differences were very small and not statistically
significant, the cost-effectiveness results estimate that, in terms of the cost per child with dentine caries
avoided, and for cost per QALY, FV dominates FS. This result (and interpretation) should be treated with
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caution, particularly in the CUA, given the very small QALY differences that would be highly unlikely to
translate into meaningful benefits to children. In terms of the cost per QATY analysis, there was a very
small difference in effect in favour of FS, but, when the ICER was estimated, FV dominates FS. As outlined,
the cost-per-QATY analysis should be treated as exploratory.
The CEAC for the CUA shows that, if the NICE guidelines are followed, there would be a 70% probability
of FV being at a NICE societal WTP threshold of £20,000 per additional QALY and, as such, FV could be
considered cost-effective.
An exploratory model-based analysis undertaken to look at the potential longer-term cost-effectiveness of
FS and FV was consistent with the within-trial analysis.
Overall, even taking into account the need for further examination of the impact of missing data, the
analysis shows that FV costs less than FS and could result in moderate cost savings to the NHS if it was
delivered as the preferred treatment in the prevention of caries in the FPMs of children at high risk of
dental caries.
Although the health economic evaluation has focused on reporting the relative cost-effectiveness and
budget impact of FS versus FV, understanding the practical implications is important. As shown in Table 66,
there are hypothetical savings to be achieved, and an estimated additional 93 children could be treated if FV
was used rather than FS.
However, such a scenario is too simplistic. Further consideration would be needed to ascertain how this
would impact on the service. The MDC is despatched to specific schools with different population sizes, so,
although in theory greater child throughput could be achieved, this would be dependent on the number
of children available to treat during one session and other logistical issues involved in organising and
delivering the MDC service. Other MDC factors would need to be taken into account (e.g. delivering FV
may not necessarily require the current vehicle and staff mix). Although the trial showed that FV is less
costly than FS, the trial may not reflect real practice in terms of the ability to deliver FS as a one-off
treatment compared with repeated applications of FV. Although the scenario analysis reported in Table 17
of our findings suggests that in such a context FS would be seen as less costly, the clinical effectiveness
results achieved were under the trial conditions and, thus, appropriate caution must be placed on any
interpretation that the same clinical benefits could be achieved in a different treatment protocol. The
importance of child and school factors (such as turnaround of children from the classroom, having to fit
with a school timetable and children not wanting the FV applied) would also need to be fully considered.
An important question to address next would be ‘what does this mean in practice in terms of service
design, capacity and planning?’. There is an opportunity to take this research further by applying the trial
results to an expansion of the health economic analysis to allow the modelling of plausible scenarios to
support decision-makers and the dental clinical community, translating the findings from this trial into
optimal models of service delivery for preventative dental health in children.
Strengths and limitations of the health economic analysis
This health economic analysis has been undertaken as part of a rigorous randomised trial to assess the
clinical effectiveness and cost-effectiveness of FS and FV delivered within a MDC. Data were collected
prospectively alongside the trial with the economic evaluation, which was an integral component of the
trial design from the outset. It also benefits from reporting a budget impact analysis. Any changes to
funding arrangements in health care over the next 5 years and the impact of any decision on local and
national NHS dental budgets can now be informed by our findings. However, some limitations are
acknowledged, particularly in relation to undertaking health economic evaluations in this context, and
should be fully considered.
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Consideration of the longer-term impact of fissure sealant versus fluoride varnish in
preventative dental health programmes
Exploration of the longer-term costs and outcomes of the two technologies was an important
consideration in developing the health economic analysis, given that this was done as a preventative
intervention to improve the longer-term dental health of children who are at high risk of caries. A Markov
model was built and validated with the trial clinicians as commensurate with the expected caries pathway
as a result of having preventative treatment with FS or FV. The results show that FV remains dominant over
FS, with this result remaining reasonably robust in the sensitivity analysis. However, caution must be
exercised when interpreting these results.
The model-based analysis beyond the trial period was significantly hampered by the lack of evidence of
the longer-term costs and outcomes in order to populate the model. The Cochrane review16 highlighted
the lack of data available to compare FS and FV applications; only one study provided any data beyond
our trial period,61 but this was limited by several biases, particularly the fact that only a limited number
of children were followed up in the longer term. Only informed assumptions could be made about the
longer-term costs and outcomes of FS versus FV based on clinical opinions from the trial team, informed by
the trial results. Although it could be argued that, in the absence of good-quality evidence, the feasibility
of modelling outside the trial period is questionable, this has been done to ascertain the framework for a
model-based economic analysis and, importantly, the evidence that would be needed to populate the
model. In the absence of data from previous trials, undertaking further follow-up of the trial cohort could
provide an excellent opportunity to formally address the question of the longer-term clinical effectiveness
and cost-effectiveness of FS versus FV.
Choosing and using appropriate health outcomes to inform the health economic analysis
An important issue that has arisen from this study is the need to give thorough attention to the outcomes
of interest for the health economic analysis. A plethora of literature has examined oral health outcomes
in the adult population but, in comparison, the evidence base for children is sparse. The strength of our
evaluation is that we choose three outcomes that we expected to provide a comprehensive picture of costs
and outcomes of the two technologies to support decision-making, both from a UK NHS decision-making
perspective and in the clinical dental community.
Providing an estimation of the incremental cost per QALY is seen as the cornerstone of demonstrating
cost-effectiveness within a UK NHS context. For example, the NICE reference case for health technology
assessment57 highlights the inclusion of a QALY as its health outcome of choice. When the trial was
originally conceptualised, a pragmatic decision had to be made on which measure to use, given the paucity
of measures available for children and, in particular, the lack of evidence in the utility of generic HRQoL
measures. We decided, after discussion with the developer and following recommendations made by the
Health Technology Assessment funding panel, to use the CHU-9D, even though it had only just been
published and its utility in a dental health context was still unknown. CHU-9D score was not measured at
baseline; however, as this was a randomised trial, it is reasonable to assume that any differences between
the two groups at that point were due to chance. The inability to consider utility curves over outcome time
points only, rather than including baseline, could be seen to result in a reduction in power, but, given the
preventative nature of this study (i.e. the study was not missing assessing utility during an episode of illness)
and the fact that there were assessments of utility on multiple occasions, this is unlikely to be a major issue.
A study published since the start of the trial suggests that CHU-9D can be used in children aged 6 or
7 years.53 That work, which considered the psychometric performance of the CHU-9D versus the EuroQol-5
Dimensions Youth version, suggested that children at this age can understand and complete the measure.
This supported our own informal and limited evaluation of the CHU-9D that was undertaken prior to the
start of the trial. The CHU-9D was assessed in the context of a child dental community clinic in New
Zealand54 and was found to have the potential to capture HRQoL across different caries experience,
showing that those with no apparent caries had a higher mean score than those with caries (0.88 vs. 0.87,
SD 0.10), although the difference was small. Interestingly, this cross-sectional sample had lower HRQoL
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scores than our trial sample, although it is difficult to assess whether or not the patient populations are
comparable. In terms of QALYs generated, this study reported that the difference in QALYs between those
with and those without caries was 0.12. This is a fairly moderate difference, but it could suggest the
potential of the CHU-9D to identify small but important changes in QALYs as a result of caries. Because of
the lack of clinical differences in caries between our trial arms, we were unable to detect differences in
utilities and QALYs. Subsequently, Foster Page et al.69 undertook a randomised controlled trial to further
assess the CHU-9D in terms of its responsiveness to changing components of the decayed, missing, filled
tooth surfaces in primary dentition (dmfs) and DMFS scores in children aged 6–10 years over a 1-year
period. They found that the mean CHU-9D improved from 0.88 to 0.9 from baseline to follow-up, with no
significant difference found between caries status and CHU-9D. Again, CHU-9D scores from their study are
lower than those in the present trial and lower than those in other studies, such as the 0.86 reported in
the Canaway and Frew study,53 indicating that, as in this study, the impact of children receiving dental care
under trial conditions cannot be ruled out. Similar to the later Foster Page et al. study,69 this trial suggests
that the CHU-9D is insufficiently responsive to changes in caries experience.
An important question is ‘what could be done to improve measures aimed at capturing HRQoL in relation to
this patient population?’. Whether the focus should be on generic HRQoL measures or on condition-specific
measures is the subject of much debate, and it is important also to consider the context of this trial within a
preventative/public health context. For example, the NICE public health guidance70 recognises the possible
challenges of undertaking a CUA, and other approaches such as a cost–consequence analysis could be
considered, although CUA is advocated (along with the need for HRQoL measures that can derive
appropriate utilities) to ensure comparability across other parts of NICE.
The authors suggest that patient-reported outcome measures (including HRQoL) for use in a dental
public health context should have a stronger conceptual and methodological basis. Understanding
children’s preferences for treatment, the properties of measures and the association that these have with
(1) dental-related health and (2) HRQoL warrants careful attention. Moreover, understanding and capturing
the utility/disutility associated with caries experience over time will assist in ensuring longer-term
examination of the cost-effectiveness of different strategies.
The cost-per-QATY analysis undertaken in this trial allows the consideration of a dental health state utility,
which has been suggested as a more meaningful measure in the context of dental health. Although the
QATY has been reported in studies,31,71 there has been little ‘methodological movement’ since the original
work.55,72 In this trial, published utilities were used alongside clinical opinion from the trial team to attribute
a utility to (1) each individual tooth and (2) a composite QATY drawing on other studies31 and preliminary
work undertaken as part of a NICE public health guideline.56 The present analysis suggested that QATY
gain was greater with FS than with FV, suggesting that FS could potentially be cost-effective. The results
should be viewed with appropriate caution, given the approach taken to derive the number of QATYs.
QATY gain appears to be a potentially useful dental health outcome, and further work is recommended to
improve the underpinning work to derive suitable utilities for calculation of QATYs.
The importance of collaboration between health economists and the dental health research and clinical
community will be instrumental to improving the quality of economic evaluations within preventative
dental health.
Treatment acceptability
That so few participants withdrew from the study (as opposed to simply moving to a non-participating
school) is in itself evidence that both treatments are acceptable. That is not a novel finding. These
treatments have been in routine clinical use since the 1960s and have been received by a great many
children around the world.
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However, there are some interesting observations from the process evaluation reported in Chapter 5 that are
likely to be of value in considering the future provision of these technologies in community programmes.
Evaluation using the DTF scale correlated with the intensity of the treatment, with those receiving FV being
significantly happier at baseline and this situation being reversed at the 30-month treatment session. This
presumably reflects the fact that at baseline the FS-treated children had to spend longer in the dental chair
than those receiving the FV treatment. The FS recipients were also subject to the use of three-in-one syringes
and aspirators; in contrast, in the FV arm, treatment consisted of the simple act of placing cotton wool rolls
in the mouth and painting the FV onto included FPMs. At the final treatment session, children in the FS
needed treatment only if a FS had been lost, was judged to be incomplete or required top-up. In contrast,
in the FV arm the time required in the chair was similar to that required for the baseline examination.
The feature of both treatments that was most remarked upon during the interviews was taste. This is
interesting because in clinical teaching dental professionals, perhaps using ‘tell–show–do’ techniques, are
taught to explain the sensations and experiences to a child before treatment. Clearly, an explanation of
what may be expected in terms of taste when treating children is an important element of preparing them
for treatment.
However, it is clear from the qualitative work carried out in this study that it is not so much the treatments
themselves that children remember but rather the wider issues surrounding the treatments. Reward
stickers, the movement of the dental chair (the chair was routinely reclined to allow children to have both
the dental clinical examination and the treatment) and the coloured protective glasses that the children
were required to wear all featured highly in their narratives of the experience. The novelty of the MDC
visiting the school and the opportunity to have a break from the routine of daily life in the classroom also
featured as a factor affecting acceptability. It was, however, interesting that in the later stages of the trial,
when the children were aged 9 or 10 years, time away from the classroom and having to catch up on
work did become a minor issue for some. In the course of the trial, the children would have visited the
MDC on up to 10 separate occasions (four dental examinations and six treatment visits), so by the end it
would have been a fairly routine experience. These findings about the broad range of factors that
contributed to the acceptability of treatment for children indicate that delivery via a child-friendly service in
a school setting is an important consideration for implementing this type of preventative dental treatment.
As this trial was based on the existing Designed to Smile programme, it is likely that the initial visit may not have
been the child’s first experience of the MDC. Consent to participate in the trial was, however, considerably
lower than the normal uptake of treatment offered by the CDS. The reason for this is unclear. Participating
and non-participating parents who were interviewed were almost universally positive about the intervention,
and reasons for non-participation are therefore likely to be a result of factors other than acceptability. A small
number of parents appear to have not participated because their children were already receiving similar
treatment and they wanted to continue with this. A more common reason for non-participation appears to be
the difficulty of communicating effectively with parents via written information delivered through schools in
areas of socioeconomic deprivation. Obviously it is necessary to ensure that parents and carers are adequately
informed before making a decision about their child’s participation in a clinical trial and in particular in a
CTIMP. The trial team worked hard with our PPI partners to ensure that the information was provided in as
non-threatening and user-friendly a way as possible, for example by incorporating the logos and colours of the
usual Designed to Smile programme patient-facing materials.
In the interviews exploring participation in the trial and in the piloting of materials, some interviewees
discussed difficulties in English or literacy that may have affected the ability of parents to read and
complete paperwork for the trial. This is likely to be a factor in participation rates in other areas of
socioeconomic disadvantage or areas where there is a high proportion of residents whose first language
is not English. A considerable amount of information was required to be offered to the parents and carers
of potential participants. This would have been in addition to other paperwork that schools send home
to parents; some interviewees mentioned that the volume of paperwork could also be a barrier for
some parents, either because they did not keep track of it all or because there was too much to read.
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The information on details of the trial that had to be included in the paperwork for SoV may have
contributed to this.
Trial fidelity
In any clinical trial, adherence to the clinical protocol (fidelity) is an important consideration. Aspects of this
are now discussed.
Number of treatments received
In the course of the trial, participants were scheduled to receive treatment on six occasions. Clearly, the
number of treatments received, whether application of FV at each visit or check-up or, if necessary, ‘top-up’
of the FS, is important. More than 70% of children attended all six treatment visits, and 95% of children
in the FS and FV arms of the trial attended at least five treatment visits, which is excellent adherence to
the scheduled treatment protocol. The CACE analysis demonstrated that such a high level of compliance
means that adherence to the treatment protocol was not an influencing factor in the results obtained at
36 months. To obtain such a level of compliance reflects the relationship between the CDS team, the
schools and their parents.
The CACE analysis was performed as a sensitivity analysis in order to explore the effect of attendance for
treatment on treatment efficacy. A CACE analysis is preferable to a per protocol analysis, as it respects the
trial randomisation, but is usually more suited to trials with two active arms rather than trials with one
active trial arm and one control arm. Hence in SoV, the FS arm was selected as the ‘control’ treatment for
the CACE analysis, as ideally it is a one-off treatment whereas FV needs to be applied regularly for full
effectiveness. It was also the current standard treatment for children in these schools. The results indicated
that, in fact, there was very little variation in treatment adherence, with the majority of children attending
either five or all six FV treatments. As such, the CACE analysis indicated only slight gains in treatment
efficacy with additional visits. In a wider context, this means that, for FV to be effective in the community
as a caries prevention tool, treatment adherence needs to be ensured.
Treatment window
The six treatment appointments were scheduled at 6-month intervals over the course of the trial. Owing to
the practicalities of scheduling visits of the MDC to schools to accommodate holidays and acknowledging
that there were days when it was not convenient for the schools to host the MDC and so forth, it was
agreed at the outset that a treatment window of 4 weeks either side of the treatment due date would not
compromise the integrity of treatment delivery and would reflect the practical nature of a pragmatic clinical
trial such as SoV. Over the course of the trial, adherence to this schedule was good. Overall, in 71.6% of
schools, all treatment visits were within the treatment window, and in a further 26.1% of schools, only one
of the six treatment visits was outside the schedule. This further indicates the fidelity of the trial.
Fissure sealant retention
The level of FS retention in this study was very high. This is because the study participants were seen at
6-monthly intervals and FS was ‘topped up’ if deficient. Furthermore, in the case of the maxillary FPMs,
the teeth were sealed if part of the mesial–occlusal pit and fissure was erupted and the distal aspect was
then sealed at a subsequent 6-month visit. At the 30-month treatment visit, only a small proportion of
previously sealed teeth were reported as being ‘lost’, with 74% of upper teeth and 88–91% of lower
teeth reported as ‘partial’, that is, sealant did not cover the whole of the occlusal surface.
Crossover
One deviation from protocol was observed. At the 12-month treatment visit, one child who had been
randomised to the FV arm received FS. This was logged and the child continued in the trial in the arm to
which they were randomised.
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Examiner reproducibility
Throughout the trial, efforts were made to ensure that the dentists undertaking the clinical examinations
were appropriately trained and calibrated. A professor of paediatric dentistry who was involved in the
development of the ICDAS index trained the examiners at baseline and a second professor of paediatric
dentistry undertook the annual training and calibration exercise before each round of examination began.
The kappa scores achieved indicated that all examiners demonstrated a high level of intra-examiner
reproducibility, and that inter-examiner reproducibility was also high.
Study considerations
From the issues previously discussed, the authors are of the view that this was a very robust and
well-conducted study. The trial protocol was rigidly adhered to and compliance was excellent, as were
follow-up and completion rates. Fidelity was as high as could possibly be expected. The trial team are
content that there was nothing that they would have done differently in answering the question
proposed at outset. Some aspects of the trial are considered further here.
Study numbers
The caries risk status of the participants is an important consideration. The SoV trial was set in areas of
social and economic deprivation and more than half of the participants had decay into dentine in their
primary dentition at the start of the study. The finding that approaching one in five of the participants
experienced dental caries in at least one FPM at 36 months, across trial arms, makes clear that the study
population was appropriate and typical of those whom the technologies tested are designed to benefit.
The consistent finding from the regression analysis of caries experience in the primary dentition at baseline
being a significant predictor of caries in the permanent dentition is as would be expected.73 This of course
did not affect the conclusions about differences in the relative caries-protective effect of FS and FV.
It is clear that the randomisation and stratification procedure employed was very successful and that the
trial arms were well balanced at baseline.
The trial was more than adequately powered. This arose for the following reason. Calculations based on a
previous study in South Wales and estimates of treatment effectiveness suggested that 313 participants
were required per arm. The original intention was to recruit all participants in the same school year.
However, this effectively meant recruiting all children in the period September–December in the first
school term in order that the 6-monthly treatment visits could be accommodated. By December just over
500 children had been recruited, too few to satisfy the power calculations. With the funder’s support,
recruitment was extended to a second school year. This resulted in two study cohorts, each of which was
followed for 36 months. There was no observed cohort effect on the clinical outcome.
In planning the study, allowance was made for an 8% withdrawal per annum. In the event, many fewer
children were lost from the study, with the most common reason for failure to complete the study being
moving away from the area or to a different school that was not participating in the trial. When children
moved to a participating school they continued in the trial. Recruitment to the trial in the second cohort
proceeded at a much quicker pace than in the first year and so the study over-recruited by around 100
participants. The view was taken that, having invited the parents of the children to participate in the study,
it would have been problematic to refuse the opportunity to participate to already consented children.
This, together with the much lower than expected dropout rate, meant that in both trial arms the number
of children completing was in excess of the numbers required to satisfy the power calculation.
Questionnaire return rate
Information to inform oral health-related habits and the health economics utility scores was collected via
a self-complete questionnaire. The efforts taken to maximise the return rate are described in Chapter 2.
The revised follow-up strategy was found to boost return of the follow-up questionnaires, with the overall
return rate of the DHQ rising to 60% for the whole trial.
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Clearly, this limited the number of participants who were available for the secondary analyses, which were
dependent on information on covariates gained via the questionnaire. However, there was no evidence of
a difference in return rates between treatment arms. It should be remembered that this trial was conducted
in Community First areas, which are areas designated by the Welsh Government as being of high social and
economic deprivation. A response rate of 60% is probably as good as can be expected in this setting.
Adverse events
Care was taken in recruitment to the trial to exclude any participants with a known history of allergy to
colophony, a constituent of the FV, and also those with severe asthma, that is, those who had ever been
admitted to hospital overnight for the treatment of asthma. No adverse events were observed or reported
in relation to the use of either FS or FV, and it is concluded that these treatments are suitable for use in
children aged between 6 and 10 years.
Implications for health care
This is the largest ever study to address the question of the clinical effectiveness and cost-effectiveness of
FS and FV. The very high standard to which this work was conducted and the excellent fidelity obtained
mean that the findings reported here are robust.
Given that the previous systematic reviews of the clinical effectiveness of the technologies tested suggest
that FS may be clinically superior, the results obtained in this trial are perhaps contrary to what many
paediatric and public health dentists would have expected.
The SoV trial has clearly shown that, although at 36 months fewer than one in five children had developed
decay into dentine in their FPMs, there was no clinically important difference in the proportion of children
developing decay (D4–6MFT) on any FPM whether treated with FS or FV. That leads to the question of costs.
The heath economic analysis suggests that the costs favour FV. The budget impact analysis at 3 years showed
that FV resulted in a cost saving of £68.13 per participant over the 3-year period compared with FS.
Both treatments are acceptable and the qualitative work undertaken has shown that factors other than
the treatments themselves are uppermost in the children’s recollection of having received the treatments.
The very low numbers of children stopping treatment is further proof of the acceptability of FS and FV
when placed in the context of a community dental programme using MDCs. This type of intervention
delivered in a school setting was also found to have high acceptability for parents and school staff.
Implications for research
There are number of research questions and issues that arise from this work.
The findings from this robust study will add to the evidence base of the Cochrane review of relative
effectiveness of FS and FV. The Cochrane review should consequently be updated.16
In the trial, the FS was applied when the FPMs first erupted and was maintained throughout the trial and
the FV was applied at 6-monthly intervals. A key question, given the results obtained, and now that active
treatment intervention has been discontinued, is whether or not the caries-protective effects of FS and FV
will remain the same over the coming years. Presumably, the FS will remain for some months and years to
come, at least in the depths of the pits and fissures. As a result, a difference in the preventative effects
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may become apparent after, say, a further 2 or 3 years. It would be useful to re-examine the participants
in the school in 2017/18 in order to determine the effectiveness of the treatments after 5 and 6 years.
Logistics and cost limited this trial to a comparison between FS and FV. A third option that was considered
by the research team was the inclusion of a third arm applying both FV and FS; this would have proven
cost prohibitive. Whether or not such an approach is merited in future research is debatable.
In relation to trial fidelity, to our knowledge, this work is the first to apply CACE analysis in a dental trial.
More work to understand this technique in the context of dental clinical trials with two active treatments
would be advantageous.
Regarding the health economic element of the work, an important question is what could be done to
improve measures aimed at capturing HRQoL in relation to this patient population. Whether the focus
should be on generic HRQoL measures or condition-specific measures is a subject of debate, and it is also
important to consider the context of this trial within a preventative/public health context. For example, the
NICE public health guidance70 recognises the possible challenges of undertaking a CUA and that other
approaches such as cost–consequence analysis could be considered, although CUA is advocated (along
with the need for HRQoL measures that can derive appropriate utilities) to ensure comparability with other
parts of NICE.
We suggest that there is a need for a greater conceptual and methodological basis to patient-related
outcome measures (including HRQoL) for use within a dental public health context. Understanding
children’s preferences for treatment, the properties of measures and the association that these have on
(1) dental-related health and (2) HRQoL warrants careful attention. Moreover, understanding and capturing
the utility/disutility associated with caries experience over time will assist in ensuring longer-term
examination of the cost-effectiveness of different strategies.
The cost per QATY analysis undertaken in this trial allows the consideration of a dental health state utility,
which has been suggested as a more meaningful measure in the context of dental health. There has been
little ‘methodological movement’ since the original work.55 In this trial, we used published utilities and
sought clinical consensus to (1) attribute a utility to each individual tooth and (2) create a composite QATY
drawing based upon other studies31 and preliminary work undertaken as part of a NICE public health
guideline.70 The present analysis suggested that FS derived more QATY gain than FV, suggesting that this
could result in FS being potentially cost-effective. However, it is important that appropriate caution is
exercised when considering these results, given the approach taken to derive the QATY. However, the
QATY appears to be a potential useful dental health outcome and further work is recommended to
improve the underpinning work to derive suitable utilities for the calculation of the QATY.
The importance of collaboration between health economists and the dental health research and clinical
community will be instrumental to improve the quality and subsequently drive up the quality of economic
evaluations within preventative dental health.
Conclusions
The findings of this trial demonstrate that in community oral health programmes targeted at children at
high caries risk, the application of FV as a caries preventative measure will result in caries prevention
that is not significantly different from that obtained by applying and maintaining FS after 36 months.
There is a cost saving of £68.13 per child treated, using FV compared with the application of FS over
this time period. Both treatments are acceptable to children aged 6–10 years; perceptions of undergoing
treatment are influenced by aspects of treatment (especially taste) but also by wider factors associated with
a child-friendly MDC. Acceptability to parents and to schools was also high.
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Appendix 8 Cardiff and Vale University Health
Board Community Dental Service clinical protocol for
application of Delton® Pit and Fissure Sealant
 
 
It is necessary to remove plaque and debris from the enamel and the pits and fissures 
of the tooth. Any debris that is not removed will interfere with the proper etching 
process and the sealant penetration into the fissures and pits.  Children who are to 
have fissure sealant applied should brush their teeth / have their teeth brushed with a 
toothbrush beforehand.   
Risk Assessment 
This risk assessment reduces the possibility of children with oral/ facial infections 
being included. 
The risk assessment is carried out BEFORE the application procedure is started. This 
is to ensure that any child with any abnormality of the lips, face or soft tissues of the 
mouth is excluded. Children who are showing obvious signs of systemic illness e.g. 
colds, ‘flu, chicken pox etc should also be excluded on that day. 
The Risk Assessment should be carried out as follows: 
The Extra-Oral Assessment 
Check the skin of the face and around the mouth for abnormalities (spots, 
inflammation, swelling etc) 
Check the lips for lesions/ infections 
 
The Intra-Oral Assessment 
Check the right and left inner cheeks and the insides of the lips using the 
disposable mirror provided in the pack 
Check the top and underneath the tongue. 
 
The teeth and gums should be checked for signs of decay and/ or infection in the 
following order: 
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Check the upper right teeth and gums 
Check the upper left teeth and gums 
Check the lower right teeth and gums 
Check the lower left teeth and gums 
 
If everything appears normal the fissure sealant may be applied. Children with 
abnormalities of the skin around the mouth, lips (e.g. cold sores), or soft tissue lesions  
should not have the fissure sealant applied. 
If the child has any abnormality of the lips or mouth, they should be referred for a 
dental opinion.  
The Application Procedure 
Once the risk assessment has been carried out, the application procedure can begin. If 
a child gets upset or protests during any part of the procedure, the procedure should 
be abandoned. 
Step 1: Isolate the tooth/teeth  
 It is absolutely imperative to keep the tooth free from salivary contamination 
 Use dry guards, cotton wool rolls or saliva ejectors to aid moisture control 
Step 2: Dry the surfaces 
Step 3: Etch the surfaces 
 The etchant should be applied to all the pits and fissures. In addition, it should 
be applied at least a few millimeters beyond the final margin of the sealant and 
in accordance with manufacturer directions  
 Do not allow the etchant to come into contact with the soft tissue. If this 
occurs, rinse the soft tissue thoroughly 
Step 4: Rinse and dry the tooth/teeth 
 Rinse all the etchant material from the tooth in accordance with manufacturer 
directions  
 The tooth is dried until it has a chalky, frosted appearance. If it does not, the 
tooth should be re-etched in accordance with manufacturer directions. It is 
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imperative to avoid salivary contamination. There is agreement that moisture 
contamination at this stage of the process is the most common cause of sealant 
failure  
Step 5: Apply the material and evaluate for voids, marginal discrepancies or retention 
problems  
Be careful not to incorporate air bubbles in the material 
Follow protocol for light cured dental sealant material in accordance with 
manufacturer directions  
After the sealant has set, the operator should wipe the sealed surface with a 
wet cotton pellet. This allows for the removal of the air-inhibited layer of the 
non-polymerized resin. Failure to perform this step may leave an objectionable 
taste in the child’s mouth 
Step 6: Evaluate the sealant 
The sealant should be evaluated visually and tactically. Attempt to dislodge it 
with a probe 
If there are any deficiencies in the material, more sealant material should be 
applied  
Step 7: Evaluate the occlusion  
 Unfilled resins will wear down naturally and do not require occlusal 
adjustment  
Step 8: End of Procedure 
 Reward child with a motivation sticker 
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Appendix 9 Duraphat® summary of product
characteristics
1. NAME OF THE MEDICINAL PRODUCT 
Duraphat 50 mg/ml Dental Suspension 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
1 ml of suspension contains 50 mg Sodium Fluoride equivalent to 22.6 mg of 
Fluoride 
 
For a full list of excipients, see section 6.1. 
 
3. PHARMACEUTICAL FORM 
Dental Suspension 
 
Brown/yellow, opaque suspension 
 
4. CLINICAL PARTICULARS 
 
4.1 Therapeutic indications 
For the prevention of caries in children and adults as part of a comprehensive 
control programme. 
For the: 
- prevention of recurring (or marginal) caries 
- prevention of progression of caries 
- prevention of decalcification around orthodontic appliances 
- prevention of pit and fissure (occlusal) caries. 
For the desensitisation of hypersensitive teeth as part of a treatment regimen 
which includes the daily use of a suitable toothpaste. 
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4.2 Dosology and method of administration 
 
Duraphat 50 mg/ml Dental Suspension is to be applied by the dentist.   Before 
applying Duraphat, excess plaque should be removed and the teeth dried.  
Duraphat is applied as a thin layer to the most susceptible areas of dentition 
using a brush, probe or swab. 
Recommended dosage for single application: 
For milk teeth: up to 0.25 ml (=5.65 mg Fluoride) 
For mixed dentition: up to 0.40 ml (=9.04 mg Fluoride) 
For permanent dentition: up to 0.75 ml (=16.95 mg Fluoride) 
For caries prophylaxis, the application is usually repeated every 6 months but 
more frequent applications (every 3 months) may be made.   
For hypersensitivity, 2 or 3 applications should be made within a few days.  
The patient should not brush the teeth or chew food for 4 hours after treatment. 
 
Method of administration: For dental use 
 
4.3 Contraindications 
Hypersensitivity to colophony and/or any other constituents. 
Ulcerative gingivitis. 
Stomatitis. 
Bronchial asthma. 
 
4.4 Special warnings and precautions for use 
Application of Duraphat 50 mg/ml Dental Suspension to the whole dentition 
should not be carried out on an empty stomach. 
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On the day when Duraphat has been applied, no high dose Fluoride 
preparations, such as Fluoride gels, should be used.  The administration of 
Fluoride supplements should be suspended for several days after applying 
Duraphat. 
 
4.5 Interaction with other medicinal products and other forms of interaction 
The presence of alcohol in the Duraphat formula should be considered. 
 
4.6 Pregnancy and lactation 
As this product contains 33.8% of ethanol (each dose contains up to 0.2 g of 
alcohol), it is recommended to avoid its use in pregnant women and during 
lactation. 
 
4.7 Effects on ability to drive and use machines 
None known. 
 
4.8 Undesirable effects 
Gastrointestinal disorders:  
Very rare (<1/10,000): Stomatitis, gingivitis ulcerative, retching, oedema mouth 
and nausea may occur in sensitive (allergic) individuals - if necessary, the 
dental suspension layer can easily be removed from the mouth by brushing and 
rinsing.  
 
Skin and subcutaneous tissue disorders:  
Very rare (<1/10,000): Irritation in sensitive individuals, angioedema 
 
Respiratory, thoracic and mediastinal disorders:  
Very rare/Isolated report (<1/10,000): Asthma 
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4.9 Overdose 
In very high doses, Fluoride has an acute toxic action through inhibition of 
enzymes resulting in hypocalcaemia.  Doses of several milligrams of Fluoride 
per kg body weight may cause nausea and vomiting, and diarrhoea. 
Tetany and convulsions can occur, as well as cardiovascular disorders. 
The dental suspension layer can easily be removed from the mouth by brushing 
and rinsing. 
 
5. PHARMACOLOGICAL PROPERTIES 
 
5.1  Pharmacodynamic properties 
 Pharmacotherapeutic group: Stomatological preparations, caries prophylactic 
agents 
ATC code: A01A A01 
Sodium Fluoride applied topically after tooth eruption reduces caries by 
inhibiting demineralisation and promoting remineralisation of the tooth surface 
and by inhibiting the cariogenic microbial process. 
Duraphat 50 mg/ml Dental Suspension also reduces dentinal hypersensitivity. 
In the management of dental erosion associated with the frequent consumption 
of acidic beverages or gastric reflux, high concentration topical Fluoride agents 
are considered to be of value.  Duraphat is at least as effective as 2% Sodium 
Fluoride Solution in inhibiting erosion in vitro 
 
5.2 Pharmacokinetic properties 
After oral administration, Fluoride absorption is rapid and extensive (90-100%) 
with peak Fluoride plasma levels reached within 30 to 60 minutes after 
ingestion.  Fluoride is widely distributed through the body and concentrates in 
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bone and teeth.  About 50% of Fluoride is stored.  Excretion is primarily 
through the kidneys with less than 10% being excreted in the faeces and less 
than 1% in sweat and saliva. 
Duraphat covers teeth with a film of suspension which hardens in the presence 
of saliva and then persists, and which over the following hours causes Fluoride 
to accumulate at a measurable depth in the tooth enamel. 
 
5.3 Preclinical safety data 
The product is used under total control of the dentist and the amount of Fluoride 
introduced to the patient at one time is within acceptable safety limits.  The 
recommended doses are up to 0.75 ml for permanent dentition.  Treatment is 
recommended every 6 months or a maximum of every three months.  For 
hypersensitivity 2-3 applications are recommended within a few days.  These 
levels of Fluoride introduced are again within acceptable safety limits. 
 
Due to the slow release of Fluoride, the plasma levels are even lower than levels 
known to produce no side effects in children. 
 
6. PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients 
Ethanol 96%  
White Wax (E901) 
Shellac (E904) 
Colophony  
Mastic  
Saccharin (E954) 
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Raspberry Essence (containing Ethyl Butyrate, Geraniol, Iris Resinoid, Isoamyl 
Acetate, Jasmine Absolute, Vanillin and Propylene Glycol). 
 
6.2 Incompatibilities 
None known 
 
6.3 Shelf life 
Unopened 3 years.  For aluminium tube: after opening, use within 3 months. 
 
6.4 Special precautions for storage 
Do not store above 25°C 
 
6.5 Nature and contents of container 
Boxes of 1 x 10 ml or 5 x 30 ml tubes made of internally lacquer-coated 
aluminium, externally printed, with white plastic screw cap with sealing plug. 
Boxes of 1 x 1.6 ml or 5 x 1.6 ml glass cylinders with a cream bromobutyl 
rubber stopper and gold aluminium cap at the top and dark blue chlorobutyl 
rubber stopper at the bottom. 
 
6.6 Instruction for Use/Handling  
If necessary the teeth should be cleaned, especially at the sites most susceptible 
to caries.  When groups of patients (e.g. children) are to be treated, they should 
clean the teeth themselves using a toothbrush. 
To start, clear one or two quadrants of excessive saliva using an air syringe (or 
dabbing with cellulose).  Duraphat 50 mg/ml Dental Suspension is applied from 
the tube using a miniature cotton swab, probe or brush, painting and dabbing 
repeatedly to form a thin layer.  Then treat the next quadrants in the same 
manner.  It is advisable to begin by applying the dental suspension to teeth in the 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
160
lower jaw before too much saliva collects and interferes.  It may not be 
necessary to paint the lingual surfaces since these are generally more caries-
resistant; Duraphat should preferably be applied to those spots most susceptible 
to caries attack. 
Application of Duraphat from the cylinder is particularly suited to targeted, low-
dose application.  A blunt cannula is used with the end bent to an angle to 
facilitate application to approximal and distal surfaces.  For application to 
approximal surfaces place the cannula between adjacent teeth and deliver a 
small amount of Duraphat.  The dental suspension should be applied from both 
sides of the interproximal space and occlusally. 
For fissures, a drop of Duraphat should be spread along the fissure using the 
cannula.  Edges of fillings and crowns and hypersensitive tooth necks can be 
treated in the same way. 
The smooth surfaces of the teeth should be treated when caries activity is high, 
particularly if decalcification is evident.  The cannula should be placed 
tangentially to the teeth and Duraphat distributed with the side of the curved 
cannula end. 
Areas around fixed orthodontic devices can be treated with Duraphat using the 
cannula. 
The yellowish colour of Duraphat facilitates its application and control.  
Duraphat sets in the presence of saliva.  The effect of Duraphat depends upon 
the prolonged activity of the Fluoride.  The dental suspension film should not be 
removed prematurely.  Patients should be advised not to brush their teeth or 
chew food for at least 4 hours after treatment; during this time, soft foods and 
liquids may be consumed.  However, if you need to, the dental suspension layer 
can easily be removed by brushing or rinsing. 
Instruments, clothing, etc. which comes into contact with Duraphat can be 
cleaned with alcohol. 
 
7. MARKETING AUTHORISATION HOLDER 
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Colgate-Palmolive (UK) Limited 
Guildford Business Park 
Middleton Road 
Guildford 
Surrey 
GU2 8JZ 
 
8. MARKETING AUTHORISATION NUMBER(S)  
PL 0049/0042 
 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE 
AUTHORISATION 
First Authorisation: 06/03/1998 
Renewals: 06/03/2008 and 15/07/2008 
 
10. DATE OF REVISION OF THE TEXT 
 10 February 2012 
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Appendix 10 Cardiff and Vale University Health
Board Community Dental Service clinical protocol for
application of Duraphat® fluoride varnish
Risk Assessment 
This risk assessment reduces the possibility of children with oral/ facial infections 
being included. 
The risk assessment is carried out BEFORE the application procedure is started. This 
is to ensure that any child with any abnormality of the lips, face or soft tissues of the 
mouth is excluded.  Children who are showing obvious signs of systemic illness e.g. 
colds, ‘flu, chicken pox etc should also be excluded on that day. 
The Risk Assessment should be carried out as follows: 
The Extra-Oral Assessment 
Check the skin of the face and around the mouth for abnormalities (spots, 
inflammation, swelling etc) 
Check the lips for lesions/ infections 
 
The Intra-Oral Assessment 
Check the right and left inner cheeks and the insides of the lips using the 
disposable mirror provided in the pack 
Check the top and underneath the tongue. 
 
The teeth and gums should be checked for signs of decay and/ or infection in the 
following order: 
 Check the upper right teeth and gums 
 Check the upper left teeth and gums 
 Check the lower right teeth and gums 
 Check the lower left teeth and gums 
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If everything appears normal the varnish may be applied. Children with abnormalities 
of the skin around the mouth, lips (e.g. cold sores), or soft tissue lesions should not 
have the varnish applied. 
If the child has any abnormality of the lips or mouth, they should be referred for a 
dental opinion. 
Safety 
Children should not take fluoride supplements on the day before, of or following 
varnish application. 
There should be no opportunity for child to ingest more than a single dose. 
In the mixed dentition, the recommended dose is 0.4ml. 
Acute fluoride toxicity causes nausea and vomiting.  If suspected, give milk to drink 
and arrange for immediate transfer to A&E. 
The Application Procedure 
1 The teeth should be ‘toothbrush’ clean prior to application of varnish 
2 Gently retract the cheek using a finger or disposable mirror 
3 Dry the tooth to be treated using a cotton wool roll 
4 Place the cotton wool roll in the buccal sulcus  
5 Apply a thin layer of varnish to pits, fissures and smooth surfaces of first 
permanent molars using a disposable microbrush  
6 Remove cotton wool roll 
7 Repeat in all remaining quadrants 
8 Advise the child not to eat or drink for 30 minutes and not to brush their teeth 
for 4 hours after application 
9 Reward child with a motivation sticker 
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Appendix 11 International Caries Detection and
Assessment System training and calibration protocol
A. Summary 
This protocol describes the training and calibration of dental examiners who will 
undertake clinical assessments as part of the Seal or Varnish Clinical Trial. These 
examiners will be experienced Community Dental Officers, employed by Cardiff and 
Vale University Health Board with substantial clinical experience of the examination 
of young children.  A Training and Calibration exercise will be undertaken on four 
occasions during the study at baseline before the baseline clinical assessment and at 
12, 24 and 36 months ahead of the caries assessments.  
B. Aim 
To train two dentists involved in the caries assessment to use the ICDAS caries 
assessment. 
C. Training of dental examiners 
 The Training and Calibration will be based on British Association for the Study of  
Community Dentistry (BASCD) Training and Calibration Guidance(74) with 
substitution of the International Caries Detection & Assessment System (ICDAS). 
(75) 
 Training will involve an online International Caries Detection & Assessment 
System (ICDAS)(26) training package and a training day. Examiners and recorders 
will be given access to the training package ahead of the training day to give them 
the opportunity to familiarise themselves with all aspects of the criteria and 
conventions prior to the start of the training day. The training day will be lead by 
Professor Christopher Deery (University of Sheffield) an experienced ICDAS 
examiner. It will involve a seminar to review the criteria followed by caries 
assessments of twenty 6-7 year old primary school children from a Community 
First school in South Wales to practice use of the criteria. A formal Calibration 
carried out on ten different children will be undertaken after the practice 
examinations. 
D. Recruitment of children for training purposes 
 Recruitment of children for the training exercise will take place in a Community 
First school in South Wales once agreement has been obtained from the head 
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teacher. A letter to head teachers is included (Section M). The school used for the 
Training and Calibration exercise will not be used in the main study. 
 Written consent will be obtained for the children to be examined as part of the 
training course.  A letter will be sent (via the school) to the parents of children 
aged 6-7 years ages and positive consent obtained for them to take part. A letter / 
consent form for parents is attached (Section L).  
 Sufficient children (30-35) will be recruited for the training session to ensure that 
they are not examined continuously. If any child does not wish to participate on 
the day or becomes tired, another will be substituted. 
E. Conduct of Dental Examination 
 Dental examinations will be conducted within the schools using conventional 
dental epidemiological survey techniques in line with British Association for the 
Study of Community Dentistry -co-ordinated surveys.(74) 
 The examiner will be seated behind the subject who will be in a supine position on 
a table or reclined sun-lounger.  
 Children will be given a new, sterile toothbrush of appropriate size and asked to 
brush their teeth.  No toothpaste will be used and the toothbrush will immediately 
be discarded and treated as clinical waste.  This aspect of the examination is 
necessary to allow visualisation of the tooth surfaces to record dental caries in its 
earliest stages (enamel caries). In the event that plaque or food debris remains 
adherent, supragingival deposits will be removed by the dentist using either a 
toothbrush or probe.   
F. The examination equipment 
 A purpose built light yielding 4000 lux at 1 metre (e.g. Daray) or a similar 
protected light source will be used for illumination.  
 Extension flex and plug adapter for use when necessary with the lamp. 
 Disposable paper roll for laying out instruments. 
 Materials to ensure cross-infection control including containers for clean 
instruments, containers for dirty instruments, disinfectant spray/wipes, clean latex-
free gloves, eye protection for subjects, clinical waste bags together with 
sufficient cotton wool buds/rolls etc. for each child. 
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 Examiners will wear a fresh pair of gloves for each examination.   
 Diagnoses will be visual using a plane mouth mirror. A blunt ball-ended probe 
(CIPTN) with an end diameter of 0.5mm will be used as described below. 
 All necessary steps must be taken to prevent cross-infection. A fresh set of 
previously sterilised instruments will be used for each subject. 
G. Examination procedure 
Data will be recorded onto a paper chart chairside. 
Teeth will be examined for caries in the following order: 
 (a) Upper Left to Upper Right 
(b) Lower Right to Lower Left 
 Surfaces will be examined in the following order:- 
 Distal, Occlusal, Mesial, Buccal, Lingual 
 Each tooth will be identified and each surface recorded according to the 
diagnostic criteria for caries. 
 Presence or absence of sepsis in the mouth will be noted and coded. 
 If a primary tooth is missing, the state of the permanent successor will be 
recorded.  In cases where both the primary tooth and its permanent successor are 
present further details will be recorded for the permanent tooth only. 
 A tooth is deemed to be present if any part of it is visible. 
 
H. Caries Criteria (ICDAS) 
 The ICDAS detection codes for coronal caries range from 0 to 6 depending on the 
severity of the lesion.  There are minor variations between the visual signs 
associated with each code depending on a number of factors including the surface 
characteristics (pits and fissures versus free smooth surfaces), whether there are 
adjacent teeth present (mesial and distal surfaces) and whether or not the caries is 
associated with a restoration or sealant.  Therefore, a detailed description of each 
of the codes is given under the following headings to assist in the training of 
examiners in the use of ICDAS: Pits and fissures; smooth surface (mesial or 
distal); free smooth surfaces and caries associated with restorations and sealants 
(CARS).  However, the basis of the codes is essentially the same throughout: 
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Code  Description 
0  Sound 
1 First Visual Change in Enamel (seen only after prolonged air drying or 
restricted to within the confines of a pit or fissure) 
2  Distinct Visual Change in Enamel 
3 Localized Enamel Breakdown (without clinical visual signs of dentinal 
involvement) 
4  Underlying Dark Shadow from Dentin 
5  Distinct Cavity with Visible Dentin 
6  Extensive Distinct Cavity with Visible Dentin 
 
ICDAS two-digit coding method.  A two-number coding system is suggested to 
identify restorations/sealants with the first digit, followed by the appropriate caries 
code, for example a tooth restored with amalgam which also exhibited an 
extensive distinct cavity with visible dentin would be coded 4 (for an amalgam 
restoration) 6 (distinct cavity), an unrestored tooth with a distinct cavity would be 
06.  The suggested restoration/sealant coding system is as follows: 
0 = Sound: i.e. surface not restored or sealed (use with the codes for primary caries) 
1 = Sealant, partial 
2 = Sealant, full 
3 = Tooth colored restoration 
4 = Amalgam restoration 
5 = Stainless steel crown 
6 = Porcelain or gold or PFM crown or veneer 
7 = Lost or broken restoration 
8 = Temporary restoration 
9 = Used for the following conditions 
96 = Tooth surface cannot be examined: surface excluded 
97 = Tooth missing because of caries (tooth surfaces will be coded 97) 
98 = Tooth missing for reasons other than caries (all tooth surfaces will be coded 98) 
99 = Unerupted (tooth surfaces coded 99) 
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I. Procedure in the event of serious pathology being suspected 
In the course of the training or calibration, an examining dentist may encounter 
suspected serious pathology (e.g. malignancy).  This is very unlikely as the 
prevalence of such potentially serious pathology is extremely low in this age 
group.  The examination is not a screening exercise and does not involve 
examination of the oral soft tissues. However, it is possible that such a lesion may 
be noticed and, as the implications are serious, a protocol to deal with this 
eventuality is in place. 
In the event that such a lesion is noted, the examiner is obliged to follow a set 
protocol, which is designed to make sure that the participant’s parent or carer is 
informed, whilst not causing unnecessary worry or alarm. 
The examiner will note the child’s name, date of birth and school and will contact 
one of the survey consultants by telephone, a Consultant in Paediatric Dentistry 
(Professor Barbara Chadwick).  The Consultant will liaise with the examining 
clinician to obtain parental / carers contact details.  Parents will then be contacted 
by telephone and arrangements made for the child to be seen by their general 
medical practitioner.  A follow-up letter will be sent to the parents/carers and the 
child’s medical practitioner.  
J. Data analysis 
 A master sheet will be completed for each training session to allow comparison 
between examiners at the tooth or surface level.   
 The number of decayed missing and filled teeth or surfaces each examiner has 
recorded when examining the same child will be compared to and differences 
highlighted and discussed.  
 For training, no formal statistical analyses will be undertaken and discussions use 
differences identified from the master sheets and individual charts for instant 
feedback. 
 For calibration ten children will be examined and data entered onto a master sheet. 
 Calculation of mean indices (DMFT,FT,dmft,dt) by examiner and the size and 
direction of the deviation from the benchmark examiner will be compared. 
 Subsequently inter and extra examiner agreement will be determined using Kappa 
statistics.  
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Appendix 12 Delighted–Terrible Faces scale
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Appendix 13 Dental health questionnaire
(version 2.2)
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Appendix 14 Child Health Utility Index
9D questionnaire
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Appendix 15 Serious adverse event form
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Appendix 16 Dental hygienist observation scale
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Appendix 17 Children interview schedule
PRELIM 
 What is your name and year in school? 
 [Introduction of researcher] 
 [Explanation of study and confidentiality, and why asking questions] 
 
IMPLEMENTATION 
What did you think of visiting the dental van on school grounds during the 
school day? 
How did leaving your classroom and going to the dental van affect your 
normal school day?  
 
TRIAL IMPLEMENTATION 
What did you think about coming for treatment? Have you been in the dental 
van before you got this treatment? Have any of your brothers or sisters been in 
the dental van? Do you have a local dentist?  
What do your friends think of you getting this dental treatment? What do 
people in your class think? What does your family think of you getting this 
dental treatment?  
How did you find filling in the forms in the van after your treatment? [prompt 
for whether they are easy/difficult] 
 
TREATMENT ACCEPTABILITY 
 What did you think of the dental treatment you got? What did you like or not 
like? [Prompt for taste: length of treatment, dental equipment, things 
explained by staff]. 
 Were your friends with you when you had the treatment? Did that make you 
feel any differently about it? 
 Have you been to a dentist before? How was the dental van visit different 
from that?  
 How would you feel about going back to the dental van and having the 
treatment again?  
 
RECEPTION 
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Do you think your teeth are any different since you had the treatment? 
Did your teeth change colour after the treatment? How did that affect you? 
Since you had this treatment, have you changed how you look after your 
teeth? [Prompt for changes in eating sweets and soda, changes in how often 
brush teeth, visits to dentist]  
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Appendix 18 Participating parents interview
schedule
PRELIM 
 [Introduction of researcher and purpose of study] 
 [Explanation of confidentiality] 
 What is your name, the name of your child and their year in school? 
 
TRIAL IMPLEMENTATION 
 What were your reasons for deciding to participate in the study? Were you 
influenced by family and friends in your decision? [prompt also for existing 
use of dental services and any difference this made] 
 What did you think of the information sheet and forms you received about the 
study? [prompt for understanding of study purpose, what intervention involves 
and consent] 
 Did you have any problems or concerns when you joined the study? [prompt 
for ease of joining, perceptions of treatment, contact taking place via school, 
concerns about losing place at local dentist, being comfortable with trial 
element, being comfortable with randomisation] 
 Overall how did you find the experience of joining the study? 
 
IMPLEMENTATION  
 What do you think about your child receiving treatment in a school setting? 
[prompt for being removed from classroom for treatment, receiving treatment 
in a mobile dental clinic] 
 How do you think your child felt about receiving treatment in the school 
setting? [prompt for being removed from classroom for treatment, receiving 
treatment in a mobile dental clinic] 
 
TREATMENT ACCEPTABILITY  
 How do you think your child felt about receiving the treatment? [prompt for 
taste, discomfort, time taken]  
 How do you think receiving treatment in the mobile dental clinic compares to 
your child’s normal dental care [prompt for whether have usual dentist and 
whether family is familiar with mobile dental clinics] 
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RECEPTION 
 Do you think your child’s teeth have changed in any way since they received 
the treatment? If so, how?  [prompt for whether they feel they are more or less 
likely to get caries] 
 Did your child experience any discolouration of their teeth and if so how did it 
affect them? 
 Have you changed anything about how you take care of your child’s teeth 
since joining the study? [prompt for diet, tooth brushing and visiting local 
dentist, receiving fluoride or other treatment] 
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Appendix 19 School/head teachers interview
schedule
IMPLEMENTATION 
What do you remember about being initially approached for this study? 
How did you find the recruitment process for this study? [prompt for clarity of 
information, understanding of intervention and trial aspect, dealing with 
parents, communicating with dental team] 
How did you find working with dental team for the study, in comparison to the 
Smile programme, once the intervention was underway? 
Were there any particular barriers or problems in having the study at your site, 
compared to the usual Smile programme? 
What impact did having the dental van on school grounds make? 
Did the study have an impact on the school day for staff or children, such as 
creating extra paperwork or removing children from lessons? 
Did being part of the study change your communications with parents once the 
trial was underway? 
 
TRIAL IMPLEMENTATION 
What do you think are the reasons for some parents not wanting to participate 
in the trial? 
Are you aware of any parents who withdrew from the trial, and if so what their 
reasons were? 
Were there particular groups or types of parents who you think were 
underrepresented in the trial? 
 
RECEPTION 
How do you think children who participated in the study felt about their teeth 
after treatment? (if had any comments from them) 
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Appendix 20 Community dental staff interview
schedule
IMPLEMENTATION 
 How did you find delivering the treatment in this trial? 
 How did you find working with schools and school staff in delivering an 
intervention in a trial setting? 
 How did you find delivering the treatment in a van in school grounds? 
 Were there any difficulties with identifying children and removing them from 
the classroom, compared to the “Designed to Smile” programme? 
 Were there any differences in delivering the PFS compared to FV? 
 Did being part of the trial affect how you delivered the PFS and FV treatment 
compared to the normal “Designed to Smile” programme? [prompt for how 
children are removed from classroom, number of staff in team, paperwork, 
getting children to complete scales] 
 Did you experience any problems/barriers in delivering the treatment itself or 
additional work (such as forms) for the trial? 
 
 
ACCEPTABILIITY OF TREATMENT 
 What responses have you seen to both PFS and FV treatments? 
 Based on delivering the treatments, do you think children find PFS or FV 
more acceptable?  
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Appendix 21 Non-participating parents
interview schedule
PRELIM 
 
 What is your name, the name of your child and their year in school? 
 [Introduction of researcher and purpose of study] 
 [Explanation of confidentiality] 
 
 
TRIAL IMPLEMENTATION 
 
 What were your reasons for deciding not to participate in the study? Were you 
influenced by family and friends in your decision? 
 Did you have any particular problems or concerns about joining the study? 
[prompt for ease of joining, perception of treatment, contact taking place via 
school, concerns about losing place at local dentist, being comfortable with 
trial element] 
 What did you think of the information sheet and forms you received about the 
study? [prompt for understanding of study purpose, what intervention involves 
and consent] 
 Overall how did you find the experience of being contacted about the study? 
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Appendix 22 Schools questionnaire
1.  Thinking about how you found the initial approach about Seal or Varnish 
taking place in your school, what was your experience? (Please tick all that 
apply) 
 
 It was time consuming 
 It was straightforward 
 The material was easy to understand 
 Interesting to be part of a study 
 Concerned about parent reaction 
 Concerned about teacher reaction 
 Concerned about extra disruption to classes 
 Thought it would be very similar to current arrangement with mobile 
dental clinics visiting school 
 Thought it would be a lot more work or disruption compared to current 
arrangement with mobile dental clinics visiting school 
 Thought it would enhance image or reputation of school 
 Concerned it would have an adverse impact on image or reputation of 
school 
 Other:  Click here to enter text. 
 
2. What was your actual experience in relation to any concerns that you had? 
 
Click here to enter text. 
 
3.  Were there any particular problems or barriers to hosting Seal or Varnish 
that affected you or other staff who were involved in helping coordinate Seal or 
Varnish activity in your school? 
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 Explaining the study to parents 
 Explaining the study to teachers 
 Explaining the study to children 
 Communicating with members of dental or study teams about the trial 
 Finding time to respond to requests for data [interviews, questionnaires – including 
this one] 
 Other: Click here to enter text. 
 
4. Did the school provide any assistance with recruiting parents e.g. phoning up 
particular parents to remind them about the study? If so, what type of staff 
member did this e.g. (administrator, teacher)? 
 
Click here to enter text. 
 
5. Can you describe how you found coordination with the dental teams both 
before, during and after visits by the mobile dental clinics? 
 
a) Communicating before and after visit of mobile dental clinic to the 
school:  
 Very easy/no problems 
 Somewhat difficult/a few problems 
 Very difficult/lots of problems 
 
Please explain: Click here to enter text. 
 
 
b) Organising child visits to mobile dental clinics around other school 
activities: 
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 Very easy/no problems 
 Somewhat difficult/a few problems 
 Very difficult/lots of problems 
 
Please explain: Click here to enter text. 
 
 
6. What impact did participating in Seal or Varnish have on the school day, 
including removing children from classrooms for treatment?  
 
 Major impact    Minor impact    No difference 
 
Please explain:  
 
Click here to enter text. 
 
7. On average, how much time did each child spend away from their class/usual 
school activities to attend each clinic visit? 
Approximately    minutes per child 
8. On average, how much time was given by the teacher (time away/disruption 
from their normal teaching duties) to support each clinic visit (e.g. to enable the 
child to leave/return to the classroom)?  
You may answer either by indicating the teaching time per child or the overall 
teacher time taken away from usual classroom activities for each mobile dental clinic 
visit. 
 
Approximately   minutes per child OR    minutes per mobile dental 
clinic visit. 
 
Please indicate the grade/spine point of the classroom teacher involved. 
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Grade/spine point   
 
9. On average, how much classroom assistant/other teaching staff time was given 
to support each clinic visit? 
 
You may answer either by indicating the teaching time per child or the overall 
teacher time taken away from usual classroom activities for each clinic visit. 
 
Approximately    minutes per child OR    minutes per clinic visit. 
 
 
Please indicate the grade/spine point of the teaching staff/classroom assistant support 
involved. 
 
Grade/spine point   
10. Did Seal or Varnish create extra work (including paperwork) for the school 
and if so how significant was this?  
 
No difference         A little more paperwork             A lot more 
paperwork 
 
11. Please list any school administrative/clerical support time for administrative 
tasks undertaken to support the programme. This should include: 
a) support to set up/administer the study in your school (e.g. sending out study 
information, responding to parental queries, speaking to the research team)  
Administrative task Grade/spine 
point of staff 
Approximate time per task 
(minutes) 
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b) support for each clinic visit (e.g. contacting parents if child is upset/unwell after the 
clinic visit) 
 
Administrative task Grade/spine 
point of staff 
Approximate time per task 
(minutes) 
 
12. Please list any other school resources or consumables (e.g. photocopying, 
telephone) used to support the programme. 
Resource/consumable used Approx number/minutes used 
 
13. Was Seal or Varnish integrated with or used to support any existing policies 
or programmes (such as ‘Healthy Schools’) already operating in your school? 
 
Yes  No  Don’t know 
 
Please 
explain: 
Click here to enter text. 
 
14. Did Seal or Varnish affect your communications with parents (e.g. did you 
receive phone calls  
about it)? 
 
Yes  No  Don’t know 
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Please 
explain: 
Click here to enter text. 
 
15. Do you think having Seal or Varnish in your school changed how the 
participating children felt about their teeth after treatment (if they made any 
comments about it in school)? 
 
    Yes  No   Don’t know 
 
Please explain: Click here to enter text. 
 
 
16. Do you think the participating children, and their parents, changed how they 
look after the child’s teeth as a result of being part of Seal or Varnish (if they 
made any comments about it in school)? 
 
 Yes  No   Don’t know 
 
Please explain: Click here to enter text. 
 
17. Do you have an idea of which parents did not participate in Seal or Varnish: 
if there were particular groups who did not participate? 
 
 Children in families already engaged with health and dental services were more 
likely to participate 
 Children in families already engaged with health and dental services were less 
likely to participate 
  
 Children whose parents who speak little English were more likely to participate 
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 Children whose parents who speak little English were less likely to participate 
  
 Children who receive free school meals were more likely to participate 
 Children who receive free schools meals were less likely to participate 
 
Other parents who were less likely to participate: Click here to enter text. 
 
Reasons for non participation: Click here to enter text. 
 
 
18. So far, have there been any types of parents who were more likely to 
withdraw their child from Seal or Varnish? 
 
 Children whose parents who speak little English were more likely to 
withdraw 
 Children whose parents who speak little English were less likely to 
withdraw 
  
 Children who receive free school meals were more likely to withdraw 
 Children who receive free schools meals were less likely to withdraw 
  
 We haven’t had any parents withdraw their children from the study yet 
 Don’t know 
 
Please comment on any reasons for withdrawal from Seal or Varnish that you are 
aware of: 
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Click here to enter text. 
 
Thank you. Please return this questionnaire to:  
ScobleC@cardiff.ac.uk, or by post in the envelope provided. 
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Appendix 23 Non-participating parents
questionnaire
We are interested in reasons why some parents may not wish their child to take part in the Seal or Varnish 
dental study. We would be grateful if you could complete this questionnaire – answers are confidential 
and will have no impact on any future dental treatment of you or your child. We will use this information 
to help us design future dental studies and services. Please only complete this if you did NOT give 
consent for your child to receive treatment as part of the study. Thank you. 
 
I did not want my child to take part in the dental study because (tick as many as apply): 
I did not understand what the study would involve 
I wanted my child to continue their normal treatment from the mobile dental clinic and didn’t want 
them to receive anything different 
I wanted my child to continue with their current/normal dental treatment at a local dental surgery  
I was afraid my child might lose their place at the local NHS dentist if they went somewhere else 
for treatment 
I wasn’t confident that the treatment would be good for my child 
My child did not want the treatment and I did not want to make them have it 
I was worried about what a dental examination might find in my child’s teeth 
I do not like the school being involved in or knowing too much about my child’s health care 
I do not like taking part in research 
I did not like being unable to choose which treatment my child received in the study 
I did not want to have to fill out questionnaires for the study 
I did not want to be interviewed for the study 
Other (please state): _________________________________________________________ 
 
Please tell us a bit about your normal dental habits (please tick all that apply): 
My child currently has a regular dentist at a local surgery 
My child is currently receives treatment from the ‘Designed to Smile’ programme (in the mobile 
dental clinics which visit the school) 
My child has never visited the dentist before 
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Appendix 24 Participant withdrawal form
(version 2.1)
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Appendix 25 Dental nurse observation scale
(version 1.0)
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Appendix 26 F00 study eligibility case report
form (version 2.3)
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Appendix 27 C01 caries follow-up case report
form (version 2.5)
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Appendix 28 C02 caries re-examination case
report form (version 2.6)
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Appendix 29 F1S sealant baseline treatment
record case report form (version 2.3)
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Appendix 30 F1V varnish treatment record form
(version 2.4)
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Appendix 31 FTP treatment plan (version 1.2)
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Appendix 32 F2S sealant follow-up treatment
record case report form (version 2.4)
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Appendix 33 Letter to school (version 1.0)
<<To be produced on appropriate headed paper>> 
 
Professor I.G. Chestnutt 
 
Tel:  
 [DATE] 
Dear Headteacher, 
RE: Seal or Varnish a Clinical Trial – Pilot study 
The National Health Service (Health Technology Assessment division) have 
commissioned a clinical trial to test two different methods of protecting children’s 
teeth. The study is being carried out by the Cardiff University School of Dentistry. It 
will involve 920 children from Community First schools in South Wales aged 
between 6 and 7 years and the start of the study and follow them for thirty six months. 
The study will help to identify the best way of protecting the childrens’ teeth from 
tooth decay. 
The first stage of the study involves piloting the methods that will be used in the 
mainstage of the study. We hope that you will agree to let your school take part in the 
Pilot study to do this. We need to identify approximately 35 children aged between 6 
and 7 years whose parents will consent to their child undergoing a dental 
examination. 
Parent/guardians of children aged 6 to 7 will be sent a letter explaining the study and 
asking them to allow their child to take part in the study and undergo a short dental 
examination.   
When the dentist visits the school they will require a room in which to carry out the 
examinations and some assistance in bringing the selected children to the room to be 
examined.  The school will also need to keep a list of any children whose parents 
withdraw them from the study to give to the dentist when they visit the school.   
I appreciate schools have many demands on their time but I hope you will feel able to 
help us. Participation in the study is voluntary. The dental visits are planned for the 
<<insert date>>.  If you are able to take part please return the attached slip in the 
envelope provided so that I can arrange a date for the dentist to visit. 
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If you have any queries about the survey, please contact me, Professor Ivor Chestnutt 
on 029 2074 2447 / 6680. 
Thank you. 
 
Yours sincerely 
 
Professor Ivor Chestnutt 
 
 
School: …………………………………………  
 
I am willing to allow my school to take part in the dental training exercise. 
 
Signed: ……………………………………. Head Teacher         Date: ………….
APPENDIX 33
NIHR Journals Library www.journalslibrary.nihr.ac.uk
232
Appendix 34 Baseline examination follow-up
letter (version 1.1)
 
Dear Parent/Guardian, 
 
Your child’s teeth were examined by a dentist today as part of the Seal or Varnish study. 
 
The outcome of the examination was: 
Your child is suitable to be included in the study and will receive treatment in the next 
2 to 4 weeks.  Please do not give your child any fluoride-containing dental medication 
(tablets, gels etc) other than their normal fluoride toothpaste while your child is in the 
study. 
 
Your child is is not suitable to be included in the study, but his/her teeth may still be 
treated through the existing Designed to Smile programme 
 
Your child is is not suitable to be included in the study, and his/her back teeth are not 
yet ready to be treated through the Designed to Smile programme (because they have 
not yet come through into the mouth).  The Mobile Dental Clinic will be back at your 
child’s school next year when they will review their teeth again. 
 
 
Are any other treatments required for my child’s teeth? 
The dentist did not find anything during the examination that requires immediate 
attention.  However if your child is registered with a dentist it is important to attend 
regularly. 
 
The dentist recommends that you make an appointment for your child to see a dentist 
for a more detailed examination as further treatment may be necessary.  If your 
child is not registered with a family dentist or community clinic, please contact the 
Designed to Smile team on 02920 ****** who can help you find a dentist. 
 
 
Seal or Varnish  Baseline Exam follow-up letter Version 1.1 – 12Jul2011 
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Appendix 35 Clinical examination follow-up
letter (version 2.0)
Dear Parent/Guardian, 
 
Your child was seen by the Dental Team today as part of the Seal or Varnish study: 
 
 
Your child received fissure sealant.  This will be checked again in 6 
months and replaced if required. 
 
Your child received fluoride varnish and will have the same 
treatment applied in 6 months. 
 
 
 
Information regarding the above treatments may be found in the ‘Seal or Varnish’ 
Information Booklet provided to you before the start of the study.  If you would like 
to receive another copy of this booklet please call the study team on 02920 *****. 
 
 
PLEASE LET US KNOW IF YOU CHANGE ADDRESS BY CALLING THE 
DENTAL TEAM ON 02920 ****** 
 
 
Seal or Varnish Initial Application follow-up letter Version 2.0 – 29May2012
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Appendix 36 Consent follow-up letter (LR)
(version 1.0)
Dear <<INSERT PARENT NAME>>, 
Earlier in the school year you agreed for <<INSERT CHILD’S NAME>>  to take part in the Seal or 
Varnish study, which is evaluating two different ways of protecting children’s teeth from tooth decay.  
Unfortunately, the mobile dental unit was unable to see <<<<INSERT CHILD’S NAME>> at that time. 
The mobile dental clinic will be returning to <<INSERT SCHOOL NAME>>  during the next school 
year to check if <<INSERT CHILD’S NAME>> is suitable to take part in the study. 
If you are still happy for <<INSERT CHILD’S NAME>> to take part in the study, we need to make 
sure they are still suitable to take part.  Therefore we need you to let us know if there has been any 
significant change in <<INSERT CHILD’S NAME>>’s health in the last year by looking at the 
questions on page 2. 
If the answer is YES to ANY of the questions on the form, please complete the form and return 
it to the study team in the enclosed pre-paid envelope. 
If there has been NO CHANGE to <<INSERT CHILD’S NAME>>’s health in the last year you 
DO NOT need to return the form 
 
If you have changed your mind and would NOT like <<INSERT CHILD’S NAME>> to take part in the 
study, or would like to discuss the study with a member of the dental team, please call the Community 
Dental Service on 02920*******. 
 
Thank you! 
 
The Seal or Varnish study team 
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Appendix 37 Consent follow-up letter (UE)
(version 1.0)
 
 
Dear <<INSERT PARENT NAME>>, 
Earlier in the school year you agreed for <<INSERT CHILD’S NAME>>  to take part in the Seal or 
Varnish study, which is evaluating two different ways of protecting children’s teeth from tooth decay.  
At the time <<INSERT CHILD’S NAME>>’s teeth were not quite ready to be treated because the back 
teeth had not come through enough, and therefore <<INSERT CHILD’S NAME>> was not able to 
participate in the study at that time. 
The mobile dental clinic will be returning to <<INSERT SCHOOL NAME>>  during the next school 
year to check if <<INSERT CHILD’S NAME>>’s teeth are now ready to be treated, and therefore able 
to take part in the study. 
If you are still happy for <<INSERT CHILD’S NAME>> to take part in the study, we need to make 
sure they are still suitable to take part.  Therefore we need you to let us know if there has been any 
significant change in the information you provided about<<INSERT CHILD’S NAME>>’s health last 
year.  Please look at the questions on page 2. 
• If the answer is YES to ANY of the questions on the form, please complete the form and return 
it to the study team in the enclosed pre-paid envelope. 
• If there has been NO CHANGE to <<INSERT CHILD’S NAME>>’s health in the last year you 
DO NOT need to return the form 
If you have changed your mind and would NOT like <<INSERT CHILD’S NAME>> to take part in the 
study, or would like to discuss the study with a member of the dental team, please call the Community 
Dental Service on 02920 ******. 
 
Thank you! 
The Seal or Varnish study team 
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Appendix 38 Interim visits follow-up letter
(version 2.0)
Dear Parent/Guardian, 
Your child was seen by the Dental Team today as part of the Seal or Varnish Trial: 
 
• The previous treatment (plastic sealant) your child received is still in place 
and did not need replacing.  This will be checked again in 6 months and 
replaced if required. 
 
 
• The previous treatment (plastic sealant) your child received had become 
dislodged/lost and was replaced with a new one.  This will be checked 
again in 6 months and replaced if required. 
 
 
• Your child received fluoride varnish and will have the same treatment 
applied in 6 months. 
 
 
 
REMINDER: 
Please do not give your child any fluoride-containing dental medication (tablets, gels etc) other than 
their normal fluoride toothpaste while your child is in the study. 
 
PLEASE LET US KNOW IF YOU CHANGE ADDRESS BY CALLING THE DENTAL 
TEAM ON 02920 ****** 
Seal or Varnish Interim Visit follow-up letter Version 2.0 – 29May2012 
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Appendix 39 Interim visits missed treatment
follow-up letter (version 2.0)
Dear Parent/Guardian, 
 
The Mobile Dental Clinic was at your child’s school today as part of the Seal or Varnish study. 
 
Your child was due to receive treatment today, but we were unable to carry out this treatment 
because they were: 
 
Uncooperative  
Feeling unwell 
 
 
Absent 
 
 
 
We will be returning to the school in approximately 6 months time and will see your child then. 
Should your child require routine dental care and is not registered with a family dentist or 
community clinic, please contact the Designed to Smile team on 02920 ****** who can help you 
find a dentist.  
 
PLEASE LET US KNOW IF YOU CHANGE ADDRESS BY CALLING THE DENTAL 
TEAM ON 02920 ****** 
 
Seal or Varnish Missed Treatment Follow-up letter Version 2.0 – 29May2012 
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Appendix 40 Annual examination follow-up
letter (parent guardian) (version 1.0)
Dear Parent/Guardian, 
 
Your child’s back teeth were examined by a dentist today as part of the Seal or Varnish study.   
 
The outcome of the examination was: 
 
The dentist did not find anything during the examination that requires 
immediate attention.  However if your child is registered with a dentist it is 
important to attend regularly. 
 
The dentist recommends that you make an appointment for your child to see 
a dentist for a more detailed examination as further treatment may be 
necessary.  If your child is not registered with a family dentist or 
community clinic, please contact the Designed to Smile team on 02920 
****** who can help you find a dentist. 
 
 
 
Seal or Varnish Annual Exam follow-up letter Version 1.0 - 12Jan2011 
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Appendix 41 Annual examination follow-up
letter (dental practitioner) (version 1.0)
<<Insert date>> 
 
Dear << insert name of General Dental Practitioner>>, 
<<Insert name, address and date of birth of child>> 
 
The above named child, whose parent or guardian has informed us is under your care, has been 
consented to participate in a randomised clinical trial, the aim of which is to determine the relative 
cost and effectiveness of fluoride varnish and fissure sealants in the prevention of dental caries in 
first permanent molars. 
<<Insert  name of child>> will be seen at six monthly intervals by the Community Dental Service 
when the mobile dental clinic visits their school to provide either the fluoride varnish or sealant 
treatment (depending on the arm of the study the child was allocated to).  We have advised the 
child’s parent or guardian that they should remain under your care.  However,  if you would refrain 
from placing fissure sealants on first permanent molars or using topical fluoride treatments 
over the next 36 months that would be a great help in ensuring a valid outcome to the trial. 
If you have any queries regarding the trial, please contact us on the above telephone number.  The 
study is being funded by the NHS Health Technology Assessment Programme, with the assent of the 
Chief Dental Officer and in collaboration with the South East Wales Trials Unit and the Dental 
Public Health Unit at Cardiff University Dental School. 
Your co-operation in this matter will be very much appreciated. 
Yours sincerely, 
 
Ceri Hoddell 
Senior Dental Officer & Principal Investigator 
Cardiff and Vale University Health Board, Community Dental Service 
01443 ****** 
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Appendix 42 Letter to child’s dentist withdrawal
(version 1.0)
«Dentist_Name» 
«Dentist_Address» 
 
23rd October 2013 
 
Dear «Dentist_Name» 
 
«Child_First_Name» «Child_Surname», «Child_Address_1» «Child_Address_2», «Child_DOB» 
 
I wrote to you on «Dentist_Letter_Sent_Date» informing you that the above child was enrolled in the 
Seal or Varnish clinical trial.  The aim of the trial is to determine the relative cost and effectiveness of 
fluoride varnish and fissure sealants in the prevention of dental caries in first permanent molars.  At that 
time, I asked if you would refrain from placing fissure sealants on first permanent molars or using 
topical fluoride treatments to ensure a valid outcome to the trial. 
 
However «Withdrawal_Reason» due to having moved to a school that is not involved in the study / at 
the request of his/her parent/, «Child_First_Name» is no longer participating in the trial and there is 
therefore no longer any need for you to take any specific measures in his / her clinical management. We 
therefore return this child fully to your care. 
 
If you have any queries regarding the trial, please contact us on the above telephone number.  The study 
is being funded by the NHS Health Technology Assessment Programme, with the assent of the Chief 
Dental Officer and in collaboration with the South East Wales Trials Unit and the Dental Public Health 
Unit at Cardiff University Dental School. 
 
Your co-operation in this matter is very much appreciated. 
 
Yours sincerely, 
 
Ceri Hoddell 
Senior Dental Officer & Principal Investigator 
Cardiff and Vale University Health Board, Community Dental Service 
01443 ****** 
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Appendix 43 Participant newsletter issue 1
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Appendix 44 Participant newsletter issue 2
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Appendix 45 Participant newsletter issue 3
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